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Breast cancer is the leading site of new cancer cases in women and the second leading 
cause of cancer related deaths.  Improvements in detection and treatment in the past three 
decades has led to a significant decline in breast cancer deaths, yet just this year more than 
42,000 people are expected to die from breast cancer.  Immunotherapy, boosting the anti-
tumor immune response, is a valuable advancement for the field of cancer therapy.  Immune 
checkpoint therapy focuses on blocking inhibitory receptors expressed on activated immune 
cells.  Two prominent checkpoint inhibitory receptors are cytotoxic T lymphocyte-associated 
antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1).  Unfortunately, most triple 
negative breast cancer patients do not benefit from immune checkpoint inhibition despite 
immune infiltration into the tumors.  In the work presented here, we aim to find ways to 
improve immunotherapy through projects studying the effectiveness of immune checkpoint 
blockade in cancer.   
First, we evaluated several models of breast cancer and found the heavily immune 
infiltrated claudin-low subtype was not able to respond to immunotherapy due to the 
suppressive tumor microenvironment.  This subtype of breast cancer responded to checkpoint 
inhibition only in the context of specific and complete regulatory T cell (Treg) depletion.  Second, 
we studied the role of PD-1 blockade on Tregs in a model of claudin-low breast cancer.  We 
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found that PD-1 blockade increased proliferation and survival of Tregs in the tumor 
microenvironment, leading to increased immunosuppression.  Third, we observed the role of 
PD-1 expression on NK cells in cancer and chronic viral infection.  We saw that NK cells may not 
be a beneficial target for immunotherapy due to the inconsistency of PD-1 expression.  
 Together, this work provides insight into potential mechanisms involved in the poor 
response to immune checkpoint therapy in some cancers.  Although tumors may be heavily 
immune infiltrated, this does not predict response to immunotherapy, and a more thorough 
analysis of the tumor microenvironment should be done such as determining which subsets of 
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CHAPTER 1:  INTRODUCTION TO THE TUMOR MICROENVIRONMENT AND IMMUNOTHERAPY 
 
1.1 Breast Cancer 
In the United States this year alone, more than 268,000 new cases of breast cancer are 
expected to be diagnosed in women and more than 2,600 cases in men.  In women, breast 
cancer will account for 30 percent of newly diagnosed cancer cases [1].  In fact, breast cancer is 
the leading site of new cancer cases in women and the second leading cause of cancer related 
deaths, just behind lung cancer [2].  Improvements in detection and treatment have led to a 40 
percent decline in breast cancer deaths since 1989, yet just in 2019 more than 42,000 men and 
women are expected to die from breast cancer [1].  Risk factors for breast cancer include age, 
sex, family history, and deleterious gene sequence variations such as BRCA1, BRCA2, CHECK2, 
and others [3].  The high mortality rate from breast cancer despite advances in treatment is in 
large part due to the heterogenous nature of the disease [4].  Breast cancer prognosis depends 
on multiple factors including lymph node involvement [5], tumor grade, and expression of 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER-2).   
Breast cancer is classified into different subtypes based on molecular phenotype including 
the presence or absence of ER, PR, and HER-2 [6].  Luminal A and Luminal B subtype are 
characterized by the overexpression of ER and PR.  HER-2 subtype is characterized by the 
overexpression of HER-2.  Lastly, tumors that lack expression of these growth factor and 
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hormone receptors are termed triple negative breast cancer (TNBC).  TNBC itself is very 
heterogenous with different subtypes of breast cancer falling into this classification.  Two of 
these subtypes, basal-like and claudin-low [6 7], are characterized by increased expression of 
genes related to tumor cell proliferation and immune involvement.  Claudin-low subtype is 
further characterized by decreased expression of tight junction proteins claudin 3, 4, and 7 and 
E-cadherin, increased epithelial to mesenchymal transition features [8], and increased immune 
response [9].  TNBC subtype has the worst clinical prognosis due to the lack of targeted 
therapies and higher risk of recurrence [10].  Conversely, Luminal A, Luminal B, and HER-2 have 
a better clinical prognosis due to the targeted therapies available.    
1.2 Breast Cancer Treatment 
The largest diagnosed subtypes of breast cancer are Luminal A and Luminal B with 75 
percent of patients having 1 percent or greater ER or PR expression levels [4].  Patients 
diagnosed with these subtypes of breast cancer, in addition to surgery, radiation, or 
chemotherapy, can benefit from hormone or endocrine therapy.  Luminal breast cancer 
subtypes use overexpression of the hormone receptor to enhance tumor growth, so blocking 
the hormone can prevent recurrence and improve overall survival rate [11].  This can be done 
by blocking estrogen binding on breast cancer cells by selective estrogen receptor modulators, 
such as Tamoxifen.  Another approach is by eliminating the circulating estrogen through 
aromatase inhibitors or ovarian suppression therapy or removal.  HER-2 overexpressing tumors 
make up 15-20 percent of breast cancer cases [12].  Tumors with overexpression or 
amplification of HER-2 had clinically poor prognoses before the introduction of HER-2 directed 
monoclonal antibody therapies [13].  Today, there are several HER-2 targeted therapies 
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available to patients greatly improving overall outcomes.  Triple negative breast cancers make 
up a smaller percentage of breast cancer cases, around 10-15 percent.  Because there are no 
targeted therapies for these tumors, first-line treatment consists of surgery, radiation, and/or 
chemotherapy.  In the past few decades though, a new form of cancer treatment has emerged 
that utilizes the patient’s own immune system to work with other first-line treatments to 
eliminate the tumor.  Immunotherapy today is considered a “fifth pillar” of cancer therapy in 
addition to surgery, chemotherapy, radiation, and targeted therapies [14].     
1.3 Immune Response to Cancer 
It had long been proposed that the immune response could affect tumor growth.  Burnet 
and Thomas derived the concept that the immune system was able to detect “non-self” 
malignant cells in their cancer immunosurveillance hypothesis [15 16], which was initially 
rejected as true.  Both the innate arm of the immune system including natural killer (NK cells), 
neutrophils, macrophages, eosinophils, basophils, and mast cells, along with the adaptive arm 
of the immune system including B and T cells have been shown to play a role in tumor 
elimination.  This was demonstrated in studies showing that immunodeficient mice with no B or 
T cells are more susceptible to spontaneous and carcinogenic tumor development [17].  While 
most studies investigating immune response against tumors focuses on adaptive immunity in B 
and T cells, there is also work suggesting that the innate immune response is important in 
tumor killing demonstrated by work showing that NK cells could lyse tumor cells without prior 
stimulation [18].  The dynamic between the immune system and tumor cells has been 
discovered to be quite complex with both tumor intrinsic and extrinsic factors affecting the 
balance between tumor elimination and tumor escape and metastasis.  In fact, the ability of 
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tumors to evade the immune response has been proposed as an additional hallmark of cancer 
for the multistep development of tumors [19].  Tumors employ many mechanisms to evade the 
immune response from recruiting suppressive cells into the tumor microenvironment (TME) to 
upregulating ligands for inhibitory receptors that when bound are able to tamper the immune 
function. 
Myeloid-derived suppressor cells 
 Myeloid-derived suppressor cells (MDSCs) are derived from bone marrow 
hematopoietic precursor cells and are limited in healthy individuals.  MDSCs, which are closely 
related to neutrophils and monocytes, only differentiate under conditions of chronic 
inflammation.  Typically, when a pathogen is detected, there is expansion and activation of 
neutrophils and monocytes which culminates in robust phagocytosis, respiratory burst, and 
release of pro-inflammatory cytokines.  But in instances of chronic antigen exposure and 
prolonged inflammatory states, such as during cancer progression, myeloid cells are 
differentiated to have different functional outcomes.  MDSCs, possess a potent ability to 
suppress various types of immune responses.  Enhanced recruitment of MDSCs can be achieved 
in the TME through tumor expression of IDO, an immune modulating enzyme, and activated 
regulatory T cells [20].  Once recruited into the TME, MDSCs exert immunosuppression through 
release of nitric oxide, arginase, and reactive oxygen species [21].  In melanoma patients, the 
presence of MDSCs has been reported to negatively impact survival and has been inversely 
correlated with tumor specific T cells infiltrating into the tumor [22].  High numbers of MDSCs 
has also been correlated with poor prognosis in breast cancer [23].  Overall, MDSCs represent a 
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key factor aiding in immune suppression in the TME, and also an obstacle for effective 
immunotherapy.      
Tumor-associated Macrophages 
 Tumor-associated macrophages (TAMs) are immunosuppressive cells that are able to 
inhibit T cell responses [24] through poorly defined molecular mechanisms, but partially 
through VEGF and TGFb.  Not only are TAMs able to suppress T cell responses in the TME, but 
they also accelerate tumor growth through promotion of angiogenesis, fibrous stroma 
deposition, and metastasis formation [25].  Several analyses have correlated TAM infiltration 
with overall survival and it has been shown that TAMs are associated with a poor prognosis in 
most solid tumors [26].  In breast cancer, high infiltration of TAMs is associated with poor 
survival rates and also significantly associated with negative hormone receptor status [27].  
There are strategies available to target TAMs through blocking colony-stimulating factor 1 
receptor (CSF-1R), which is essential for their recruitment, differentiation, and survival [28]. 
Blocking CSF-1R has been shown therapeutically to relieve immunosuppression and improve 
cancer therapies [29 30].   
Immature Dendritic Cells 
 While CD103+ myeloid dendritic cells (DCs) have been identified in tumors as potent 
antigen presenting cells, these cells are extremely rare and the tumor has ways of suppressing 
DC function and preventing tumor antigen presentation to T cells [31].  Tumor infiltrating DCs 
have been reported to have correlations with both positive and negative cancer prognoses.  
This prognostic impact may have more to do with the phenotype of the DC rather than the 
proportions of subtypes within the TME.  Tumor infiltrating DCs tend to demonstrate sub-
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optimal tumor antigen cross-presentation [32], low expression of co-stimulatory molecules 
[33], and high expression of regulatory molecules and receptors [34].  All of these factors 
suggest that the DCs infiltrating into the TME may be tolerogenic and induce more 
immunosuppression than T cell stimulation.  It has been shown that tumor cells can release 
factors that reverse or inhibit DC maturation and normal function [35] such as certain 
chemokines and VEGF.  Immature DCs in the TME can suppress both the innate and adaptive 
immune systems through expression of inhibitory receptor ligands [36], upregulation of 
arginase I, which degrades arginine required for T cell activation [37], and expression of 
immune suppressing cytokines and molecules.  There are ongoing investigations to determine 
ways to induce maturation in tumor infiltrating DCs.  One of these is in vivo manipulation of DCs 
by gene therapy to induce production of Flt3 ligand or Il-18.  In tumor bearing mice treated with 
these DC immunotherapies, a significant antitumor effect was seen with some mice achieving 
complete tumor eradication [38].  Targeting DCs with immunotherapies in the TME will be 
challenging given the complexity of immune regulation. 
Regulatory T Cells 
  Regulatory T cells (Tregs) are appreciated as an important suppressive cell subset for 
preventing autoimmune disease and maintaining immune tolerance.  In 1995, a group 
identified a population of CD4+ T cells that expressed high levels of CD25, the Il-2 receptor a 
chain, that were crucial for maintaining immunologic self-tolerance [39].  These regulatory T 
cells, or Tregs, were subsequently found to be suppressive in humans as well [40-45].  In 2003, 
Foxp3 was described as a master regulator gene for Treg cell development and function [46-48].  
Not only is Foxp3 crucial for development and maintenance of Tregs, but Foxp3 levels play a role 
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in Treg function as well.  Increased Foxp3 levels in Tregs have been shown to be associated with 
increased suppressive capabilities [49].   
Tregs are able to suppress immune cells through multiple mechanisms.  Expression of the 
inhibitory receptor CTLA-4, the Il-2 receptor CD25, and secretion of suppressive cytokines Il-35, 
Il-10, and TGF-b are well characterized mechanisms of suppression utilized by Tregs [50].  Tregs 
express high levels of CTLA-4 during resting conditions as opposed to T effector cells, which 
upregulate CTLA-4 after activation.  CTLA-4 functions to suppress the activation of T cells by 
competing with the co-stimulatory molecule CD28 to bind to CD80 and CD86 on antigen 
presenting cells, necessary for T cell activation.  CD25 is the Il-2 receptor a chain, which binds 
to the cytokine Il-2, a critical mediator of the immune response.  While high levels of CD25 
expression are often used as a marker for Tregs, this is also thought to play a suppressive role by 
binding free Il-2 in the microenvironment, thus preventing the Il-2 from being available to 
nearby cells for activation and proliferation.  An additional, more recently described, receptor 
expressed on Tregs called Glucocorticoid induced TNF receptor (GITR) is expressed at high levels 
on Tregs [51] and has been shown to contribute to their suppressive capabilities, although the 
exact mechanism is not understood [52]. Tregs are able to suppress activation, proliferation, and 
effector functions or a wide range of immune cells including CD4+ and CD8+ T cells, NK cells, B 
cells, and antigen presenting cells [53].  Tregs are important in maintaining immunological self-
tolerance and preventing autoimmunity as shown extensively by the spontaneous occurrence 
of autoimmune disease when Tregs are deficient or have impaired development [53 54].  While 
Tregs are crucial for normal immune homeostasis, Tregs can also suppress anti-tumor immune 
responses leading to tumor progression. Tregs are broadly divided into two groups, thymically 
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derived and peripherally induced.  The neonatally derived thymic Tregs, are selected for during T 
cell development and are crucial for preventing autoimmune disease and controlling self-
reactive T effector cells that escape negative selection.  Tregs can also be generated from naïve 
CD4+ T cells in the periphery, called inducible Tregs.  Depending on the mode of stimulation, co-
stimulation, and cytokine milieu, naïve T cells can be driven to differentiate into different cell 
subsets.  Tregs are thought to be induced during the conditions of poor dendritic cell activation, 
sub-immunogenic levels of antigen, and the presence of cytokines TGF-b and Il-2 [55-58].  
Inducible Tregs are important for the dampening of the immune response during infection or 
injury to prevent tissue damage and chronic inflammation.  While thymically derived and 
induced Tregs are found in both the periphery and within the tumor microenvironment, it is 
unknown what role these different subsets of Tregs individually play in the suppression of the 
anti-tumor immune response [59].                
Tregs are understood to be an important suppressive population in tumors [60].  
Decreased ratios of CD8+ T cells to Tregs infiltrating into various cancer tissues is most often 
associated with a poor clinical prognosis [61-63].  It is unknown why Treg activity is so dominant 
in the tumor microenvironment of some tumors.  It is possible that Tregs are recruited to or 
expand in the TME due to the self-antigens expressed by the tumor.  Because the T-cell 
receptor (TCR) of Tregs is skewed to a certain extent to recognizing self-antigens, it is possible 
that Tregs are able to recognize a tumor self-antigen more easily than a naïve conventional T cell.  
They then become activated and thus promote Treg dominance in the TME.  It is also possible 
that the tumor is secreting factors to recruit and activate Tregs to the TME to aid in immune 
escape.  As previously mentioned in this chapter, tumors are able to produce the immune 
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modulating enzyme IDO.  IDO has been shown to activate Tregs in tumors [64] aiding in the 
suppression of a productive anti-tumor immune response.  Tumors have also been found to 
produce strong chemotactic molecules for lymphocytes such as CXCL12.  Tregs express high 
levels of the CXCL12 chemokine receptor, CXCR4, allowing the tumor to employ this mechanism 
to attract Tregs to the tumor site [65].  Another potential mechanism for the generation of Tregs is 
the PD-1/PD-L1 axis leading to generation of Tregs in the TME.  Tumor cells are able to 
upregulate expression of PD-L1, ligand to PD-1, in the presence of IFNg.  Multiple studies have 
shown PD-L1 is able to convert naïve T cells during activation into inducible Tregs, demonstrating 
a key role of PD-L1 in promoting iTreg development and function [66-68].  This could be another 
potential hypothesis as to high Treg activity in the TME.  It is clear that Tregs are a large 
impediment to a productive anti-tumor immune response, and because of this there are many 
ongoing lines of study to discover ways to deplete or inhibit Tregs specifically in the TME.  There 
has been some limited success in therapeutic Treg depletion with complications mostly arising 
from either specificity of the therapy towards Tregs, or autoimmunity arising from Treg depletion.  
An anti-CCR4 antibody has been used in humans and shown to be effective against effector 
Tregs, increasing anti-tumor CD4+ and CD8+ T cell responses [69].  Cyclophosphamide, an 
alkylating chemotherapy agent, has been used in low doses to target Tregs [70].  
Cyclophosphamide functions by interfering with DNA replication in rapidly dividing cells, and 
because Tregs are proliferating at a higher rate than conventional T cells, low-dose 
cyclophosphamide is thought to interrupt Treg expansion in the TME.  Additionally, conditional 
knock-out or administration of a small-molecule inhibitor of phosphatidylinositol-3-kinase 
(PI3K) p110d has been shown to lead to a decrease in Treg numbers and function in mice 
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allowing for an effective anti-tumor response without incurring autoimmunity [71].  While all of 
these therapies may affect Treg function or numbers is some way, our work has suggested that 
for the balance in the TME to shift from immunosuppression to anti-tumor immune response in 
tumors with high numbers of infiltrating Tregs, the Treg depletion needs to be robust and specific. 
Checkpoint co-inhibitory receptors PD-1 and CTLA-4 
The classic understanding of naive T cell activation is initial binding of the TCR of the T 
cell to its specific antigen in the context of MHC, which is referred to as step 1.  Subsequently 
necessary for full T cell activation is step 2, which involves binding of co-stimulatory molecule 
CD28 on T cells to CD80 or CD86 on the antigen presenting cell.  Our understanding of co-
stimulatory and co-inhibitory molecules has greatly expanded since the notion of step 2 for T 
cell activation was introduced.  More than 20 co-stimulatory and co-inhibitory molecule pairs 
have been discovered [72].  These co-inhibitory molecules are often called checkpoint 
inhibitory receptors.  Checkpoint inhibitory receptors are another mechanism the immune 
system has evolved to dampen the immune response after activation to avoid autoimmune 
pathology and are important for normal immune homeostasis.  Two prominent checkpoint 
inhibitory receptors are cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed 
cell death protein 1 (PD-1).  CTLA-4 competes with CD28 for binding to the co-stimulatory 
molecules CD80 and CD86.  When CTLA-4 is bound, CD28 is not able to give the co-stimulatory 
step 2 necessary for complete T cell activation and the immune response is halted at this stage.  
PD-1 inhibits the T cell response through a slightly different mechanism.  PD-1 is expressed after 
T cell activation and functions to dampen T cell function after the T cell has responded to the 
pathogen.  There are two known ligands for PD-1, PD-L1 (B7-H1) [73] and PD-L2 (B7-DC) [74].  
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PD-L1 is constitutively expressed at low levels and can be induced on nearly all tissues in the 
presence of IFNg.  The broad expression pattern of PD-L1 suggests it may serve to dampen 
auto-reactive T cells in the periphery [75].  PD-L1 has also been shown to interact with CD80, 
although the consequences of this interaction are less well understood [76].  Expression of PD-
L2 is restricted to antigen presenting cells.  When ligated by PD-L1 or PD-L2, PD-1 becomes 
phosphorylated on the two intracellular tyrosines of its ITIM and ITSM domains, although 
phosphorylation of the ITSM domain has been shown necessary for PD-1 mediated inhibition 
[77].  In T cells, when the phosphatase SHP-2 is recruited to PD-1 it is able to de-phosphorylate 
TCR signaling molecules CD3 and ZAP-70.  This shows that PD-1 acts to disrupt the earliest 
antigen receptor signaling events [78].  PD-1 activation also results in inhibition of AKT 
activation but not p38 and JNK activation suggesting that PD-1 signaling does not just cause 
global defects in TCR signaling but that PD-1 signaling selectively targets certain TCR signaling 
pathways [79].  Once activated, PD-1 expression can be detected within 24 hours of stimulation 
and functional effects of PD-1 are detectable within a few hours [77].  In acute illnesses, this 
downregulation mechanism through the PD-1/PD-L1 axis is important to avoid prolonged 
inflammation leading to tissue damage, but in situations with repeated antigen exposure such 
as chronic viral infection or cancer, this can be detrimental to eliminating the pathogen.  Many 
tumors have evolved ways to exploit this checkpoint mechanism by upregulating PD-L1 on the 
tumor surface.  In a recent analysis looking at 410 breast cancer tumors, the researchers found 
that 53 percent of ER/PR tumors, 73 percent of HER2+ tumors, and 84 percent of triple negative 
tumors were PD-L1+ [80].  With large numbers of cancers expressing PD-L1 as a mechanism to 
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suppress the anti-tumor immune response, it follows that blocking these immune checkpoint 
inhibitory receptors would be beneficial to the anti-tumor immune response.                 
1.4 Immunotherapies 
One of the first scientific findings that set the stage for immunotherapy was the discovery 
that human tumor antigens from melanoma patients could be recognized by cytotoxic T cells 
[81].  Many different immunotherapies have been proposed to boost the immune response 
against the tumor and prevent tumor evasion.  Here, I will discuss three different forms of 
tumor immunotherapy; active cancer vaccination, adoptive cell therapy and checkpoint 
inhibitor therapy.         
Cancer Vaccines 
While vaccines today are much more sophisticated and less dangerous, the same basic 
principles apply.  Vaccine utility has been applied to cancer as well with the rational being that 
inoculation with cancer antigens in addition to an immune boosting adjuvant, will allow the 
immune system to develop an adaptive response against the tumor, allowing for tumor 
elimination.  There are three types of cancer vaccines in development; cellular, virus vector, 
and molecular.  One cellular cancer vaccine FDA approved for use in prostate carcinoma is 
Sipuleucel-T where dendritic cells are isolated from a patient and exposed to prostatic acid 
phosphatase and granulocyte-macrophage colony-stimulating factor (GM-CSF), and then re-
infused back into the patient.  This vaccine has been shown to increase survival in these 
patients by an average of 4.1 months [82].  This strategy has also been tested in melanoma 
patients with promising results.  Autologous DCs are isolated and pulsed with melanoma 
antigen and then re-infused back in the patients [83].  A cellular vaccine for pancreatic cancer 
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called GVAX takes a different approach.  For this vaccine, autologous tumor cells are removed 
from a patient and genetically modified to secrete GM-CSF and irradiated to prevent further 
cell division, then these cells are transplanted back into the patients.  The production of GM-
CSF by the killed tumor cells promotes activation of dendritic cells [84] and results in 
proliferation and stimulation of macrophages and neutrophils [85].  Cancer vaccines using viral 
vectors take advantage of the fact that the immune system has evolved to respond robustly to 
viruses.  These naturally immunogenic viruses can be genetically engineered to express tumor 
antigens.  Another advantage to this type of system is that viral vectors can be utilized that are 
known to infect dendritic cells, which then express the tumor antigen and promote activation 
of T cells [86 87].  Several clinical trials in metastatic renal cell carcinoma have been conducted 
with the TroVax vaccine.  This vaccine consists of recombinant pox virus vector MVA expressing 
tumor-associated antigens.  There has been no significant difference between treatment arms 
in clinical trials though, suggesting more research needs to be done to improve this form of 
cancer vaccine.  One limitation is that because the immune response is able to respond to viral 
infection, upon vaccination an adaptive immune response against the viral vectors can produce 
neutralizing antibodies which prevents the vectors from infecting cells and depositing tumor 
antigens.  These viral based vaccines may need to be given with adjuvants or potentially with 
additional immunotherapies to be effective.  Finally, in molecular based cancer vaccines, 
peptides, RNA, or DNA encoding for tumor antigens are used to boost the anti-tumor immune 
response.  Neoantigens arise from mutated proteins in cancer cells.  Because these antigens are 
removed from “self” proteins, they are truly cancer-specific and can be highly immunogenic.  
Although these antigens are able to stimulate the immune system, neoantigens are largely 
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unique to each patient and therefore require development of personalized vaccines [88].  In 
two small clinical trials in patients with skin cancer, personalized vaccines using neoantigens 
prevented early relapse in patients [89].  In contrast to neoantigens, tumor-associated antigens 
are self-proteins that are abnormally expressed by the tumor.  A complication to vaccines 
utilizing tumor-associated antigens is that B and T cells that strongly recognize these antigens 
may have been deleted during central and peripheral tolerance.  The goal for tumor-associated 
antigen vaccines is to break tolerance by stimulating low-affinity T cells [90].  This can be done 
through the use of strong adjuvants, co-stimulators, or repeated vaccines to amplify activation 
and expansion [91].  One potential downside to tumor-associated antigen vaccines is that 
antigen expression in non-cancerous cells may lead to on-target off-tumor toxicity.   
Adoptive Cell Transfer 
Adoptive cell transfer as an immunotherapy consists of isolation of autologous T cells, ex 
vivo modification and/or expansion of tumor specific T cells, followed by infusion back into the 
patient.  Adoptive cell transfer can be performed using three main types of cells; tumor-
infiltrating lymphocytes, T cells modified with TCR gene therapy, and T cells modified to express 
chimeric antigen receptors (CARs).  Adoptive cell therapy using tumor-infiltrating lymphocytes 
involves ex vivo expansion of lymphocytes isolated from resected tumor material, then 
adoptively transferring these cells back into the patient.  This often involves additional 
lymphodepletion using either chemotherapy or irradiation to create a niche for the expanded 
cells or to enhance their ability to bind to trophic cytokines such as IL-15 and/or IL-2, and 
subsequent administration of IL-2.  This type of adoptive cell therapy has had success in 
melanoma [92] and has been tried in many solid tumors, including breast cancer [93], with 
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varying success.  In adoptive cell therapy using T cell receptor gene therapy, peripheral blood 
mononuclear cells (PBMCs) are isolated from a cancer patient and a tumor specific population 
of T cells isolated.  The T cell receptor from one of these cells is isolated and cloned often with 
approaches to enhance TCR affinity by substitution of specific amino acids in the cloned 
product.  This is then introduced via a viral vector into a population of non-specific T cells.  
These TCR modified T cells, which now express both the endogenous TCR and the cloned TCR, 
are able to recognize tumor antigen in an MHC dependent manner [94 95].  This has been 
shown to be a potent anti-tumor therapy, however antigens restricted to the tumor are crucial 
so as not to have on-target off-tumor toxicity.  Additionally, the presence of a second TCR in 
these cells increases the risk of allogeneic anti-host responses termed graft-versus-host disease.  
Finally, a rapidly progressing type of adoptive cell therapy is autologous T cells modified to 
express chimeric antigen receptors (CAR).  These hybrid receptors are genetically constructed 
to contain an antigen-binding portion of a monoclonal antibody on the cell surface, and a TCR 
CD3 zeta chain for signaling expressed intracellularly in addition to a co-signaling domain.  The 
antigen-binding portion constructed from an antibody allows for the modified T cells to 
recognize tumor antigen in an MHC independent manner.  There have been several generations 
of CAR T cells development since the original was published in 1989 [96].  The second and third 
generation CAR T cells added additional co-stimulatory domains such as 4-1BB [97] and CD28.  
Fourth generation CAR T cells are adding cytokines or co-stimulatory ligands to aid in CAR T cell 
persistence [98 99].  While CAR T cells are an exciting new cancer therapy, there are still many 
challenges to overcome such as CAR T cell persistence and specificity for solid tumors.   
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Immune Checkpoint Inhibitors 
Immune co-inhibitory receptors bind to their ligands and function to dampen T cell 
function.  It was hypothesized that blocking these inhibitory receptors would allow the T cells to 
remain functional and lead to more efficient tumor elimination.  Two inhibitory receptor axes 
that have received attention as cancer therapies are CTLA-4 and PD-1.  The first report of using 
monoclonal antibodies to block CTLA-4 signaling to treat tumors in animal models was from 
James Allison’s lab in the late 1990’s [100].  These blocking monoclonal antibodies have 
become known as immune checkpoint inhibitors.  CTLA-4 blocking antibody ipilimumab was the 
first immune checkpoint inhibitor approved for treating patients with melanoma [101], but 
CTLA-4 blocking antibodies have shown significant levels of adverse immune related events.  
Blocking antibodies against PD-1 and its ligand PD-L1 for use as cancer therapy were developed 
after it was shown that blocking PD-1 could restore T cell function during chronic viral infection 
[102].  Pembrolizumab and nivolumab, immune checkpoint inhibitors targeting PD-1, have 
shown promising results with overall response rates as high as 30 percent in melanoma and 
non-small cell lung carcinoma.  PD-1 and PD-L1 blocking cancer therapies have resulted in less 
severe toxicity than CTLA-4 with 5-20 percent adverse immune related events [103].  Immune 
checkpoint inhibitors against PD-1 are currently in clinical trials for nearly 20 different types of 
cancers [104].  In general, despite intense enthusiasm for their use, the response rate for 
patients with cancers that are not metastatic melanoma is low.  Thus, considerable additional 
work is needed to better understand which patients to treat with immunotherapy and why only 
certain patients respond to this therapy.   
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1.5 PD-1 Blockade on Tumor Infiltrating Immune Cells   
PD-1 blocking therapies have had moderate success in multiple solid tumors, but the 
response rates are low in most tumor types.  This leads to the question, why don’t all patients 
respond to immune checkpoint therapy?  The search for reliable biomarkers to predict a 
positive response to checkpoint blockade is ongoing.  One hypothesis is that heavily immune 
infiltrated or “hot” tumors are predicted to respond to immune checkpoint inhibition therapy 
and immune scarce or “cold” tumors are predicted to be resistant to immune checkpoint 
inhibition therapy.  This hypothesis does not explain all immune checkpoint therapy outcomes 
as it has been shown that a heavily immune infiltrated model of claudin-low breast cancer does 
not respond to immune checkpoint inhibitor therapy [65].  In a clinical trial where triple 
negative breast cancer patients were treated with pembrolizumab, the overall response rate 
was 18.5 percent [105].  Additional trials using anti-PD-1 or PD-L1 mAb have demonstrated a 
response rate to be 4-19 percent in TNBC patients.  Additionally, none of these responses were 
durable.  In a heavily immune infiltrated tumor, the tumor-specific CD8+ T cells expressing PD-1 
will come into contact with PD-L1, either expressed on other immune cells or the tumor cells 
themselves, and the CD8+ cytotoxic T cell will begin to lose function.  It is predicted that with 
the addition of PD-1 blockade in these tumors, the CD8+ cytotoxic T cells will be able to remain 
functional and aid in tumor elimination.  One complication to this model of PD-1 blockade 
success is that more immune cell subsets than CD8+ T cells have been shown to express PD-1.  
While in the TME PD-1 blockade may boost the cytotoxic capabilities of activated CD8+ T cells, it 
is also affecting the other cell subsets in the TME expressing PD-1, which are largely unstudied. 
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Natural Killer Cells 
Natural killer (NK) cells are a member of the innate immune system related to innate 
lymphoid cells.  In humans, there are two main populations of NK cells defined by the level of 
CD56 surface expression [106].  CD56dim NK cells express high levels of the cytotoxic molecules 
perforin and granzyme, while CD56bright NK cells secrete inflammatory cytokines and are found 
in tissues and secondary organs.  These innate cells play a major role in anti-tumor immunity 
through their capacity to directly kill tumor cells and produce IFNg [107].  In an increasing 
number of studies, PD-1 has been detected to be expressed on a subset of NK cells in cancer 
patients [108-112].  It has been shown that glucocorticoid signals on NK cells induce PD-1 
expression which regulates IFNg production [113]. Additionally, the effect of PD-1 blockade on 
NK cells during cancer immunotherapy has been demonstrated in multiple models of cancer.  In 
these studies, PD-1 engagement suppressed NK cell-mediated anti-tumor immunity [114].  PD-1 
blockade in combination with NK cell stimulating treatments increase survival in mouse tumor 
models [115 116].  Unlike T cells where upon activation all T cells express PD-1, these studies 
show that only a subset of NK cells express PD-1 and the percent of PD-1+ NK cells is wildly 
variable.  While it is clear that PD-1 expressing NK cells found in tumors have the potential to 
respond to checkpoint blockade, it is still unknown if the small percentages of NK cells 
expressing PD-1 have a significant effect on tumor response.      
Dendritic Cells 
Dendritic cells (DCs) are an important myeloid cell linking the innate and adaptive 
immune responses.  DCs are able to respond to pathogen signals and secrete cytokines that 
alter the surrounding immune environment.  They are also crucial antigen presenting cells 
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necessary to activate tumor-antigen specific T cells in the TME.  DCs play in important role 
shaping the anti-tumor immune response in the TME, and there are an increasing number of 
studies demonstrating that these cells also express PD-1 within the tumor.  In ovarian cancer, 
infiltrating DCs had progressively increasing PD-1 expression over time, and these PD-1+ DCs 
were found to be suppressive in function [33] PD-1 ligation suppressed NF-kB activation, 
release of immune regulatory cytokines, and upregulation of co-stimulatory molecules.  In 
ovarian cancer, PD-1 blockade reduced tumor burden and increased antigen-specific T cell 
responses through increased function of DCs.  This study suggests that PD-1 ligation on DCs 
reduces their functional capabilities, but this deficiency is able to be reversed by PD-1 blockade 
[117].  Additionally, in a mouse model of hepatocellular carcinoma, PD-1 expression on DCs 
suppressed CD8+ T cell function and anti-tumor immunity.  They also demonstrated that in 
patients with hepatocellular carcinoma, CD11c+ infiltrating DCs express PD-1 [118].  PD-1 
expression has also been shown to be detrimental during DC maturation as blocking PD-1 
resulted in enhanced DC survival and immunostimulatory properties [119].  This implies that if 
PD-1 expressing DCs migrate into the TME, PD-1 ligation could lead to an arrest in a suppressive 
DC state.  While there are currently no studies on the effects of PD-1 blockade on intra-tumoral 
DCs in humans, pre-clinical data suggests that PD-1 blockade could have a positive effect on DC 
immunostimulatory properties.        
B Cells 
B cells are part of the adaptive immune response and with CD4+ T cell help, differentiate 
to produce antigen-specific antibodies.  There is some evidence that B cells can express PD-1, 
but similar to NK cells, only a small percentage of B cells may express PD-1 and it is unclear the 
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stimulation needed to upregulate PD-1.  One group has shown that BCR signaling on B cells can 
induce expression of PD-1, which can inhibit proliferation as well as cytokine production upon 
ligation [120].  Only two studies have addressed the role of PD-1+ B cells in cancer.  In a study 
involving patients with differentiated thyroid tumors, PBMCs and tumor samples were taken 
from patients and the researchers saw an increased number of PD-1+ B cells in the tumors of 
these patients.  In in-vitro studies, only continuous, long-term anti-Ig plus CD40L stimulation 
was able to induce expression of PD-1 and PD-L1 on B cells.  They went on to show that PD-1+ B 
cells could suppress the proliferation of CD4 and CD8 T cells during stimulation with CD3/CD28, 
but this suppression was found to be due to expression of PD-L1 rather than PD-1 [121].  
Another study in patients with hepatocellular carcinoma found a pro-tumorigenic subset of 
regulatory B cells that express high levels of PD-1.  These PD-1+ B cells were shown to suppress 
tumor specific T cell function and promote cancer growth [122].  Several studies done in breast 
cancer models and patients with invasive breast cancer have shown PD-L1+ B cells play a role in 
suppressing T cell anti-tumor immune response, but these studies concluded the PD-1 ligand, 
PD-L1 was responsible for this suppression as these B cells did not express the PD-1 inhibitory 
receptor [123-125].  Most of these studies saw tumor-infiltrating B cells were acting in a 
regulatory capacity.  If PD-1 expression on B cells alters tumor specific antibody production is 
unknown.  It also remains to be determined if PD-1 expression on B cells has a significant role to 
play during checkpoint blockade in cancer. 
T follicular helper/regulatory cells 
T follicular helper cells (Tfh) and follicular regulatory cells (Tfr) are cells found in 
germinal centers of secondary lymphoid organs along with B cells.  Tfh cells provide the co-
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stimulation and cytokines necessary for B cells to undergo antibody diversification and 
differentiate into plasma cells or memory B cells.  Tfr cells are also found in the germinal 
centers and are found to regulate Tfh cells and shape the germinal center by production of 
cytokines and direct cell to cell interactions with Tfh cells and B cells.  Both of these cell subsets 
express a high level of PD-1.  In Tfh cells though it appears that the function of PD-1 is 
independent of TCR stimulation [126].  PD-1 restricted CXCR3 expression on Tfh cells results in 
positioning these cells in the germinal center [126].  PD-1 has also been shown to regulate 
selection and survival of Tfh cells during the contraction phase of the germinal center [127].  
While PD-1 is highly expressed on Tfh cells, it appears that it does not function in a way similar 
to other T cell subsets and may regulate Tfh cell motility and position.  Very little is known how 
PD-1 might function in Tfr cells.  There have been two studies published and both suggest that 
PD-1 on Tfr may limit their function.  Tfr cells from mice deficient in PD-1 resulted in greater 
abundance of these cells with enhanced suppressive abilities [128].  Another study found that 
Tfr cells circulating in the blood were inhibited by PD-1 ligation with PD-L1 [129].  While these 
studies do not definitively define the role of PD-1 on Tfr cells, they suggest that PD-1 may affect 
the function of these cells rather than positioning.  It is unknown if Tfr cells would be affected 
by PD-1 blockade in the germinal centers, but the circulating cells could possibly be affected if 
PD-1 binding is blocked.     
Regulatory T cells  
Regulatory T cells (Tregs) are known to play an important role in suppression of the tumor 
microenvironment.  They also express high levels of PD-1 [130].  In chronic viral infections, 
blocking PD-1 seems to lead to enhanced Treg function in Tregs from livers of patients chronically 
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infected with hepatitis C virus [131].  Because Tregs are a major regulator of the anti-tumor 
response, it is important to know if PD-1 blockade also alters the function of these cells in the 
TME.  There has been conflicting literature on the effect of PD-1 on Tregs in the cancer setting.  
PBMCs from healthy donors and breast cancer patients treated in vitro with anti-PD-1 did not 
affect Tregs [132].  Also, in a study looking at PD-1+ Tregs in melanoma patients undergoing PD-1 
blockade, they found a decrease of PD-1+ Tregs in the blood of patients after the first cycle of 
anti-PD-1 treatment [133].  It is possible that in this study what they observed was either a 
downregulation of PD-1 after checkpoint therapy, or a steric hinderance from the blocking 
antibody keeping the fluorescent antibody from binding to the same epitope.  The number of 
Tregs may have not decreased, but rather PD-1 binding was prevented.  Several studies to date 
suggest that PD-1 blockade may increase the proliferation of Tregs.  In patients with melanoma 
treated with the PD-1 blockade nivolumab, peripheral Tregs cultured ex vivo with PD-1 blocking 
antibody resulted in an increase in Treg percentages and Il-10 production [134].  In mouse 
squamous cell carcinoma, PD-1 blockade enhanced Treg to T effector cell ratios suggesting 
increased Treg numbers [135].  In a recent study with Tregs isolated from patients with gastric 
cancer, PD-1+ Tregs were amplified by PD-1 blockade ex vivo.  These Tregs were highly activated 
and ex vivo culture with PD-1 blocking antibody increased their suppressive capabilities [136].  
This study notes that in gastric cancer patients, about 10 percent of patients have rapid cancer 
progression called hyperprogressive disease after receiving PD-1 inhibitor therapy.  It is 
hypothesized that this could be due to the increased immunosuppression due to amplification 
of Tregs in the tumor after PD-1 blockade.  Additionally, two other recent studies indicate that 
patients with advanced non-small cell lung cancer undergo hyperprogressive disease after PD-1 
 23 
blockade [137 138].  These studies point to a potentially serious consequence of PD-1 blockade 
on Tregs in the cancer immunotherapy setting.  Increasing evidence points to the possibility that 
while PD-1 blockade is able to reinvigorate CD8+ cytotoxic T cells in the tumor, it is also able to 
increase immune suppression due to enhanced Tregs.  This would negate any positive effects 
from checkpoint therapy for the patient.  
1.6 Dissertation Aims 
Immunotherapy is a valuable advancement for the field of cancer therapy.  Traditional 
cancer treatments, such as chemotherapy and radiation, have systemic effects and adverse 
consequences that can lead to discomfort for the patient.  Immunotherapy, on the other hand, 
allows for a more specific response by boosting the tumor-specific immune cells and promoting 
tumor elimination.  While immunotherapy has seen high response rates in some cancers, in 
others only a small fraction of patients benefit from immune checkpoint therapy.  Many 
researchers are attempting to find biomarkers that would allow us to predict who would 
respond to checkpoint therapy.  The current paradigm is that immune infiltrated tumors should 
respond to checkpoint inhibition, but this is not always the case.  Triple negative breast cancer 
has a poor clinical prognosis and no current targeted therapies.  Unfortunately, most triple 
negative breast cancer patients do not benefit from immunotherapy despite immune 
infiltration into the tumors.  This dissertation aims to address ways to improve immunotherapy 
in models of cancer, specifically in a model of claudin-low breast cancer.  To address ways to 
improve immunotherapy, we undertook three projects looking at improving checkpoint 
blockade in cancer.  First, we evaluated several models of breast cancer and found the heavily 
immune infiltrated claudin-low subtype could benefit from checkpoint inhibition only in the 
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context of specific and complete Treg depletion.  Second, we studied the role of PD-1 blockade 
on Tregs in a model of claudin-low breast cancer and found that PD-1 blockade increased 
proliferation and survival of Tregs in the TME.  Third, we observed the role of PD-1 expression on 
NK cells in cancer and chronic viral infection.  Our work contributes to the field of 
immunotherapy the knowledge that while tumors may be heavily immune infiltrated, a more 
thorough analysis of the TME should be done.  Multiple subsets of immune cells in the TME 
expressing PD-1 can potentially be affected by checkpoint blockade, and if there are significant 
numbers of immunosuppressive cells, such as Tregs, then the patient might not benefit from 
checkpoint therapy.                   
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CHAPTER 2: REGULATORY T CELL DEPLETION POTENTIATES CHECKPOINT INHIBITION IN 
CLAUDIN-LOW BREAST CANCER 
 
2.1 Introduction   
Breast cancer is the leading cancer diagnosis and second-leading cause of cancer death 
for women in the United States [1].  Patient prognosis is determined largely by stratification 
based on age, lymph node involvement, tumor grade, and tumor cell-surface expression of 
Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor 
Receptor 2 (HER2) [2-7].  Early diagnosis and targeted therapies, both hormonal and 
1immunologic, are critical for the effective treatment of ER, PR and HER2-positive disease.  
Given the lack of targeted therapies for patients whose tumors do not express ER, PR, and 
HER2, termed triple-negative breast cancers, the survival benefit from recent therapeutic 
advances has eluded this group of patients.  This is especially important for clinicians and 
patients, as triple-negative tumors present with higher grade at diagnosis and an increased 
incidence for disease relapse, early metastasis, and death [8-11]. 
                                                        
1This chapter contains a manuscript published in the Journal of Clinical Investigation on which I 
am co-first author.  I performed experiments for Figure 2 and Figure 8 in the manuscript and 
Supplementary Figures 1, 4, 5, 7, 8, and 9.  JS Serody, NA Taylor, and BG Vincent wrote the 
original draft, and I revised the manuscript and performed all experiments after peer review.  
The original citation is: Taylor NA*, Vick SC*, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, 
Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS.  Treg depletion 
potentiates checkpoint inhibition in claudin-low breast cancer.  J Clin Invest 2017 Sep 
1;127(9):3472-3483.      
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 Transcriptome profiling has defined five intrinsic molecular subtypes of breast cancer: 
Luminal A, Luminal B, HER2-Enriched, Basal-like, and Claudin-low [12 13].  The basal-like and 
claudin-low subtypes are distinguished by increased expression of genes associated with tumor 
cell proliferation and adaptive and innate immunity [14 15].  Claudin-low tumors are further 
separated from basal-like tumors by their decreased expression of cell-cell adhesion claudin 
proteins, increased expression of genes associated with epidermal-to-mesenchymal transition, 
and stem cell-like characteristics [16].  Importantly, basal-like and claudin-low tumors comprise 
the majority of triple-negative tumors and have a significantly poorer prognosis than luminal 
and HER2-enriched tumors [17]. 
 In addition to tumor-intrinsic genetic features, tumor growth is dependent on tumor-
extrinsic factors, which include the tumor stroma and the local immune response [14 18].  
Tumor-infiltrating lymphocytes (TILs) can have divergent effects in the tumor 
microenvironment (TME).  Whereas the presence of multiple immune cell types may herald 
productive anti-tumor immunity [15], TILs may also contribute to tumor progression through 
immune suppression or the production of soluble factors that regulate cell proliferation, 
migration, and angiogenesis [19].   
While the presence of TILs is associated with an improvement in the survival of patients 
with multiple different tumor subtypes, this has not been found for specific subtypes of breast 
cancer.  The luminal A subtype, which exhibits no appreciable immune infiltration, carries the 
best prognosis, whereas the basal-like and claudin-low subtypes exhibit a marked immune 
infiltrate with worse clinical outcomes [20].  In this study we sought to understand the 
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mechanism by which immune infiltration is associated with a poor clinical outcomes for 
patients with claudin-low tumors.  
We show that patients with claudin-low tumors have an increased number of CD4+ T 
cells with focal increases in regulatory T cells (Tregs) in the TME compared to other intrinsic 
subtypes.  To understand the mechanism for this, the p53-/- T11 and T12 genetically engineered 
mouse models (GEMM) were used, which closely recapitulated the cell intrinsic and extrinsic 
characteristics of human claudin-low breast cancer.  In human and mouse studies, gene 
expression profiling revealed increased expression of immune genes and Treg associated genes 
in the claudin-low subtype.  Importantly, checkpoint inhibition was found to be effective for 
claudin-low tumors only combined with stringent Treg depletion.  Taken together, these 
experiments highlight the role of Tregs in suppressing the immune response in claudin-low 
breast tumors and provide a new understanding of the differential response to immune 
checkpoint inhibition in breast cancer. 
2.2 Methods 
Mice and cell lines 
BALB/cJ and C57Bl/6J (B6) females and C.B6-Tg(Foxp3-DTR/EGFP)23.2Spar/Mmjax (DEREG) 
were purchased from The Jackson Laboratory (Bar Harbor, ME).  Neu-N mice were purchased 
from Charles River Laboratory (Wilmington, MA).  Female mice (8-14 weeks) were used for all 
experiments.  Rat Neu-expressing NT2 cells (HER-2/Neu) and the 2250 (luminal A), 2225 (basal-
like), and T11 (claudin-low) tumor models have been described [21-23].  T12 cells were 
prepared by harvesting a T12 tumor from a tumor bearing mouse, followed by manual 
digestion with razor blades and chemical digestion with Liberase TM (Roche, Basel, Switzerland) 
 43 
and DNase I (Sigma-Aldrich, St. Louis, MO).  Digestion was stopped by addition of EDTA.  2250 
cells were prepared by harvesting a 2250 tumor from a tumor-bearing mouse, followed by 
manual digestion with razor blades and chemical digestion as described above.  BALB/c mice 
were injected with 1 x 106 2250 cells (luminal A) in Matrigel HC Low Growth Factor, 1x104 or 
1x105 T12 (claudin-low) cells in Matrigel HC Low Growth Factor, or 1 x 104 T11 (claudin-low) 
cells in PBS.  Neu-N mice were injected with 5 x 104 NT2 cells (Neu) in PBS.  Tumors were 
orthotopically transplanted by intradermal injection into a mammary fat pad and measured as 
previously described (11).  Blood and serum samples were harvested by cardiac puncture at the 
termination of the experiment. 
Human breast tumor microarray data sets 
All human tumor and normal tissue samples were obtained from fresh frozen invasive 
breast carcinomas that were profiled, as described previously, using oligo microarrays (Agilent 
Technologies, Santa Clara, CA) (18, 19).  We used the microarray data set previously published 
as the UNC337 data set (GEO accession number: GSE18229) (4).  All microarray and patient 
clinical data are available in the University of North Carolina Microarray Database (20).  The 
probes for all analyses were filtered by requiring the lowest normalized intensity values in both 
sample and control to be greater than 10.  The normalized log2 ratios cyanine-5 (Cy5) dye 
intensity for experimental sample/cyanine-3 (Cy3) dye intensity for reference of probes 
mapping to the same gene (EntrezGene ID as defined by the manufacturer) were averaged to 
generate independent expression estimates.  The METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) dataset contains 1,981 samples derived from breast tumors 
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of patients participating in the METABRIC trial [24].  Gene expression data acquired by Illumina 
HT 12 microarrays.  
Mouse breast tumor microarray data sets 
 All mouse samples from fresh frozen invasive breast carcinomas, were analyzed as 
described previously, using Agilent mouse oligo microarrays (18).  Data normalization and 
preprocessing were identical to that described for the UNC337 data set.  We used 2 samples 
obtained from the combined data set previously published (GEO accession numbers: GSE3165, 
GSE8516, GSE9343, GSE14457, GSE15263, GSE17916, GSE27101, and GSE42640) (21).  The 
remaining 57 samples represent newly obtained tumor samples using methods approved by 
IACUC guidelines.  Total RNA was purified from 20 to 30 mg of mouse mammary tumor using 
the Qiagen RNeasy Mini Kit (Valencia, CA) following the manufacturer’s protocols.  RNA 
quantity and quality were determined using the Nanodrop spectrophotometer and Agilent 
Bioanalyzer, respectively.  Total RNA was reverse transcribed and labeled with Cy5 dye for 
experimental samples and Cy3 dye for mouse reference samples using the Agilent Low RNA 
Input Fluorescent Linear Amplification Kit (18).  Equal quantities of labeled mouse reference 
RNA and tumor RNA were co-hybridized overnight to Agilent microarrays, washed, scanned, 
and signal intensities were determined. 
Microarray data analysis 
 Hierarchical clustering of the UNC337 data set to group samples by intrinsic subtype was 
performed using the intrinsic gene list as described. (22).  Centroid linkage hierarchical 
clustering was performed using Cluster v3.0 (23).  Student’s t-tests for gene expression data 
were performed using R (24). 
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H&E and Immunofluorescence analyses of patient samples 
 Staining was performed on tumor infiltrating lymphocytes in 85 breast cancer whole 
tissue sections (WTS) obtained from UNC hospitals surgical pathology archive.  
Immunohistochemistry (IHC) and dual immunofluorescence (IF) on WTS with immune infiltrates 
were performed in the Bond fully-automated slide staining system using Bond Polymer Refine 
Detection kit (DS9800, Leica Microsystems, Norwell, MA).  Slides were deparaffinized in Bond 
Dewax Solution (AR9222) and hydrated in Bond Wash Solution (AR9590).  Antigen retrieval was 
done at 100oC either in Bond Epitope Retrieval Solution 1 pH6.0 (AR9661) or in Solution 2 pH 
9.0 (AR9640).  IHC slides were visualized with the 3,3’-diaminobenzidine (DAB) and 
counterstained with hematoxylin using Bond Polymer Refine Detection.  Stained slides were 
dehydrated.  IF slides were counterstained with Hoechst 33258 (Invitrogen, Carlsbad, CA) and 
mounted with ProLong Gold antifade reagent (P36934, Life Technologies, Waltham, MA).  
Tumor tissue slides (n = 10 per subtype) were stained for CD8, CD4, and FoxP3 and analyzed for 
co-expression at the cellular level using TissueStudio on-slide cytometry to measure tumor 
infiltration by Tc (CD8+), Th (CD4+FoxP3-), and Treg (CD4+FoxP3+) cells.  All samples were 
evaluated by pathologists blinded to the tumor subtype.   
Imaging and digital image analysis 
 H&E and IF (CD4, CD8, CD19, and FoxP3) stained slides were digitally imaged at 20X 
magnification using the Aperio ScanScopes XT and FL (Aperio Technologies, Vista, CA).  The 
hematoxylin and DAB OD parameters were adjusted for both algorithms.  The nuclear 
segmentation factor and the weak positive threshold were tuned for the cytoplasmic v2 and the 
color deconvolution v9 algorithms, respectively.  High-resolution acquisition (20X objective) of 
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the stained slides in the DAPI, Cy3 and Cy5 channels was performed in the Aperio ScanScope FL 
(Aperio Technologies).  Cell nuclei were visualized in DAPI channel (blue); CD8, CD19, and FoxP3 
were visualized in the Cy3 channel (green); CD4 was visualized in the Cy5 (red) channel.  To 
determine the number of cells co-expressing FoxP3/CD4, slides were analyzed using the 
Definiens Tissue Studio image analysis software (Architect XD v 2.0.4, Tissue Studio v 3.5, 
Munich, Germany). 
Antibodies and flow cytometry reagents 
 Human antibodies: Mouse monoclonal antibodies against human CD4 (clone 4B12), CD8 
(clone 4B11), and CD19 (clone BT51E) were purchased from Leica Microsystems.  FoxP3 (clone 
236A/E7) was purchased from Abcam (Cambridge, MA).  CD279 (PD-1, clone J105) was 
purchased from eBioscience (San Diego, CA).  
 Mouse antibodies: Flow cytometry monoclonal antibodies against murine CD4 (GK1.5 or 
RM4-5), CD8 (53-6.7), PD-1 (J43 or RMP1-30), CD45 (30-F11), CD62L (MEL-14), and CXCR4 
(2B11) were purchased from eBioscience. CD19 (6D5) and CD44 (IM7) were purchased from 
BioLegend.  Intracellular antibodies FoxP3 (FJK-16s), TNF (MP6-XT22), and IFN-γ (XMG1.2), and 
Helios (22F6) were purchased from eBioscience.  Cell viability was determined using Blue or 
Aqua Fluorescence Reactive Dye (Life Technologies).  
 Flow cytometry: Cells were surface stained, fixed/permeabilized overnight using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience), and intracellular staining 
performed the following day according to manufacturer’s instructions.  Data were acquired 
using the MACSQuant (Miltenyi Biotec, Cambride, MA), BD Canto or LSR II (BD Biosciences, San 
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Jose, CA).  Acquired data were analyzed using FlowJo Flow Cytometry Analysis Software (Tree 
Star Inc., Ashland, OR). 
Isolation of murine tumor-infiltrating lymphocytes (TILs) 
 Murine tumors were resected and digested in Liberase TM (Roche), DNase I (Sigma), 
Hyaluronidase (Sigma), and Collagenase XI (Sigma), as previously described (25).  Single cell 
suspensions were enriched for lymphocytes by isolating cells at the interface of a 44% Percoll 
(Sigma) in media and Lympholyte-M (Cedarlane, Burlington, NC) gradient.  Isolated cells were 
stimulated for 4 hours in PMA/ionomycin prior to intracellular cytokine staining.  
In vivo cell inhibition and depletion 
 Monoclonal antibodies used for in vivo antibody inhibition and depletion were 
purchased from BioXCell (West Lebanon, NH) or obtained from the laboratory of Bruce Blazar 
(anti-PD-1 mAb).  Mice undergoing immune checkpoint inhibition received intraperitoneal (i.p.) 
injection of 100 μg anti-CTLA-4 (9D9), 200 μg anti-PD-1 (J43), or isotype antibody on day -1 
post-tumor implantation (PTI) and then every other day throughout the experiment [25 26].  
 Mice undergoing regulatory T cell (Treg) depletion (Foxp3DTR mice) received i.p. 
injections of 1 μg diphtheria toxin in PBS on day -1, +1, +6, and +7 (27). 
Mice undergoing specific inhibition of p110δ PI3K were given drug (75 mg/kg PI-3065, once 
daily) or vehicle (0.5% methylcellulose with 0.2% Tween 80) by oral gavage from day +1 for the 
duration of the experiment [27].  
Treg suppression assay 
 For the Treg suppression assays we evaluated splenic Tregs.  FoxP3+GFP+ cells were sorted 
using a MoFlo cell sorter (Beckman Coulter, Pasadena, CA).  Stimulator cells were isolated from 
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WT B6 splenocytes following CD90 microbead-depletion (Miltenyi) and irradiation at 2100 cGy.  
Responder cells were isolated from WT BALB/c mice using the Cedarlane T recovery column kit.  
Isolated cells were then B220 and CD25 depleted using phycoerythrin (PE) conjugated 
antibodies and anti-PE magnetic bead sorting (Miltenyi).  Responder cells were stained with the 
Cell Proliferation Dye eFlour 670 (eBioscience) and plated at varying Treg:TEffector cell ratios.  Cells 
were co-cultured for 3 days, stained, and FACS analyzed. 
Real-time PCR array 
 Whole tumor RNA was isolated using RNEasy kit (Qiagen) and reverse-transcribed.  Real-
time PCR was performed on the ABI 7300 (Applied Biosystems Inc.), using master mix from the 
Mouse Inflammatory Cytokines and Receptors (PAMM-011) RT2 Profiler PCR Array System 
(Qiagen).  Ct values were determined by the ABI software.  Data analysis was performed using 
the web-based RT2 Profiler PCR Array Data Analysis version 3.5 (Qiagen).  
AMD3100 and Cyclophosphamide 
 Alzet osmotic pumps, model 2002 (Alza, Palo Alto, CA), were loaded with 10 mg 
AMD3100 (Tocris, Bristol, UK) in PBS or PBS alone (28).  Pumps were subcutaneously implanted 
dorsally on day -2.  Mice were then challenged with 1 x 104 T11 cells and tumors were 
harvested 12 days later at approximately 20 mm2 in accordance with IAUCU guidelines.  For low 
dose cyclophosphamide studies, a single dose of 100 mg/kg cyclophosphamide was given after 
tumor injection.  This dose is sufficient to deplete 60% of the Tregs for approximately 8 days with 





 T11 cells were treated with 4 μg/mL Polybrene and cultured overnight with Mission 
shRNA Lentiviral Transduction Particles (Sigma-Aldrich, St. Louis, MO) containing shRNA specific 
for CXCL12 or a non-target control (“Scramble”) at an MOI of 10.  Lentiviral particles were 
removed the next morning and new media was added.  The following day, cells were cultured in 
media containing 6 μg /mL puromycin and expanded to select for transduced cells.  Cells were 
tested for CXCL12 production by real-time PCR and ELISA.  Two different knockdown cell lines 
with different levels of knockdown of CXCL12 as evaluated by ELISA assay were characterized.  
Knockdown of CXCL12 had no impact on the growth of T11 cells in vitro (data not shown).  
Statistics 
 Data are presented as mean ± standard error of the mean (SEM).  Statistical differences 
were determined using Student’s t-test, Mann-Whitney test, or Kruskal-Wallis test, with Dunn’s 
post-test for multiple comparisons, where appropriate.  Survival data are presented using the 
Kaplan-Meier survival analysis.  Survival results were analyzed using the Log-rank test.  
Statistical analyses were conducted using GraphPad Prism 6 software, unless otherwise noted.  
Results were considered statistically significant (*) if p ≤ 0.05. 
Study Approval 
 All animal experiments were conducted in accordance with protocols approved by the 
University of North Carolina Institutional Animal Care and Use Committee (IACUC).  All human 




Claudin-low tumors show increased expression of immune genes relative to other intrinsic 
subtypes of breast cancer.   
 
The original microarray used to classify the intrinsic subtypes of breast cancer included 
over 1700 genes [28 29], with an emphasis on cell intrinsic transcriptional characteristics.  We 
were interested in determining if there were cell extrinsic transcriptional differences that could 
be used to classify breast cancer subtypes.  For this analysis, we evaluated the expression of 
102 immune genes that encompass downstream effector molecules, chemokines and 
chemokine receptors, immune response signal mediators, cell-specific markers, and markers of 
oxidative stress, termed the Intrinsic Immune Genes.  Gene expression profiling by microarray 
analysis was done on three-hundred and thirty-seven breast tumors as previously described 
[30].  Unsupervised hierarchical clustering of UNC337 by only those genes in the IIG list divides 
patients into three clusters: low-expressing luminal, moderate expressing HER-2 enriched, and 
high expressing basal-like and claudin-low tumors (Figure 1A).  By gene expression signature 
quantification, HER2 expressing tumors had significantly lower immune gene expression than 
claudin-low tumors (p < 0.05)(Figure 1B).  Furthermore, claudin-low tumors showed 
significantly increased expression of a gene-signature associated with Treg activity (p = 0.001, 
data not shown).  To confirm these findings, we performed transcriptome evaluation using the 
IIG classifier from a previous published breast cancer database (METABRIC) as the stringency 
filter for tumor purity eliminated the inclusion of claudin-low tumors from the TCGA database. 
Unsupervised hierarchical clustering of the METABRIC data by only those genes in the IIG list 
revealed that clinical breast cancer samples divided into three clusters: low-expressing luminal, 
moderate expressing HER-2 enriched, and high expressing basal-like and claudin-low tumors 
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similar to the UNC337 data (Supplementary Figure S1).  The claudin-low subtype had a 
significantly increased immune gene expression compared to the other subtypes in the 
METABRIC dataset (p<0.0001).      
Claudin-low breast tumors show increased infiltration by CD4+ cells.    
In order to determine whether IIG expression was associated with differences in tumor-
infiltrating helper (Th), regulatory (Treg), or cytotoxic T cells (Tc), patient biopsy samples were 
studied by histology and immunofluorescence (IF).  Figure 1C shows H&E stains of the greatest 
area of immune infiltration of a representative luminal A and claudin-low tumor.  Tumor tissue 
slides were analyzed for Tc (CD8+), Th (CD4+FoxP3-), and Treg (CD4+FoxP3+) cells.  Representative 
images of CD4 (red) and FoxP3 (green) IF staining from the highlighted areas shown in Figure 1C 
demonstrate CD4+FoxP3+ cell infiltration into the tumor (Figure 1D).  Claudin-low tumors recruit 
significantly more CD4+ T cells to the tumor site than luminal A tumors (p = 0.002; Figure 1E) 
with areas of focally increased numbers of Tregs (Figure 1D).  No difference in the number of 
CD8+ T cells was found across the different intrinsic subtypes (data not shown).  These data 
indicate the heterogeneity of the immune response in breast cancer subtypes with claudin-low 
tumors having a significant T cell infiltrate dominated by the presence of CD4+ T cells and focally 
increased numbers of Tregs.  In contrast, luminal tumors showed an extremely limited number of 
CD8+ and/or CD4+ T cells.  
Claudin-low genetically-engineered mouse models (GEMM) closely recapitulates human claudin-
low breast cancer.   
 
Given the difficulties with standardizing tumor latency using clinical samples and the 
extreme difficulty evaluating the tumor microenvironment at the onset of tumor formation, we 
sought an in vivo method to better evaluate mechanisms for immune infiltration in claudin-low 
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breast cancer.  For this analysis, we used genetically engineered mouse models (GEMM) of the 
claudin-low subtype, which have been found to be genotypically similar to human claudin-low 
tumors [31].  Unsupervised clustering of the GEM models using the IIG list (Figure 1F) recreated 
the clustering profile seen in human samples with very modest expression of immune genes in 
2250 tumors (luminal A) compared to very high expression in T11 tumors (claudin-low).  We 
generated a cell line from T11 tumors to standardize claudin-low tumor growth in vivo.  Gene 
expression profiling of these tumors showed that the parental T11 tumor and tumors derived 
from injection of the T11 cell line cluster tightly together within the claudin-low subtype, 
demonstrating that T11 cell line is genetically quite similar to T11 tumor cells (Supplementary 
Figure S2).   
Claudin-low tumors recruit increased numbers of immune cells to the tumor.   
Tumors representing the subtypes luminal A, HER2/Neu, and claudin-low were studied 
in GEMMs to evaluate the immune response during tumor progression.  In order to evaluate 
both early and late time points, tumors were harvested at approximately 20 mm2 (Figure 2A – 
2D) or 100 mm2 (Figure 2E – 2H) respectively, and analyzed by flow cytometry to determine the 
composition of TILs over time.  FACS analysis workflows are shown as Supplementary Figure S3 
and representative FACS plots are shown as Supplementary Figure S4.  The total number of 
immune cells was significantly increased in T11 claudin-low tumors (Figure 2A-2H).  Specifically, 
the number but not the frequency of CD4+FoxP3- T cells was increased in the tumor 
microenvironment in both 20mm2 and 100 mm2 tumors (Figure 2A, 2E).  Interestingly, we found 
an increase in the number of Tregs both at 20mm2 and 100mm2 in the T11 claudin-low model.  
There was a statistically significant increase in the number of CD19+ B cells in mice with 20 mm2 
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T11 claudin-low compared to Neu tumors and a significant increase in B cells in mice with 100 
mm2 T11 tumors compared to luminal A tumors (Figure 2C, 2G).  Additionally, we found very 
few CD8+ T cells in the TME of mice with either luminal A or Neu-expressing tumors.  There was 
a statistically significant increase in the number and frequency of CD8+ T cells in mice with 20 
mm2 and 100 mm2 claudin-low tumors.  There was an inverse correlation between the presence 
of Tregs and diminished number of both CD8+ T cells and CD19+ B cells (Figure 2I, 2J).  To confirm 
our results were not specific to the T11 cell line, we utilized an additional claudin-low tumor cell 
termed T12 to examine immune infiltration into the TME at late stage tumor growth.  We found 
an increase in Tregs in mice with 100mm2 tumors in the T12 model although the increase was 
not significant.  We investigated the activation status of the cells migrating into the TME by 
looking at naïve and memory T cell populations (Supplementary Figure S5).  Compared to 
luminal A and Neu-expressing tumors, the T11 and T12 claudin-low tumors had increased 
effector memory cells in both the CD4+FoxP3- and CD8+ T cell populations. (Supplemental Figure 
S5B, S5D). Thus, these data indicated that there was a significant difference in the population of 
immune cells in the TME in mouse luminal A, Neu-expressing or claudin-low tumors.  
Additionally, our data suggest that the early presence of Tregs was associated with diminished 
numbers of CD8+ T cells and B cells in mice with claudin-low tumors.   
Tregs in mice with tumors show enhanced suppression and chemokine production.  
Next, we evaluated whether the regulatory T cells isolated from tumor-bearing mice 
were efficient at suppressing T cell responses.  As shown (Figure 3A, 3B), Tregs were capable of 
suppressing T cell proliferation in a mixed lymphocyte reaction assay.  At high ratios of 
Treg:Teffectors, Tregs were more effective when isolated from mice with 100 mm2 compared to 20 
 54 
mm2 tumors.  Thus, tumor-bearing mice have functional Tregs that displayed enhanced 
suppression in mice with larger tumors.  To determine what mediators were responsible for 
recruiting Treg cells to the claudin-low tumor site, we compared gene expression differences 
between Neu-expressing and claudin-low tumors (Figure 4A).  T11 tumors expressed 
significantly higher levels of multiple chemokines, with CXCL12 being 22-fold higher expressed 
(95% CI: 17.1 – 28.3; p < 0.001) compared to Neu-expressing tumors.  ELISA of tumor 
homogenate for CXCL12 confirmed the array findings, with claudin-low tumors expressing 
higher levels of CXCL12 protein than Neu-overexpressing tumors (Figure 4B).  Elevated levels of 
CXCL12 protein were also found in the serum of claudin-low-tumor bearing mice (Figure 4C).  
Treg cells that infiltrate T11 tumors demonstrated higher expression levels of CXCR4, a receptor 
for CXCL12, compared to conventional CD4+ T cells (p = 0.03) or CD8+ T cells (p = 0.003; Figure 
4D and 4E).  To evaluate whether the CXCL12/CXCR4 axis was critical to the recruitment of Treg 
cells in mice with claudin-low tumors, mice were treated with the CXCR4 inhibitor AMD3100.  
There was a trend toward decreased Treg cell number in AMD3100 treated mice (Figure 5A), 
which was greater when comparing the number of FoxP3+PD-1+ Treg (p = 0.07) cells (Figure 5B).  
To further evaluate whether the CXCL12/CXCR4 axis was critical to the recruitment of Treg cells, 
shRNA knockdown of CXCL12 was achieved by lentiviral expression of CXCL12-targeted shRNA 
into T11 tumor cells. (Figure 5C, 5D).  We generated two cell lines, one with a 55% knockdown 
of CXCL12 (KD1) and one with an 85% knockdown (KD5).  There was a non-significant reduction 
in both Tregs and PD-1+ Tregs in the TME using the more robust knockdown of CXCL12 at day 13 
post tumor implantation (Figure 5E, 5F).  Thus, these data indicate that inhibition of the 
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CXCL12/CXCR4 axis in vivo had a modest but not significant effect on Treg accumulation in 
claudin-low tumors.   
Checkpoint inhibition therapy does not alter T11 tumor growth.  
Because of the increased number of immune cells infiltrating the tumor, we 
hypothesized that the T11 claudin-low model would be responsive to checkpoint inhibition 
therapy with blocking antibodies against the inhibitory receptors programmed death receptor 1 
(PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4).  Surprisingly, checkpoint 
inhibition therapy conferred no benefit on tumor growth or survival in the T11 claudin-low 
model (Figure 6E-6F), despite expression of PD-1 on CD8+ T cells (Figure 6A).  This result was 
confirmed in the T12 claudin-low model (Supplementary Figure S6).  However and 
unexpectedly, FACS analysis of the immune cells infiltrating the tumor showed that Tregs, had 
the highest level of PD-1 and CTLA-4 expression as measured by FACS mean fluorescence 
intensity (Figure 6A-6D).  
Depletion of regulatory T cells delays T11 tumor growth.   
The inverse correlation between the presence of Tregs and the absence of CD8+ T cells 
and CD19+ B cells in the TME (Figure 2I and 2J) led us to hypothesize that approaches that 
target Treg cells would enhance the anti-tumor immune response.  To deplete Tregs, we made 
use of mice in which the diphtheria toxin receptor had been knocked-in to the FoxP3 locus 
(DEREG mice), and treated with diphtheria toxin (DT) to specifically deplete Treg cells in vivo.  
DEREG mice given DT exhibited a significant delay in tumor growth and a non-significant 
improvement in survival (Figure 7A and 7B), with all mice eventually succumbing to either 
autoimmunity or tumor.  As an alternative non-genetic approach to treatment, tumor bearing 
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WT mice received a single treatment of low-dose (100 mg/kg) cyclophosphamide (Cy) to 
selectively deplete Treg cells [32].  As with DT treatment of DEREG mice, a single injection of low-
dose Cy significantly delayed tumor growth (Figure 7A and 7B), but, again, all mice eventually 
succumbed to death upon tumor administration.  While Treg cell numbers were decreased 
compared to untreated T11 tumors after cyclophosphamide, they had increased to above 
baseline by the time tumors reached 20 mm2 (Figure 7C).  Thus, Treg depletion alone appeared 
to modestly impact tumor growth.   
 
Depletion of regulatory T cells plus checkpoint inhibition improves survival and increases 
cytokine production by CD8+ T cells.   
 
While depleting regulatory T cells delayed tumor growth, we evaluated whether 
addition of checkpoint inhibition therapy would enhance the benefit.  Given the finding that 
blocking CXCR4 had a modest effect on the recruitment of Tregs in T11 tumors, we initially 
evaluated if combing checkpoint inhibition with AMD3100 would impact on tumor growth.  
There were no synergistic effects between CXCR4 inhibition and checkpoint inhibition, as we 
found no difference in tumor growth using combined checkpoint inhibition and control 
treatment or AMD3100 (Supplementary Figure S7A and S7B).  Mice receiving AMD3100 had a 
reduction in Tregs 12 days after the onset of treatment (Supplementary Figure S7C and S7D), but 
by day 16 the reduction in infiltrating immune cells was no longer specific to Tregs as we saw a 
reduction in CD4+ and CD8+ T cells (Supplementary Figure S7E and S7F).  When combined with 
checkpoint inhibition, all cell subsets were significantly reduced in the TME (Supplementary 
Figure S7C-S7E).  As a more rigorous test, Tregs were depleted using DT treatment in DEREG mice 
in combination with anti-CTLA-4 and anti-PD-1 monoclonal antibody treatment.  Tregs were 
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depleted from approximately 20% to 5% after DT treatment (Figure 8F).  T11 tumor-bearing 
mice were followed for 25 days post tumor injection until tumor growth reached 170mm2 or 
mice developed significant autoimmunity from Treg depletion.  Treg depletion in combination 
with anti-PD-1 and anti-CTLA-4 therapy resulted in decreased tumor growth, and significantly 
improved survival (p=0.03) (Figure 8A-8B).  Unfortunately, because mice treated with DT 
developed severe autoimmunity, we were unable to extend the tumor growth curves past 25 
days post tumor injection per institutional IACUC guidelines.  We then sought to examine if 
delayed tumor growth was correlated with increased cytokine production by T cells.  We 
analyzed interferon gamma (IFN-γ) production by CD8+ T cells in both the tumor and the spleen 
by FACS as a measure of productive CD8+ T cell responses.  While this evaluation was limited 
greatly by the significant occurrence of autoimmunity in mice treated with DT, there was a non-
significant increase in the percentage of CD8+ T cells that generated IFN-γ, but not in total CD8+ 
T cells in mice treated with DT that also received checkpoint inhibition therapy (Figure 8C-8E).  
To circumvent the issues with autoimmunity in mice given DT treatment prior to tumor 
implantation, we treated a small group of mice with DT after tumor implantation.  While we 
were limited again in the ability to generate significant number of DEREG mice to evaluate, 
there was prolonged survival until day 40 for half of mice given DT therapy after tumor 
implantation (Supplementary Figure S8).  Because of the autoimmunity associated with the use 
of DEREG mice, we sought a pharmacological approach to suppress Treg function in vivo.  
Previous work has shown that selective inhibition of the p110δ isoform of PIK3 using a small 
molecule inhibitor delayed 4T1 tumor growth in mice and reduced Treg suppression [27].  We 
used the small molecule inhibitor PI-3065 in addition to checkpoint inhibition in our T11 
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claudin-low model.  Treatment with PI-3065 was associated with a statistically significant 
improvement in survival with a period of tumor stability in half of the treated mice 
(Supplemental Figures S9A-B).  However we were not able to mediate tumor regression or 
impact overall survival.  Treatment with PI-3065 and checkpoint therapy did significantly reduce 
the number of Tregs infiltrating into the tumor (Supplementary Figure S8C).  However, it also led 
to a reduction in the number of CD4+ FoxP3-negative T cells accumulating in the tumor 
microenvironment.   
2.4 Discussion 
Triple-negative breast cancer has the worst prognosis of the histologic subtypes due to 
presenting at higher grade at diagnosis, increased recurrence risk following treatment, and 
shortened time to metastasis [33].  The paradoxical observation that the molecular subtypes 
comprising these tumors also exhibit high levels of immune cell infiltration suggests that these 
infiltrating cells may have a deleterious impact on patient outcome.  Our study supports this 
conclusion for claudin-low breast cancer.  Clustering by the IIG alone was sufficient to separate 
triple negative basal-like and claudin-low tumors from luminal tumors and HER-2 enriched 
tumors.  This finding was not due to aberrant gene expression by tumor cells, but by increased 
immune cell infiltration into the tumor, especially CD4+ T cells.  These results are in contrast 
with prior studies where numbers of TILs were found to be favorably prognostic in breast 
cancer [5].  Importantly these studies did not stratify breast tumors by molecular subtype, 
highlighting that the significance of the immune infiltrate may vary widely by subtype.  The use 
of mouse models that mimic human tumor biology is critical for finding pathways important for 
tumor pathogenesis and potential.  The GEMMs utilized by our laboratory are derived from and 
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studied in immunocompetent mice that recapitulate tumor biology at the genetic and whole 
tumor level.  As expected by similarity to the human patient samples, murine tumors exhibited 
significant differences in immune cell infiltration based on intrinsic subtype.  
 Recently, there has been intense interest in biomarkers of response to checkpoint 
inhibitor therapy.  One stratification that has been proposed for patients with melanoma is 
immune-excluded versus immune-infiltrated, with data suggesting that checkpoint inhibition is 
not effective in immune-excluded tumors [34].  Our data would suggest that a third group of 
tumors, those that are actively immune suppressed, may also not respond to checkpoint 
inhibition.  The presence of Tregs as a biomarker for anti-tumor response has been confusing, 
with data indicating both negative and a positive clinical benefits [35-37].  This may be due to 
the critical issue of timing in the evaluation of Tregs from the TME.  In claudin-low murine 
tumors, Tregs comprise as much as 60% of all CD4+ cells in the tumor and were present in 
substantial numbers prior to the expansion of other adaptive immune cells.  These cells were 
both functional and durable, with continued presence as the tumors grew.  In many of the T11 
and T12 tumors, Treg cells dominated the immune response, which was associated with 
diminished numbers of CD19+ B cells and CD8+ T cells.  Thus, there may be a critical early period 
when tumors can recruit sufficient numbers of Tregs to abrogate a functional adaptive immune 
response.   
 We sought to determine the mechanism that accounts for the preferential recruitment 
of Treg cells to claudin-low tumors.  CXCL12, a chemokine critical for the homing of 
hematopoietic stem cells [38], was 22-fold higher expressed in mice with claudin-low compared 
to Neu tumors.  Further, Treg cells that infiltrated claudin-low tumors expressed high levels of 
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CXCR4, one of the receptors for CXCL12.  Inhibition of CXCR4 with AMD3100 demonstrated a 
modest role for this axis in Treg recruitment.  AMD3100-treated mice demonstrated a trend for 
decreased Treg cell number in the tumor compared to controls, which contained elevated PD-1+ 
Treg cells.  However, the modest decrease in the recruitment of Tregs found using AMD3100 was 
not sufficient to augment the anti-tumor immune response using checkpoint inhibitor therapy, 
in part, because exposure to AMD3100 also diminished the recruitment of CD4+ non-Tregs and 
CD8+ T cells to the TME.  Similarly, selective inhibition of p110δ isoform of PI3K using a small 
molecule inhibitor plus checkpoint inhibition reduced the number of Tregs, which was associated 
with a significant improvement in tumor growth compared to control mice receiving checkpoint 
inhibition alone.  Unfortunately, this combination did not result in tumor regression or 
enhanced overall survival.  Our data suggest that robust and specific Treg depletion is necessary 
to engender an effective anti-tumor response.  This level of depletion in our mouse studies was 
associated with profound autoimmunity.  Thus, it is not clear if prolonged, robust Treg depletion 
in patients could be tolerated to enhance checkpoint inhibitor therapy for the treatment of 
claudin-low tumors.  The function of PD-1 on the surface of Tregs is not entirely known [39 40].  
PD-1hi Tregs in the TME in glioma patients have been found to be exhausted, yet capable of 
generating pro-inflammatory cytokines such as IFN-γ [41].  This suggests that one mechanism 
for the impaired function of anti-PD-1 antibody therapy is the presence of PD-1 expressing Tregs 
that can (1) bind antibody if PD-1 is preferentially expressed on these cells and (2) become 
activated in the presence of anti-PD-1 antibody.  Our data requiring depletion of Tregs to 
mediate the anti-tumor activity of anti-PD-1 antibody therapy would be consistent with this 
mechanism.   
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 In summary, we have found that claudin-low tumors are highly enriched with regulatory 
T cells.  Enhancing the immune response to these tumors by depleting Tregs in addition to 
immune checkpoint inhibition impaired tumor growth and prolonged survival, but was 
insufficient to mediate tumor regression.  Generation of CXCL12 by the tumor cells played a 
modest role in the recruitment of Treg cells to the tumor site.  These studies suggest that future 
clinical trials for patients with triple negative breast cancer should target the 








Figure 2.1: Human tumors exhibit differential immune gene expression. (A) Unsupervised 
hierarchical clustering of breast cancer samples from UNC337 by intrinsic immune gene list. (B) 


































































staining of human subtype specific breast cancer (5X magnification). (D) Representative 
immunofluorescence staining of human tumors for CD4 (red) and FoxP3 (green) (20X 
magnification). (E) Whole slide scoring of CD4+ infiltrate for each subtype. (F) Unsupervised 
clustering by the intrinsic immune genes in GEMMs (n=59). Statistical significance determined 
by Kruskal-Wallis test, with Dunn’s post-test for multiple comparisons. * denotes p < 0.05.  
 




Figure 2.2: T11 and T12 (Claudin-low) tumors recruit elevated numbers of immune cells to the 
tumor site. WT mice were injected with 1 x 106 2250 tumor cells or 1 x 104 T11 or T12 cells.  
Neu-N mice were injected with 5 x 104 NT2 cells.  Tumors were harvested at 20 mm2 (2250 n=9, 
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NT2 n=10, T11 n=12) (A-D), or 100 mm2 (2250 n=10, NT2 n=5, T11 n=10, T12=6) (E-H), digested, 
enriched for lymphocytes, and analyzed by FACS. (A) CD4+ TILs 20 mm2. (B) CD8+ TILs 20 mm2. 
(C) CD19+ TILs 20 mm2 (2250 n=4). (D) CD4+FoxP3+ TILs 20 mm2. (E) CD4+ TILs 100 mm2. (F) CD8+ 
TILs 100 mm2. (G) CD19+ TILs 100 mm2. (H) CD4+FoxP3+ TILs 100 mm2.  (I) Correlation between 
the percentage of CD8+ T cells and FoxP3+CD4+ T cells in mice with 20 mm2 T11 tumors n = 16 
mice). (J) Correlation between CD19+ B cells and FoxP3+CD4+ T cells in T11 mice with 20 mm2 
tumors. n = 16 (taken from the same group as evaluated in I). Statistical significance 
determined by Kruskal-Wallis test with Dunn’s post-test for multiple comparisons. * denotes p 
< 0.05. ** denotes p < 0.01. *** denotes p < 0.001. **** denotes p < 0.0001.  




Figure 2.3: FoxP3+ cells from T11 tumor-bearing mice are functionally suppressive. FoxP3GFP 
mice were injected with 5 x 104 T11 cells. GFP+FoxP3+ splenocytes were sorted from tumor-
bearing mice at (A) 20 mm2 or (B) 100 mm2, and plated with irradiated allogeneic stimulator 
cells and different ratios of WT effector cells for 3 days.  Effector cells were then FACS analyzed 
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Figure 2.4: T11 tumors express high levels of CXCL12. (A) Whole tumor RNA was isolated and 
analyzed using the PAMM-011 RT2 Profiler PCR Array. Gene expression is presented relative to 
NT2 tumor controls. (B) Tumors were harvested on day 21 post tumor injection (PTI) 
homogenized, and analyzed by CXCL12 ELISA (n = 3-4 per group). (C) Serum was harvested on 
day 21 PTI and analyzed for CXCL12 ELISA (n = 3 per group). (D) Representative overlay of 
CXCR4 expression by CD4+FoxP3+ Treg cells (Treg CD4), CD4+FoxP3- T cells (Non-Treg CD4), and 
CD8+ T cells. (E) Mean fluorescence index (MFI) values for the expression of CXCR4 from TILs 
isolated from mice with 20 mm2 T11 tumors (n=6). Statistical significance was determined by 
student’s t-test (B and C) or Mann-Whitney test (E). * denotes p < 0.05. ** denotes p < 0.01.  
*** denotes p < 0.001. 
  




















































































































Figure 2.5: Role of CXCL12-CXCR4 pathway in Treg infiltration into claudin-low tumors. (A and 
B) WT mice were implanted on day -2 with osmotic pumps loaded with PBS or 10 mg AMD3100 
in PBS (n = 7 per group) and challenged with 1 x 104 T11 cells. Tumors were harvested on day 12 





































































































































































































































number of CD4+FoxP3+PD-1+ TILs. (C ) T11 cell line was transfected with lentiviral-expressing 
CXCL12-targeted shRNA and CXCL12 knockdown was confirmed using CXCL12 ELISA. (D and E) 
WT mice were injected with 1 x 104 cells of WT, scramble, or knock down (KD) lines (n = 5 per 
group). Tumors were harvested on day 13 PTI and FACS analyzed. (D) Percentage and number 
of CD4+FoxP3+ TILs. (E) Percentage and number of CD4+FoxP3+PD-1+ TILs. Statistical significance 





Figure 2.6: Tumor-infiltrating regulatory T cells express increased levels of PD-1 and CTLA-4, 
however PD-1 and CTLA-4 inhibition does not increase survival in T11 tumor bearing mice. (A) 
Representative FACS overlay and (B) total MFI values of PD-1 expression by T11 TILs at 20 mm2 
n=4. (C) Representative FACS overlay and (D) total MFI values of CTLA-4 expression by T11 TILs 
at 20 mm2 n=5. (E) Growth curves of T11 tumor bearing mice receiving anti-PD-1 and anti-CTLA-
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4. (F) Survival analysis of data presented in (E) (n=5 for each group). Statistical significance was 






Figure 2.7:  Treg depletion delays tumor growth in the absence of adoptive transfer. WT 
untreated, Cy treated, and DEREG mice were injected with 1 x 104 T11 cells (n = 5 per group). Cy 
treated mice received 100 mg/kg Cy on day +2. DEREG mice received 1 μg DT on days -1, 0, +6, 
and +7. (A) Growth curves. (B) Survival.  There was a significant difference in survival between 
both Treg depleted groups compared with the untreated control group (p < 0.05; log-rank test), 
but not between treated groups.  (C) Treg cells numbers following a single dose of Cy were 
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reduced compared to untreated T11 tumors.  Statistical significance determined by Mann-





Figure 2.8: Regulatory T cell depletion with anti-PD-1 and anti-CTLA-4 immune checkpoint 
inhibition significantly delays T11 tumor growth. WT or FoxP3-DTR mice were injected with 1 x 
104 T11 cells.  DEREG mice received 1μg diphtheria toxin (DT) on day -1, 0, 6, and 7 PTI.  DT + 
PD-1 + CTLA4 mice received 1μg DT on day -1, 0, 6, and 7 PTI, and anti-PD-1 and anti-CTLA4 
antibody on day -1 then every other day for the duration of the experiment. Tumor growth 
evaluation was terminated at day 25 PTI due to autoimmune manifestations and tumor growth 
reaching endpoint of 170mm2. (A) Mice depleted of Tregs and receiving anti-PD-1 and anti-CTLA4 
(n = 3) have a significant survival benefit compared to untreated (n=4) or anti-PD-1 and anti-
CTLA4 alone (n = 3) (CLTLA4 + PD-1 vs DT + CLTLA4 + PD-1: p = 0.03; log-rank test).  (B) 
Individual replicates of tumor growth curves. (C-E) Mice treated with anti-PD-1 and anti-CTLA4 
alone (Treg+) (n=3) or anti-PD-1 and anti-CTLA4 with DT (Treg-) (n=3).  Mice were sacrificed 25 
days PTI and FACS analyzed for percent CD8+ T cells and IFN-γ production by CD8+ T cells in 
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tumor and spleen. (C) Representative FACS plot of IFN-γ production by CD8+ T cells from tumor 
or spleen of tumor bearing mice.  (D) Percent CD8+ T cells and IFN-γ production by CD8+ T cells 
from tumor.  (E) Percent CD8+ T cells and IFN-γ production by CD8+ T cells in spleen.  (F) Percent 
and total number CD4+FoxP3+ Tregs from the tumor in mice treated with anti-PD-1 and anti-
CTLA4 alone (Treg+) (n=3) or anti-PD-1 and anti-CTLA4 with DT (Treg-) (n=3). Analysis of T cell TILs 
was not possible after day 25 in DT treated mice due to severe autoimmunity necessitating 






Supplementary Figure 2.S1: Human tumor subtypes exhibit differential immune gene 
expression. (A) Unsupervised hierarchical clustering of breast cancer samples from METABRIC 
by intrinsic immune gene list. (B) Overall expression of the immune gene signature by each 
subtype. Statistical significance determined by Kruskal-Wallis test, with Dunn’s post-test for 




























































Supplementary Figure 2.S2: Tumors derived from T11 cell line result in true claudin-low 
tumors. Three T11 cell line-derived tumors were normalized to a 385 microarray dataset 
consisting of tumors from 27 murine models of breast carcinoma and normal mammary tissue 
[21]. A supervised cluster using murine intrinsic genes was performed, with the sample 
dendrogram displayed. The eight murine classes identified as human subtype counterparts are 
highlighted. The cluster locations of the T11 parental tumor and the three T11 cell line derived 
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Supplementary Figure 2.S3: Representative FACS analysis diagram. Shown is a representative 
gating schema for the FACS analysis of tumor-infiltrating lymphocytes from an untreated 20 
mm2 T11 tumor.  Following generation of single-cell suspensions from tumor tissue and 
enrichment for leukocytes by density-gradient centrifugation, samples were analyzed by FACS.  
Viable CD45+ cells were gated on CD8 and CD19 to enumerate cytotoxic T cells and B cells 
respectively, and CD4+ cells were analyzed for FoxP3 expression to enumerate helper T cells 

























Supplementary Figure 2.S4:  Representative FACS plots of tumor infiltrating lymphocytes.  WT 
mice were injected with 1 x 106 2250 tumor cells or 1 x 104 T11 or T12 cells.  Neu-N mice were 
injected with 5 x 104 NT2 cells.  Tumors were harvested at 100mm2 (2250 n=10, NT2 n=5, T11 
n=10, T12=6), digested, enriched for lymphocytes, and analyzed by FACS.  Data are 
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Supplementary Figure 2.S5: CD4+ and CD8+ T cell activation subsets.  WT mice were injected 
with 1 x 106 2250 tumor cells or 1 x 104 T11 or T12 cells.  Neu-N mice were injected with 5 x 104 
NT2 cells.  Tumors were harvested at 100 mm2 (2250 n=10, NT2 n=5, T11 n=10, T12=6), 
digested, enriched for lymphocytes, and analyzed by FACS. CD62L+CD44lo T cells are considered 
naïve; CD62L+CD44hi T cells are considered activated or central memory; and CD62L-CD44hi T 
cells are considered effector memory.  (A) Percent and total number naïve, central memory, 
and effector memory CD4+Foxp3- T cells.  (B) Total number of each cell type from (A) graphed 
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effector memory CD8+ T cells. (D) Total number of each cell type from (C) graphed as a stacked 




Supplementary Figure 2.S6: PD-1 and CTLA-4 inhibition do not increase survival in T12 
claudin-low tumor bearing mice.  WT mice were injected in 1 x 105 T12 tumor cells. (A) Growth 
curves of T12 tumor bearing mice receiving anti-PD-1 and anti-CTLA-4. (B) Survival analysis of 
data presented in (A) (n=6 for each group).     
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Supplementary Figure 2.S7: CXCR4/CXCL12 blockade does not delay T11 tumor growth or 
enhance survival.  WT mice were implanted on day -2 with osmotic pumps loaded with PBS or 
10 mg AMD3100 in PBS (PBS n = 6, AMD3100 n=8, AMD3100+PD1/CTLA4 n=9) and challenged 
with 1 x 104 T11 cells. (A) Growth curves of T11 tumor bearing mice receiving AMD3100 with or 
without anti-PD-1 and anti-CTLA-4. (B) Survival analysis of data presented in (A). (C-D)Tumors 
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harvested on day 12 PTI and FACS analyzed. (C) Percent and total number of CD4+Foxp3-, 
CD4+Foxp3+, and CD8+ TILs. (D) The fold difference in the total number of TILs normalized to 
PBS group. (E-F) Tumors harvested on day 16 PTI and FACS analyzed. (E) Percent and total 
number of CD4+Foxp3-, CD4+Foxp3+, and CD8+ TILs. (F) The fold difference in the total number 
of TILs normalized to PBS group. Statistical significance determined by Kruskal-Wallis test with 





Supplementary Figure 2.S8: Regulatory T cell depletion after tumor establishment with anti-
PD-1 and anti-CTLA-4 immune checkpoint inhibition delays T11 tumor growth. WT or FoxP3-
DTR mice were injected with 1 x 104 T11 cells.  DEREG mice received 1μg diphtheria toxin (DT) 
on day 6, 7, 13, and 14 PTI.  DT + PD-1 + CTLA4 mice received 1μg DT on day 6, 7, 13, and 14 PTI, 
and anti-PD-1 and anti-CTLA4 antibody on day -1 then every other day for the duration of the 
experiment. (A) Individual replicates of tumor growth curves. (B) Mice depleted of Tregs and 
receiving anti-PD-1 and anti-CTLA4 (n = 2) have a non-significant survival benefit compared to 
untreated (n=2) or anti-PD-1 and anti-CTLA4 alone (n = 2).  
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Supplementary Figure 2.S9: Selective inhibition of PI3K family member p110δ by PI-3065 
combined with checkpoint inhibition slightly delays T11 tumor growth and improves survival.  
WT mice were injected with 1 x 104 T11 cells. Mice receiving PI-3065 or vehicle were given 
75mg/kg of PI-3065 or vehicle only daily by oral gavage.  Anti-PD1 + anti-CTLA4 mice received 
anti-PD1 and anti-CTLA4 antibody on day -1 then every other day for the duration of the 
experiment. (A) Individual replicates of tumor growth curves. (B) Mice receiving PI-3065 anti-
PD1 and anti-CTLA4 (n = 8) have a significant survival benefit compared to untreated (n=5) and 
anti-PD1 and anti-CTLA4 alone (n = 5) (untreated vs. PI-3065 + anti-PD1/CTLA4: p=0.0415, anti-
PD1/CTLA4 vs PI-3065 + anti-PD1/CTLA4): p = 0.0015.  Statistical significance of survival 
determined by log-rank test. (C) Percent and total number CD4+FoxP3+ Tregs isolated from the 
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or PI-3065 plus anti-PD-1 and anti-CTLA4 (n=3).  Statistical significance determined by Kruskal-
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CHATPER 3: PD-1 CHECKPOINT THERAPY PROMOTES THE FUNCTION AND SURVIVAL OF 
REGULATORY T CELLS IN A MODEL OF CLAUDIN-LOW BREAST CANCER 
 
3.1 Introduction 
Breast cancer is the most prevalent malignancy in women, accounting for 30% of newly 
diagnosed cancer cases [1].  In 2019, more than 42,000 women and men in the U.S. are 
2expected to die from breast cancer [2].  The clinical prognosis of patients with breast cancer is 
dependent on tumor grade, involvement of lymph nodes, and expression of the hormone and 
growth factor receptors Estrogen Receptor (ER), Progesterone Receptor (PR), and Human 
Epidermal Growth Factor Receptor 2 (HER2) [3].  The triple negative breast cancer (TNBC) 
subtype is characterized by the lack of expression of ER, PR, and HER2.  This clinical subtype can 
be further divided into molecular groups including the basal-like and claudin-low subtypes, 
which include the majority of TNBC tumors [4 5].  The basal-like and claudin-low subtypes are 
defined by increased expression of tumor proliferative genes and immune involvement [6].  
TNBC has the worst prognosis of the breast cancer subtypes due to the lack of targeted 
therapies that define the other breast cancer subtypes.  Because of this, surgery, radiation, and 
chemotherapy are first-line treatments for TNBC.   
                                                        
2This chapter contains work submitted to Cancer Immunology Research, for which I am first 
author.  I designed and performed all of the experiments for the original manuscript.  Jon and I 
wrote the manuscript and submitted it for peer review.   
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Immunotherapy has been a promising new approach to cancer treatment in the last 
decade.  Immunotherapy involves enhancing the patient’s immune cells to kill tumor cells.  
Previous studies have demonstrated that immune cells can lose function in the tumor 
microenvironment [7].  One mechanism for this loss of activity is engagement of the receptor 
PD-1 by its ligands PD-L1 and PD-L2.  PD-1 expression is upregulated after T cell activation and 
binding to PD-L1 expressed on tumor cells or other immune cells in the TME leading to 
dysfunction of the immune response and tumor escape.  Most of the previous studies 
evaluating the function of PD-1 has been performed using cytotoxic CD8+ T cell function in the 
context of both chronic viral infections and cancer [8].  CD8+ T cell exhaustion is characterized 
by the loss of proliferation, reduction in pro-inflammatory cytokine production, and diminished 
cytotoxic activity [9].  This loss of function can be reversed by blocking the PD-1/PD-L1 signaling 
axis, restoring cytokine production, proliferation, and leading to an enhanced immune response 
[10].   
Our group has previously shown that triple negative breast cancer is typically heavily 
immune infiltrated with both adaptive and innate immune cells [11].  Most recently, the 
IMMPassion130 study demonstrated a significant improvement in the progression-free survival 
in patients treated with the anti-PD-L1 mAb atezolizumab plus nab-paclitaxel compared to 
those receiving nab-paclitaxel alone [12].  Despite this, the clinical response for patients with 
TNBC treated with anti-PD-1 or PD-L1 monoclonal antibody (mAb) therapy alone is modest with 
6-19% of patients responding to therapy and with none of these patients responding 
persistently.   
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While PD-1 expression on cytotoxic CD8+ T cells may be the target of immune 
checkpoint inhibition, there are other immune cell subtypes that express PD-1 [13-16].  Work 
from our group has previously shown that in a mouse model of claudin-low breast cancer, 
CD4+Foxp3+ regulatory T cells (Tregs) had the highest levels of PD-1 expression compared to 
other T cells subsets [17].  As Tregs are an important mechanism of immune suppression and 
evasion in cancer progression [18], this led us to evaluate the role of immune checkpoint 
inhibition had on the function of Tregs in the TME.   
Here, we demonstrate in this same mouse model of claudin-low breast cancer, 
transcriptional differences between Tregs from untreated tumors versus tumors treated with a-
PD-1.  We further show that these transcriptional differences translate to increased 
proliferation, and increased suppressive activity in tumor infiltrating Tregs from mice treated 
with a-PD-1.  Tregs exposed in the TME to PD-1 blockade are also protected from apoptosis due 
to increased Bcl-2 expression.  Taken together, these experiments indicate that the function of 
Tregs in the TME is enhanced by PD-1 blockade and should be considered when determining if a 
patient will benefit from immune checkpoint inhibition.     
3.2 Methods  
Mice and cell lines 
BALB/cJ, BALB/c Foxp3-GFP, and BALB/c Thy1.1 females and were purchased from The 
Jackson Laboratory (Bar Harbor, ME).  Female mice (8-14 weeks) were used for all experiments.  
T11 (claudin-low) tumor models have been described [19].  BALB/c mice were injected with 1 x 
104 T11 (claudin-low) cells in PBS.  Tumors were orthotopically transplanted by intradermal 
injection into a mammary fat pad and measured twice per week using calipers.  Tumor width x 
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height was recorded, and mice were sacrificed at the specified tumor size or at the IACUC-
approved end point of 2cm2. 
Study Approval 
All animal experiments were conducted in accordance with protocols approved by the 
University of North Carolina Institutional Animal Care and Use Committee (IACUC). 
Isolation of murine tumor-infiltrating lymphocytes (TILs) 
Murine tumors were resected and digested in Liberase TL (Roche #5401020001), DNase 
I (Sigma #D4527), Hyaluronidase (Sigma), and Collagenase XI (Sigma #C9697), as previously 
described [20].  Single cell suspensions were enriched for lymphocytes by isolating cells at the 
interface of a 44% Percoll (Sigma #P1644) in media and Lympholyte-M (Cedarlane #CL5031) 
gradient.   
Antibodies and flow cytometry reagents  
Flow cytometry monoclonal antibodies against murine CD45 (30-F11 #11-0451-82), 
Foxp3 (FJK-16S #45-5773-82), PD-1 (J43 #48-9981-82), Ki67 (SolA15 #17-5698-80), Thy1.1 
(HIS51 #45-0900-80), CTLA-4 (UC10-4B9 # 12-1522-82), and GITR (DTA-1 #25-5874-82) were 
purchased from Invitrogen.  Monoclonal antibodies against murine CD4 (GK1.5 #100414), CD8 
(53-6.7 #100722), PD1 (RMP1-30 #109103), LAP-TGFb (TW7-16B4 #141405), CD25 (PC61 
#102051), and BrdU (Bu20a #339808) were purchased from BioLegend.  Monoclonal antibodies 
against murine Bcl-2 (3F11 #556537) were purchased from BD Biosciences, and monoclonal 
antibodies against murine Bim (C34C5 #948055) were purchased from Cell Signaling 
Technology.  Cell viability was determined using Aqua Fluorescence Reactive Dye (Life 
Technologies #L34965).  For flow cytometry, cells were surface stained, fixed/permeabilized 
 97 
overnight using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience #00-5523-00), 
and intracellular staining performed the following day according to manufacturer’s instructions.  
Apoptosis was measured using PE Annexin V Apoptosis Detection Kit (BD Pharmingen #559763).  
Data were acquired using the BD FACSCanto or BD LSRFortessa (BD Biosciences, San Jose, CA).  
Acquired data were analyzed using FlowJo Flow Cytometry Analysis Software (Tree Star Inc., 
Ashland, OR). 
Proliferation assays using BrdU incorporation 
Tumor bearing BALB/c mice were injected with 2mg BrdU intraperitoneally in 200µl 
DPBS 24 hours before TIL isolation.  Isolated TILs were stained using APC BrdU Flow Kit (BD 
Biosciences #51-9000019AK) adapting the manufacturer’s protocol.  Briefly, cells were stained 
for surface antigens, then resuspended in BD Cytofix/Cytoperm buffer for 30 min on ice.  Cells 
were washed with Perm/Wash and resuspended in BD Cytoperm Permeabilization Buffer Plus 
for 10 min on ice.  Cells were then re-fixed/permeabilized overnight using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience #00-5523-00).  Cells were then 
treated with 30µg DNase for 1 hour at 37°C.  Cells were then stained for intracellular proteins 
including BrdU for 30 min at room temperature.  Data were acquired using the BD FACSCanto 
(BD Biosciences, San Jose, CA).  Acquired data were analyzed using FlowJo Flow Cytometry 
Analysis Software (Tree Star Inc., Ashland, OR). 
In vivo antibodies  
Monoclonal antibodies used for in vivo antibody inhibition were purchased from 
BioXCell (#BE0033-2).  Mice undergoing immune checkpoint inhibition received intraperitoneal 
injection of 200μg anti-PD-1 (J43) or 200μg anti-PD-1 (J43) antigen binding fragments (Fabs) 
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created using Pierce Fab Preparation Kit (ThermoFisher #44985) on day +7 post-tumor 
implantation when the tumor was palpable and then every 3-4 days throughout the 
experiment.  
RNA-Seq 
Foxp3+GFP+ Tregs isolated from tumors were sorted using a MoFlo XDP (Backman Coulter, 
Pasadena, CA) to greater than 90% purity.  RNA was isolated from sorted Tregs using RNeasy 
Micro Kit (Qiagen, Germantown, MD).  RNA-Seq libraries constructed with NuGEN Ovation SoLo 
(NuGEN Technologies, Redwood City, CA).  Samples were sequenced using Illumina HiSeq 2500 
Rapid Run (Illumina, San Diego, CA).  Differential gene-expression analysis was performed using 
DESeq2 [21].  Ingenuity pathway analysis was performed in web portal 
(https://www.quiagenbioinformatics.com/products/ingenuity-pathway-analysis/).       
Treg suppression and proliferation assays 
For the Treg suppression assays we evaluated tumor infiltrating Tregs.  Foxp3+GFP+ cells 
were sorted from tumors of T11 (claudin-low) bearing mice using a MoFlo XDP (Beckman 
Coulter, Pasadena, CA) or FACSAria II (BD Biosciences, San Jose, CA) cell sorter to greater than 
90% purity.  APCs were isolated from WT BALB/cJ splenocytes following CD90 microbead-
depletion (Miltenyi #130-049-101) and irradiation at 30 Gy.  Responder cells were isolated from 
BALB/c Thy1.1 mice using a T recovery column kit (Cedarlane #CL101).  Isolated cells were then 
B220 and CD25 depleted using phycoerythrin (PE) conjugated antibodies and anti-PE magnetic 
bead sorting (Miltenyi #130-048-801).  Responder cells were stained with the Cell Proliferation 
Dye eFluor 670 (eBioscience #65-0840) and plated at varying Treg:TEffector cell ratios with soluble 
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a-CD3 (eBioscience #16-0031-85).  Cells were co-cultured for 3 days, stained, and FACS 
analyzed.   
For the assays measuring proliferation of Tregs ex vivo, we evaluated tumor infiltrating 
Tregs.  Foxp3+GFP+ cells were sorted on a cell sorter similar to above to greater than 90% purity.  
The sorted Tregs were then stained with the Cell Proliferation Dye eFluor670 (eBioscience #65-
0840) and plated with irradiated APCs and soluble a-CD3 with or without a-PD-1 Fabs in the 
cell culture.  Fabs of PD-1 made from antibody clone J43 were used in vitro cultures to 
eliminate effects from Fc mediated activity of the antibodies.  Cells were cultured for 3 days, 
stained, and FACS analyzed. 
Treg apoptosis assays 
For the assays measuring ex vivo Treg apoptosis, we evaluated tumor infiltrating Tregs.  
After isolation of TILs, the isolated lymphocytes were enriched for total T cells using a T 
recovery column kit (Cedarlane #CL101).  T cells were then cultured with 10uM Dexamethasone 
(Sigma D4902) for 24 hours with or without a-PD-1 Fabs (BioXCell #BE0033-2) in the cell 
culture.  Cells were then harvested, stained with PE Annexin V Apoptosis Detection Kit (BD 
Pharmingen #559763), and FACS analyzed.     
Bcl-2 inhibition in vivo  
Bcl-2 inhibition was accomplished using Venetoclax (ABT-199).  ABT-199 was purchased 
from MedChemExpress (MedChemExpress Cat. No. HY-15531).  ABT-199 was formulated in a 
mixture of 60% Phosal 50 PG (Fisher #NC0130871), 30% PEG 400 (Sigma #202398-5G), and 10% 
Ethanol (Fisher BP2818-500).  Mice were dosed with ABT-199 or Vehicle alone in 0.2mL at 
 100 
100mg/kg/day by oral gavage.  Mice were treated starting at day 3 after tumor injection and 
daily for the duration of tumor growth.   
MTT assay with ABT-199 
T11 cells were plated in 96 well plate in complete media and incubated overnight.  
Venetoclax (ABT-199) was dissolved in DMSO, diluted in complete media, and added to the T11 
cells at a starting concentration of 20µM.  T11 cells with ABT-199 were incubated at 37°C, 5% 
CO2 for 48 hours.  Cells were then harvested and cell death was determined using MTT Cell 
Growth Assay (Sigma CGD1) following manufacture’s protocols.  ABT-199 dose response curve 
and IC50 was calculated using Prism (GraphPad, San Diego, CA).    
3.3 Results 
In our model of claudin-low breast cancer, a large number of Tregs infiltrate into the 
tumor and express varying levels of PD-1.  While around half of infiltrating Tregs are negative for 
PD-1, we consistently found significant expression of PD-1 by populations of Tregs.  As shown 
(Figure 1A) Treg expression of PD-1 varied with Tregs found expressing low to intermediate levels 
of PD-1 and Tregs that express PD-1 at high levels (Figure 1A-B).  The PD-1hi Treg population had a 
significant increase in suppressive molecules such as CD25 (p=0.028) and CTLA4 (p=0.05) (Figure 
1C).   
While the functional difference between these PD-1+ Treg populations is unknown, it has 
been shown that for CD8+ T cells that only intermediate PD-1 expressing T cells can be rescued 
by PD-1 blockade while PD-1 high T cells are committed to exhaustion [22].  Since we observed 
a low percentage of PD-1 high expressing cells, we sought to determine the outcome of PD-1 
blockade on the PD-1+ Tregs infiltrating the claudin-low tumors.  We compared CD4+Foxp3+ 
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tumor infiltrating lymphocytes (TILs) from untreated mice to mice treated with a-PD-1 antibody 
and saw a significant increase in the percentage of Tregs in mice treated with PD-1 blockade 
(p=0.004) (Figure 1D).  We also saw a significant increase in the geometric mean fluorescence 
intensity (MFI) of Foxp3 in Tregs treated with PD-1 blockade (p<0.001) indicating higher Foxp3 
levels in these Tregs (Figure 1E).  Higher Foxp3 levels has been directly associated with increased 
suppressive capabilities in Tregs [23] suggesting that Tregs treated with PD-1 blockade could lead 
to increased suppression in the TME in claudin-low tumors.   
In order to determine if there were transcriptional differences between Tregs isolated 
from untreated claudin-low tumors versus Tregs from tumors treated with PD-1 blockade, we 
sorted GFP+ Tregs from both groups of mice and performed RNA-Seq.  This demonstrated 
transcriptional changes in the Tregs from tumors treated with PD-1 blockade (Figure 2A).  We 
found there were 27 significantly differentially regulated genes in Tregs isolated from mice 
treated with PD-1 blockade when compared to untreated controls (padj<0.05) (Supplementary 
Table 1).  We used Ingenuity Pathway Analysis (IPA) to determine if any biological pathways 
were affected by PD-1 blockade in our RNA-Seq data.  IPA predicted that the apoptosis pathway 
is inhibited when Tregs are treated with PD-1 blockade (Supplementary Figure S1).  In addition, 
Jun and Fos (p=0.001), genes responsible for T cell proliferation, [24] were significantly 
upregulated in Tregs treated with PD-1 blockade (Figure 2B).  Bcl-2, an anti-apoptotic protein, 
was also significantly upregulated (p=0.028) in Tregs treated with PD-1 blockade (Figure 2B).  
Based on these data, we hypothesized that PD-1 blockade in claudin-low tumors was promoting 
a pro-survival phenotype in Tregs.                                  
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To test this hypothesis, we first evaluated the proliferative potential of Tregs in vitro.  Tregs 
cultured with a-PD-1 Fabs proliferated significantly more than Tregs without a-PD-1 in the 
culture (p<0.0001) (Figure 3A-B).  To confirm that the significant increase in proliferation was 
related to Treg activation through CD3/CD28 engagement and not from the a-PD-1 Fabs, Tregs 
were cultured with a-PD-1 Fabs without a-CD3.  PD-1 blockade alone did not lead to Treg 
proliferation (Supplementary Figure S2), suggesting that the increase in proliferation when 
cultured with a-PD-1 Fabs is due to the blockade of the inhibitory signal from PD-1 allowing the 
Tregs to proliferate.  We next investigated if the increase in Treg proliferation was also present in 
vivo in the TME.  To address this question, we evaluated cellular proliferation by BrdU 
incorporation.  When immune cells were isolated early during tumor growth (tumor size of 
50mm2), the Tregs proliferated significantly more than CD8+ or CD4+Foxp3- T cells (p=0.029) 
(Figure 3C).  We could not detect a difference in proliferation between Tregs from mice treated 
with a-PD-1 versus untreated (data not shown) on day 15 post tumor injection.  We then 
evaluated proliferation at day 23 after tumor injection, by expression of Ki-67, which is a 
marker of proliferation [25].  We saw an increase in the percent and total number of 
proliferating Tregs from mice treated with a-PD-1 Fabs compared to untreated mice (Figure 3D).  
While it is known that blocking the inhibitory receptor PD-1 allows cytotoxic CD8+ T cells to 
proliferate, these data show that this blockade also allows suppressive Tregs to proliferate.  Tregs 
not only have increased proliferation when exposed to a-PD-1, but in our model of claudin-low 
breast cancer, the Tregs proliferate to a higher percentage than other T cell subsets (Figure 3C) 
suggesting an increased potential for Treg mediated suppression in the TME.   
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From our RNA-Seq data we found that Bcl-2 was significantly upregulated in Tregs during 
treatment with α-PD-1 (Figure 2B).  Bcl-2 is an anti-apoptotic protein and its expression can 
protect cells from apoptosis induced by various stimuli [26].  First, to confirm our RNA-Seq data, 
we confirmed that Bcl-2 protein was upregulated in Tregs isolated from tumors treated with a-
PD-1.  Mice were injected with claudin-low tumors, treated with a-PD-1 or left untreated, and 
then tumors were harvested when the tumors reached 150mm2 to analyze protein expression 
by flow cytometry.  Tregs from mice treated with a-PD-1 had a significant increase in Bcl-2 
protein levels when compared to Tregs from untreated mice (p=0.018) (Figure 4A).  We also 
measured the pro-apoptotic protein Bim and saw no difference in Bim levels between the two 
treatment groups of Tregs (Figure 4B).  Bcl-2 levels were also measured in naïve BALB/c mice to 
compare baseline expression levels of this anti-apoptotic protein in Tregs.  Bcl-2 protein levels 
were higher in Tregs isolated from naïve mice than in T11 (claudin-low) bearing mice, and Bcl-2 
levels were partially recovered in Tregs isolated from tumor bearing mice treated with a-PD-1 
(data not shown).  Bcl-2/Bim ratios are often used as a measure for survival potential in cells.  
Tregs exposed to a-PD-1 had significantly higher Bcl-2/Bim ratios than untreated Tregs (p=0.028) 
(Figure 4C) suggesting a potential for increased protection from apoptosis in the TME.  Thus, 
increased expression of Bcl-2 could increase resistance to apoptosis in Tregs treated with anti-
PD-1 mAb therapy.  
Because we found increased Bcl-2 in the Tregs in the TME of T11 (claudin-low) tumors 
(Figure 4A), we sought to test if these Tregs were protected from apoptosis ex vivo.  Because Bcl-
2 expression can inhibit glucocorticoid (GC) induced apoptosis, we sought to test if Bcl-2 
expressed in Tregs could protect them from Dexamethasone (Dex)-induced apoptosis.  Foxp3-
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GFP T11 (claudin-low) tumor bearing mice were untreated or treated with a-PD-1 twice a week 
until the tumors reached 150mm2.  Tumor infiltrating T cells were isolated from both untreated 
and treated mice, the isolated T cells were cultured ex vivo with or without Dex, and then 
apoptosis was assessed.  Tregs from mice treated with a-PD-1 were more protected from 
apoptosis induced by Dex than Tregs from untreated mice (p < 0.0001) (Figure 5A-B).  
Interestingly, we did not see this significant decrease in cell death in CD8+ T cells from mice 
treated with a-PD-1, suggesting this protection from apoptosis may be specific to Tregs in the 
TME.  We also treated mice with a Bcl-2 inhibitor to determine if there would be increased 
apoptosis in Tregs.  To do this, we utilized Venetoclax (ABT-199) an orally bioavailable, potent 
and selective inhibitor of Bcl-2.  Mice treated with Bcl-2 inhibitor ABT-199 had delayed tumor 
growth and increased survival irrespective of a-PD-1 treatment (Supplementary Figure S3A-B).  
While it is possible that ABT-199 had a direct effect on the T11 tumor cells themselves, the EC50 
against T11 cells in vitro was 2 µM (Supplementary Figure S4) while the IC50 of ABT-199 on Bcl-2 
expressing hematopoietic cells is 4nM [27] suggesting that ABT-199 does not have potent 
activity against T11 (claudin-low) tumor cells and may be acting by inhibiting Treg function.  
While the total number of Tregs infiltrating into the tumor after treatment with ABT-199 was 
decreased, the number of CD8+ T cells was also decreased (Supplementary Figure S3C) 
indicating that the effect of Bcl-2 inhibition on the presence of T cells in the TME is not specific 
to Tregs.     
Increased expression of Foxp3 has been associated with increased suppressive 
capabilities in Tregs [23].  Because we saw a significant increase in the mean fluorescence 
intensity (MFI) of Foxp3 in Tregs treated with PD-1 blockade (Figure 1E), we wanted to determine 
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if Tregs treated with PD-1 blockade had increased suppressive capabilities.  We measured 
suppressive molecules expressed on Tregs of T11 (claudin-low) bearing mice with or without PD-
1 blockade.  Expression of the inhibitory receptor CTLA-4, the high affinity Il-2 receptor chain 
CD25, secretion of the suppressive cytokine TGF-b, and expression of Glucocorticoid induced 
TNF receptor (GITR) are well characterized mechanisms of suppression utilized by Tregs [28 29] 
and have been shown to contribute to their suppressive capabilities [30].  After PD-1 blockade, 
there was a trend towards an increase in both the percent of Tregs expressing suppressive 
molecules (p=0.09, p=0.05, p=0.07) (Figure 6A), and in the MFI expression of the suppressive 
molecules in Tregs (Figure 6B).  Based on the increase in suppressive molecules, we then sought 
to test if Tregs exposed to PD-1 blockade had increased suppressive capabilities.  To address this, 
Foxp3-GFP T11 (claudin-low) tumor bearing mice were treated with a-PD-1 or left untreated 
and the tumors were harvested around 150mm2 and TILs were isolated.  Tregs that had been 
exposed in the TME to PD-1 blockade were better at suppressing naïve CD8+ T cell proliferation 
than Tregs from mice that were untreated (Figure 6C).  These differences in suppression were 
significant at a 2:1 (p=0.005) and a 1:1 (p=0.02) ratio of Tregs to CD8+ T cells (Figure 6C).  Based 
on our previous work, we know that in the T11 (claudin-low) TME the ratio of Tregs to CD8+ T 
cells is approximately 1.5:1 [17] that this difference is suppressive capabilities is biologically 
relevant to suppress T cell activation.          
3.4 Disucssion 
Triple negative breast cancer (TNBC) has the worst prognosis of the breast cancer 
subtypes despite being heavily immune infiltrated [31].  The standard dogma in cancer 
immunotherapy is that tumors with immune infiltration have the capacity to mount a 
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productive anti-tumor immune response and are therefore good candidates for immune 
checkpoint blockade.  However, PD-1 is not only expressed on CD8+ cytotoxic T lymphocytes 
but also on different populations of CD4+ T and NK cells.  Here, we show in a murine model that 
faithfully reproduces tumors found in patients with claudin-low breast cancer, that PD-1 is most 
highly expressed on Foxp3+ Tregs.  Blockade of PD-1 by α-PD-1 mAb was associated with 
enhanced suppression, increased proliferation and diminished apoptosis of Tregs in vitro, which 
was also reproduced in vivo in the TME (Figure 7).  These data suggest that the activity of 
checkpoint inhibitors is more complicated than currently evaluated.  The presence of a 
substantial immune infiltrate may not predict for response to therapy if a significant number of 
the immune cells that express PD-1 are Tregs.   
The mechanism(s) for the enhanced function of Tregs in the presence of α-PD-1 mAb 
therapy is not currently clear.  Our data indicate that α-PD-1 therapy affects at least three 
different pathways for Treg activity (Figure 7).  First, we found increased proliferation of Tregs in 
the presence of α-PD-1 mAb therapy.  This is consistent with findings evaluating the effects of 
α-PD-1 mAb on the proliferation of CD8+ T cells [10], and could be related to the increased 
expression of Jun and Fos in Tregs from α-PD-1 treated animals.  The second pathway is the 
decreased sensitivity to pro-apoptotic proteins.  Previous work has demonstrated a critical role 
for the expression of Bcl family member proteins and decreased expression of Bim in the 
maintenance of Tregs [32].  We found that α-PD-1 therapy enhanced Bcl-2 expression and 
diminished glucocorticoid-induced apoptosis in Tregs.  Interestingly, we found that the Bcl-2 
inhibitor, ABT-199 could improve the median time for tumor growth in mice receiving T11 
tumors, which was independent of co-administration with anti-PD-1 therapy.  Given the 
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extremely modest activity of ABT-199 in vitro against T11 tumor cells, these data suggest that 
inhibiting Bcl-2 in T11 tumors may diminish the function of Tregs.  Finally, Tregs exposed to α-PD-1 
therapy had enhanced suppressive function, which could correlate with the increased 
expression of Foxp3 by those cells.   
There are currently multiple ongoing clinical trials in TNBC where Pembrolizumab 
(humanized a-PD-1 antibody) is being given as a monotherapy [33].  In all reported trials to 
date the overall response rate to PD-1 inhibition in TNBC is reported to be between 4-20%, with 
only a small fraction of patients seeing any benefit from therapy [34].  Our previous work has 
suggested that immune infiltration alone is not a reliable biomarker to predict overall response 
rate to immune checkpoint therapy, but instead the complete microenvironment including 
immunosuppression in the TME should be considered [17].  While the expected outcome of PD-
1 therapy is that the inhibitory signal on cytotoxic T cells will be blocked allowing them to 
remain functional and lead to tumor killing, it is unknown if PD-1 blockade functions similarly 
on other immune cell subsets that express PD-1.  It has been hypothesized that therapeutic 
benefit from immune checkpoint blockade could be masked due to enhanced 
immunosuppression in the TME leading to hyperprogression of cancer [35-37].  Our study 
supports this hypothesis by demonstrating that PD-1 blockade promoted a pro-survival 
phenotype and enhanced suppression from PD-1+ regulatory T cells in the TME.   
Most of the previous studies looking at the role of PD-1 on Tregs have been in vitro 
studies from peripheral Tregs.  These studies broadly demonstrate that Tregs cultured in vitro with 
PD-1 blocking antibody enhance proliferation of Tregs [37-40], although these studies are limited 
by the fact that Treg function and proliferation were measured from peripheral Tregs rather than 
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tissue infiltrating Tregs.  Our study is novel in that we directly measure the proliferative capacity 
and suppressive function of tumor infiltrating Tregs treated with PD-1 blockade in vivo.   
In summary, we have shown in claudin-low tumors Tregs significantly express PD-1.  
Blockade of PD-1 on these cells by α-PD-1 therapy leads to enhanced Treg proliferation, 
suppression, and resistance to apoptosis.  The increased proliferation is associated with 
increased expression of Jun and Fos while the resistance to apoptosis is associated with 
increased expression of Bcl-2.  These studies suggest that the activity and toxicity of checkpoint 
inhibitor therapy may be correlated with differences in expression of PD-1 on CD8+ versus Treg 
cells.  This hypothesis should be tested clinically and specifically evaluated in the treatment of 
patients with triple negative breast cancer, especially those of the claudin-low/mesenchymal 
subtype.                         




Figure 3.1: Infiltrating Tregs increase in the tumor after PD-1 blockade.  Mice were injected with 
1 x 104 T11 (claudin-low) tumor cells.  Tumors were harvested at 150mm2, digested, enriched 
for lymphocytes, and analyzed by FACS.  (A) Representative flow plots gated on CD4+Foxp3+ 
Tregs showing PD-1 expression levels.  (B) Percent PD-1neg, PD-1lo, and PD-1hi CD4+Foxp3+ Tregs 
(n=6).  (C) Percent CD4+Foxp3+ Tregs expressing CD25 or CTLA4 in PD-1lo versus PD-1hi 
populations (n=4). (D-E) Mice were untreated or treated with 200µg ⍺-PD-1 antibody (J43) 
injected IP twice a week for the duration of the experiment.  (D) Percent CD4+Foxp3+ Tregs from 
CD45+ gated population (n=9).  (E) Geometric Mean Fluorescence Intensity of Foxp3 in 
CD4+Foxp3+ cells (n=9).  Statistical significance determined by Mann-Whitney test. * denotes p 
< 0.05. ** denotes p < 0.01. **** denotes p < 0.0001. 
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Figure 3.2: Treg transcriptional profile changes with PD-1 blockade compared to untreated.  
Foxp3-GFP mice were injected with 1 x 104 T11 (claudin-low) cells and were untreated or 
treated with 200 µg ⍺-PD1 antibody (J43) injected IP twice a week.  Tumors were harvested at 
150 mm2, digested, enriched for lymphocytes, and GFP+ Tregs were sorted to greater than 90% 
purity using MoFlo XDP cell sorter.  RNA was isolated from sorted cells and RNA-Seq was 
performed on the HiSeq 2500 Rapid Run platform. (n=6)  (A) Samples were clustered using 
hierarchal clustering.  Z-score of raw counts normalized among samples within each group.  (B) 
Volcano plot showing significantly differentially regulated genes with a p adjusted value <0.05 
and a log2 Fold Change >0.75.  
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Figure 3.3: PD-1 blockade increases Treg proliferation.  Mice were injected with 1 x 104 T11 
(claudin-low) tumor cells. (A-B) Tumors were harvested at 150mm2, digested, enriched for 
lymphocytes, and GFP+ Tregs were sorted using MoFlo-XDP cell sorter.  Tregs stained with 
proliferation dye were incubated with or without ⍺-PD-1 Fabs, irradiated APCs, and soluble ⍺-
CD3 in culture for 72 hours.  (A) Representative flow plots gated on proliferation of Tregs 
cultured without or with ⍺-PD-1 Fabs. (n=9)  (B) Percent proliferating CD4+Foxp3+ Tregs from in 
vitro culture.  (C) Mice were injected with ⍺-PD-1 Ab and 2mg BrdU.  Tumors were harvested at 
50mm2, digested, enriched for lymphocytes, and measured for BrdU incorporation by flow 
cytometry (n=4).  (D) Tumors were harvested at 150mm2, enriched for lymphocytes, and Ki67 
expression in CD4+Foxp3+ Tregs analyzed by FACS (n=6).  Statistical significance determined by 
Mann-Whitney test.  * denotes p < 0.05. **** denotes p < 0.0001. 
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Figure 3.4: Tregs exposed to PD-1 blockade have increased Bcl-2 expression.  BALB/c mice were 
injected with 1 x 104 T11 (claudin-low) tumor cells.  Mice were untreated or treated with 200 µg 
⍺-PD-1 antibody (J43) injected IP twice a week for the duration of the experiment.  Tumors 
were harvested at 150mm2, digested, enriched for lymphocytes, and analyzed by FACS.  (A) 
Geometric Mean Fluorescence Intensity (MFI) of Bcl-2 in CD4+Foxp3+ cells in untreated 
compared to mice treated with ⍺-PD-1 (n=5 Untreated n=8 ⍺-PD-1).  (B) MFI of Bim in 
CD4+Foxp3+ cells in untreated compared to mice treated with ⍺-PD-1 (n=5 Untreated n=8 ⍺-PD-
1).  (C) Ratio of Bcl-2 to Bim MFIs from (A-B) in CD4+Foxp3+ cells (n=5 Untreated n=8 ⍺-PD-1). 




Figure 3.5: Tregs are protected from apoptosis after PD-1 blockade.  BALB/c Foxp3-GFP mice 
were injected with 1 x 104 T11 (claudin-low) tumor cells.  Mice were untreated or treated with 
200 µg ⍺-PD-1 antibody (J43) injected IP twice a week for the duration of the experiment.  
Tumors were harvested at 150mm2, digested, enriched for lymphocytes, and total T cells were 
isolated using cell isolation column (n=9).  Isolated total T cells were cultured in 96 well plate in 
complete media or complete media + 10µM Dexamethasone.  Apoptosis was measured using 
Annexin V and 7-AAD staining.  (A) Representative flow plots gated on GFP+ Tregs isolated from 
the tumor of mice either untreated or treated with ⍺-PD-1 cultured with or without Dex.  (B) 
Percent CD4+Foxp3+7-AAD/Annexin V+ Tregs from CD45+ parent population.  (C) Percent CD8+/7-
AAD/Annexin V+ T cells from CD45+ parent population.  Statistical significance determined by 
Mann-Whitney test.  **** denotes p < 0.0001. 
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Figure 3.6: PD-1 blockade results in increased suppressive capabilities in Tregs. Mice were 
injected with 1 x 104 T11 (claudin-low) tumor cells.  Mice were untreated or treated with 200 µg 
⍺-PD-1 antibody (J43) injected IP twice a week for the duration of the experiment.  (A-B) 
Tumors were harvested at 150mm2, digested, enriched for lymphocytes, and analyzed by FACS.  
(A) Percent CD4+Foxp3+ Tregs expressing suppressive molecules; CTLA4, GITR, TGF-b, and CD25 
from mice treated with ⍺-PD-1 versus untreated (n=9).  (B) Geometric Mean Fluorescence 
Intensity of suppressive molecules in CD4+Foxp3+ cells (n=9).  Statistical significance determined 
by Mann-Whitney test.  (C) Tumors were harvested at 150mm2, digested, enriched for 
lymphocytes, and GFP+ Tregs were sorted using MoFlo-XDP cell sorter.  Naive T cells were 
stained with proliferation dye and were incubated with sorted Tregs, irradiated APCs, and soluble 
⍺-CD3 in culture for 72 hours.  Statistical significance determined by multiple t-tests.  * denotes 
p < 0.05. ** denotes p < 0.01.          
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Figure 3.7: Summary of findings.  Tregs exposed to the claudin-low tumor microenvironment 
have reduced expression of suppressive molecules leading to lower suppressive capabilities.  
These cells also have low levels of anti-apoptotic protein Bcl-2 increasing apoptosis levels.  After 
PD-1 blockade, Tregs in the tumor microenvironment have increased suppressive molecules and 
increased suppression.  Tregs also have increased Bcl-2 levels and high Bcl-2/Bim ratios resulting 




Supplementary Table 3.1: Genes significantly regulated in Tregs treated with PD-1 blockade 
compared to untreated.   Foxp3-GFP mice were injected with 1 x 104 T11 (claudin-low) cells and 
were untreated or treated with 200µg ⍺-PD1 antibody (J43) injected IP twice a week. Tumors 
were harvested at 150 mm2, digested, enriched for lymphocytes, and GFP+ Tregs were sorted to 
greater than 90% purity using MoFlo XDP cell sorter.  RNA was isolated from sorted cells and 
RNA-Seq was performed on the HiSeq 2500 Rapid Run platform. (n=6)  Differential gene-
expression analysis was performed using DESeq2. Genes listed are significantly upregulated or 
downregulated with an adjusted p value < 0.5.  
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Supplementary Figure 3.S1: Apoptosis pathway predicted to be inhibited in Tregs from tumors 
with PD-1 blockade.  Ingenuity pathway analysis was performed on significantly regulated 
genes from RNA-Seq data.  Ingenuity pathway analysis was performed in web portal 
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Supplementary Figure 3.S2: PD-1 antibody alone does not result in Treg proliferation.  Mice 
were injected with 1 x 104 T11 (claudin-low) tumor cells. (A-B) Tumors were harvested at 
150mm2, digested, enriched for lymphocytes, and GFP+ Tregs were sorted using MoFlo-XDP cell 
sorter.  Tregs stained with proliferation dye were incubated with or without ⍺-PD-1 Fabs and 
irradiated APCs without ⍺-CD3 in culture for 72 hours. (A) Flow cytometry gating strategy for 
proliferation of Tregs cultured without or with ⍺-PD-1 Fabs. (n=3) (B) Percent proliferating 
CD4+Foxp3+ Tregs from in vitro culture.   
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Supplementary Figure 3.S3: Inhibition of Bcl-2 leads to delay of tumor growth and increase in 
survival.  BALB/c mice were injected with 1 x 104 T11 (claudin-low) tumor cells.  Mice were 
untreated or treated with 200µg ⍺-PD-1 antibody (J43) injected IP twice a week for the duration 
of the experiment.    Mice were also given ABT-199 (100mg/kg) daily, or vehicle daily by oral 
gavage from day +1 for the duration of the experiment.  (A) Individual replicates of tumor 
growth curves. (B) Mice receiving Bcl-2 inhibitor ABT-199 and ABT-199 + ⍺-PD-1 (n = 3) have a 
significant survival benefit compared to mice receiving vehicle (n=3) or ⍺-PD-1 alone (n = 3) (p = 
0.0046; log-rank test for Vehicle + ⍺-PD-1 vs ABT-199 + ⍺-PD-1) (p = 0.0042; log-rank test for 
Vehicle vs ABT-199).  (C-D) Tumors were harvested at 100mm2, digested, enriched for 
lymphocytes, and analyzed by FACS.  (Vehicle + ⍺-PD-1 n=6, ABT-199 + ⍺-PD-1 n=8)  (C) Total 
number of CD4+Foxp3+ Tregs.   
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Supplementary Figure 3.S4: T11 (claudin-low) tumor cells are more resistant to killing from 
ABT-199.  T11 (claudin-low) tumor cells were plated in a 96 well plate at 1.5x104 cells/well and 
incubated for 24 hours at 37°C.  Venetoclax (ABT-199) was added at a starting concentration of 
20µM and serially diluted.  T11 cells plus ABT-199 were incubated at 37°C 5% CO2 for 48 hours.  
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CHAPTER 4: NK RESPONSE IN CROSS-SPECIES VIRAL AND TUMOR MODELS ARE NOT 
CONTINGENT ON PD-1 EXPRESSION OR UPREGULATION 
4.1 Introduction 
The introduction of immune checkpoint inhibition (ICI) to cancer therapy using blocking 
antibodies to PD-1, PD-L1, and CTLA-4 has revolutionized clinical oncology with clear 
breakthrough advances in a growing list of hematologic and solid malignancies (1–7). These 
dramatic achievements have been built on key advances in the understanding and 
manipulation of T cell biology, including fundamental observations regarding the complex 
regulation of T cell priming and T cell exhaustion in primary immune responses and following 
chronic antigen exposure (8–10). As a result, the successes of ICI in reinvigorating exhausted T 
cells have generated expansive efforts to increase the therapeutic reach of targeting these 
pathways. As part of these efforts, investigators have examined the extent and role of PD-1 
expression on other immune cells, including B cells (11, 12), NKT cells (13), innate lymphoid 
3cells (ILCs) (14), myeloid derived suppressor cells (MDSCs) (15), and tumor-associated and 
conventional macrophages (TAMs) (16, 17). This search for PD-1 expression and associated 
therapeutic manipulation of its immuno-regulatory functions has also been applied to natural 
killer (NK) cells, and some authors view ICI as a viable mechanism to unlock the therapeutic 
                                                        
3This chapter contains work from the lab of William Murphy submitted to the Journal of Clinical 
Investigation for which I am listed as a co-author.  The Serody lab provided unpublished 
TdTomato/PD-1 reporter mice to complete this work.  I had previously characterized and 
validated these mice, and for this manuscript I provided tumor immune infiltration data for 
Figure 2 and Supplemental Figure 2 using these reporter mice.   
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potential of NK cells, particularly for tumors that are refractory to T-cell based modalities with 
low major histocompatibility complex (MHC) I expression (18). 
First noted in the 1960s as radioresistant cells capable of mediating allograft rejection in 
lethally irradiated mice (19) NK cells have been aggressively pursued over the ensuing decades 
as an anti-tumor therapy due to their ability to kill virally-infected and transformed host cells in 
a MHC non-restricted manner (20, 21). Although NK cells have not gained a strong foothold in 
cancer therapy for solid tumors, their success in hematologic malignancies (acute myeloid 
leukemia in particular) has been more promising (22–26). One explanation for the modest 
clinical results of NK cells in the treatment of solid tumors is the development of an NK 
“exhaustion” phenotype comparable to the progressive exhaustion of T cells, which is observed 
following chronic antigen exposure, as occurs in the tumor microenvironment (TME) (27–29). 
Given the unrealized promise of NK cells in clinical cancer immunotherapy, much current 
attention has been focused on identifying the phenotype of NK “exhaustion” and strategies to 
reverse it (27, 28). Recent papers have reported the expression of PD-1 on both murine and 
human NK cells with an important role for PD-1 in limiting NK anti-tumor responses and 
preventing immunopathology via the glucocorticoid receptor in murine CMV (18, 30). To this 
end, anti-PD-1 therapy is being combined with NK cells in clinical strategies to augment the 
therapeutic efficacy of NK cellular therapy, including ICI combination approaches in conjunction 
with endogenous activation of NK cells with cytokines, adoptive NK cell transfer, and 
genetically-engineered NK cells (31–34).   
Despite these ongoing clinical efforts, the current literature describing PD-1 expression 
on NK cells is inconsistent and controversial, as some papers have reported no significant 
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expression on murine intra-tumoral NK cells in syngeneic tumors or human NK cells in 
melanoma patients (28, 35). Other studies have also reported seemingly contradictory results. 
Specifically, studies have demonstrated variable results for PD-1 expression on CD56bright versus 
CD56dim NK cells, variable data on whether PD-1 marks NK cells with improved or diminished 
effector function (36–38), and discordant results on whether PD-1+ NK cells are associated with 
CMV seropositivity or not (39, 40). Underlying these variable results are deeper questions 
regarding the biology and regulation of these enigmatic and highly heterogenous cells and 
whether PD-1 is fundamental to their immuno-regulation, especially given the important 
differences between cytotoxic T cells and NK cells (41).  
In view of these unresolved questions, we sought to determine the extent of PD-1 
expression on human and mouse NK cells under highly relevant in vitro and in vivo conditions 
where NK cells are maximally activated, including ex vivo cytokine stimulation, in vivo MCMV 
infection, and within the intra-tumoral microenvironment. Using a combination of flow 
cytometry, qRT-PCR of purified NK cells and RNA sequencing from wild-type mice, Rag2-/- mice, 
and patient-derived tumor specimens, we show that human and murine NK cells express 
negligible levels of PD-1 at rest, and do not upregulate PD-1 expression during diverse 
activation states. Similarly, NK cells isolated from multiple human cancer patients and murine 
tumors demonstrate comparably insignificant PD-1 expression in contrast to robust PD-1 
expression on T cells. Importantly, we also show that anti-asialo-GM1 (aASGM1) treatment in 
vivo depletes both NK cells and activated PD-1+ T cells after MCMV infection, underscoring the 
pleotropic effects of this “NK specific” depletion strategy and uncovering a possible mechanism 
for the NK-attributed effects of PD-1 blockade in pre-clinical models. Taken together, our study 
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highlights that PD-1 is not expressed at biologically relevant levels in resting mouse or human 
NK cells, is not a marker of acute NK cell activation in these species, and does not represent a 
key mechanism of NK immune-regulation in anti-tumor and anti-viral responses. 
4.2 Methods 
Mice.  
Female C57BL/6J and BALB/cJ mice were purchased from Jackson Laboratories (West 
Sacramento, CA) and female B6.129S6-Rag2tm1Fwa N12 (Rag2-/-) mice were purchased from 
Taconic Farms (Rensellaer, NY). DIO and control mice were generated as previously described 
(42). Briefly, mice were fed a purified diet consisting of either 60% or 10% fat (D12492, D12450, 
Research Diets, Inc.) starting when the mice were 6-weeks old. Mice were used when they were 
approximately 9 weeks old. Mice were housed in AAALAC-accredited animal facilities at the 
University of California, Davis (UC Davis) under specific-pathogen-free conditions. Protocols 
were approved by the UC Davis IACUC, and studies were in compliance with ethical regulations 
and humane endpoints.     
PD-1 TdTomato Reporter Mice.  
To generate the IRES/TdTomato reporter mouse, an 8573bp fragment of the PD-1 locus 
(from 5000bp upstream and 3570bp downstream of stop codon) was sub-cloned from a 
C57BL/6J BAC clone (RP23 16F24) into vector pKO LSLR. A 1431bp coding sequence for 
Tdtomato was introduced downstream of 566bp IRES sequence, and this 1997bp reporter was 
multimerized three times to generate three tandem repeats of IRES/Tdtomato. This 3x reporter 
was inserted 130bp downstream of the STOP codon in the 3’UTR region. A Neo cassette, 
flanked with FRT sites, was introduced between the reporter and 3’homology arm. B6 ES cells 
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(Primogenix, Inc., St. Louis, MO) were electroporated with 20 micrograms of linearized 
targeting vector and single colonies were isolated under positive (Neo) and negative (DTA –
from vector backbone) selection. Ninety-six colonies were screened with a long-range PCR to 
give 10 positive clones. Five clones were grown for further validation, and Southern analyses 
with 5’ and 3’ probes showed that 2/5 clones had all 3 copies of the IRES/Tdtomato reporter 
while 3/5 clones had only 2 copies of the reporter. The 2 clones showing all 3 copies of the 
reporter were injected into blastocysts to generate chimeras, which were mated to FLPE-
expressing line to generate F1 animals with the Neo cassette deleted. Reporter mice were 
housed in AAALAC-accredited animal facilities at the University of North Carolina, Chapel Hill 
(UNC) under specific-pathogen-free conditions. Protocols were approved by the UNC IACUC and 
complied with ethical regulations and humane endpoints.  
Mouse in vitro studies.  
Adherent lymphokine activated killer cells from mouse splenocytes were generated by 
culturing cells in recombinant human IL-2 (NCI, Frederick MD) for 7 days at the indicated 
concentrations. Half-volume media changes were performed every 2-3 days to refresh media 
and remove non-adherent cells. At time of collection, cells were vigorously pipetted and 
mechanically lifted from the plate surface. Cells were then washed in PBS and utilized for flow 
cytometric or PCR-based analysis.   
In vivo mouse tumor studies.  
Mouse tumor cell lines CT26 (ATCC, CRL-2638), 4T1 (ATCC, CRL-2539), B16-F0 (ATCC, 
CRL-6322), and 3LL (ATCC, CRL-1642) were obtained from the ATCC. Cells were thawed and 
passaged in complete RPMI media supplemented with 10% Nu-Serum (Corning Life Sciences) 
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for three passages prior to usage. Cells were collected using TrypLE (Thermo Fisher) washed 3x 
in PBS, filtered through sterile 70 µm strainer, then resuspended in PBS. Tumor cells were 
subcutaneously injected into the shaved right flank at the following specifications: 5x105 CT26 
cells in 100 µL PBS, 2x105 4T1 cells in 100 µL PBS, and 1x106 B16-F0 cells in 100 µL PBS. Tumor 
size was measured regularly using digital calipers, and tumor volume was calculated using v = (l 
x w x w) / 2. Mice were euthanized and tissue collected at indicated time points, or earlier if 
pre-specified criteria were met.   
Murine Cytomegalovirus (MCMV) infection.  
MCMV Smith strain was obtained from American Type Culture Collection (ATCC) and 
was maintained by repeated salivary gland passage in female BALB/c mice. Mice were infected 
with MCMV via intraperitoneal injection of virus in 200 µL RPMI 1640 at the doses specified. 
Clinical signs and weights were recorded daily. Whole blood via tail vein bleed was obtained at 
designated time points. Mice were humanely euthanized at predetermined time points or 
earlier if ³20% weight loss was present or other pre-specified criteria were met. Control mice 
were injected with 200 µL RPMI 1640 only. Spleen and liver tissue samples were snap frozen for 
MCMV viral titer quantification via real-time PCR with a plasmid standard curve using the 
Qiagen DNeasy Kit for DNA isolation and Applied Biosystems probe for amplification of IE-1 as 
previously described (79). IE-1 copy numbers were normalized to DNA quantity and tissue 
weight (10 mg for spleen, 25 mg for liver). 
In vivo NK cell depletion.  
Depletion of NK cells was completed by intraperitoneal injection of anti-ASGM1 (Wako 
Chemicals) or anti-NK1.1 (clone PK136, National Cell Culture Center), or a sham injection by 
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PBS. Injections were performed twice - two days prior to MCMV infection, and five days 
following infection.   
Processing of mouse tissue.  
Following approved euthanasia technique, the specified organs were collected and 
processed to generate single cell suspensions for analysis or culture. Collection details for each 
organ are as follows: Mouse spleens and tumors were mechanically dissociated in PBS. Tissue 
was then strained through a 70 µm filter, and cells were treated with RBC lysis buffer for 5 
minutes (BioLegend #420301). Cells were then washed with PBS, strained, and resuspended at 
specified concentrations. Mouse livers were collected and mechanically dissociated in PBS. Liver 
hematopoietic cells were isolated by density centrifugation with 32% Percoll in wash buffer (3% 
Nu-serum in PBS). Cells were treated with RBC lysis buffer for 5 minutes, washed, then 
resuspended at the indicated concentration. 
Human and canine NK cells in vitro.  
Human leukocyte reduction system chambers were obtained from healthy, unidentified 
volunteers (Blood Source, Sacramento, CA). Contents were collected and diluted 1:1 in PBS, 
followed by collection of peripheral blood mononuclear cells (PBMCs) using a density gradient 
(Lymphocyte Separation Medium, Corning Life Sciences). Red blood cells were eliminated by 
incubation with RBC lysis buffer for five minutes at 4°C. Cells were then washed with PBS and 
quantified for immediate use, storage in liquid nitrogen, or NK cell isolation. Human NK cells 
were isolated from PBMCs using the Rosette Sep Human NK Isolation Kit according to the 
manufacturer’s specifications (Stem Cell Technologies, Vancouver, BC). Following isolation, 
human NK cells were immediately used or stored in liquid nitrogen. Human PBMCs were 
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cultured in incubators at 37oC at 5% CO2 in complete RPMI media (RPMI 1640 media (Invitrogen 
Life Technologies) supplemented with 10% Nu-Serum (Corning Life Sciences), 2mM L-glutamine 
(Glutamax®, Gibco), 1% non-essential amino acids (Gibco), 5x10-5M b-mercaptoethanol (MP 
Biomedicals), 1mM Hepes buffer (Corning Life Sciences), 1mM sodium pyruvate (Gibco), and 1% 
penicillin/streptomycin (Corning Life Sciences) supplemented with the specified cytokine. For ex 
vivo NK cell activation and expansion, human NK cells were grown in complete RPMI media and 
co-cultured with irradiated K562.Clone 9-mIL21-41BBL (courtesy of Dr. Dean Lee, Nationwide 
Children’s Hospital, Columbus, Ohio) and 100 IU/mL recombinant human IL-2 (NCI, Frederick, 
MD). Human NK cells were expanded as previously described (80). The human NK cell line NK92 
was obtained from ATCC (Manassas, VA), and cultured in complete RPMI media supplemented 
with 500 IU/mL recombinant human IL-2. Cells were passaged every 3-5 days and used within 
the first ten passages. Canine NK cells were obtained from healthy farm beagles and isolated 
and expanded as described previously (55).  
Human clinical tumor and peripheral blood samples.  
For human solid tumor studies, collection of matched whole blood and tumor 
specimens was approved by the IRB at the University of California, Davis and complied with all 
ethical regulations. Study participants were both male and female donors undergoing 
scheduled surgical resection of various cancers through the UC Davis Comprehensive Cancer 
Center. Matched PBMCs from the same patients were isolated from whole blood by gradient 
centrifugation (Lymphocyte Separation Medium, Corning Life Sciences) followed by RBC lysis. 
Tumor samples were obtained from fresh surgical specimens and placed into RPMI media. 
Single cell suspensions were generated from tumors by mechanical dissociation in PBS, filtered 
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through 70 µm filters, incubated with RBC lysis buffer, and then resuspended at the desired 
concentration for flow cytometric analysis.  
RNA isolation, reverse transcription, and qRT-PCR.  
Total RNA was extracted from specified tissue, and RNA was isolated using the RNeasy 
Mini kit (Qiagen) following manufacturer’s protocol with optimal on-column DNase treatment 
to remove genomic DNA. RNA concentrations were quantified using a Qubit 4 fluorometer, and 
cDNA was synthesized using IscriptTM Reverse Transcription Supermix (Bio-Rad). mRNA 
expression was detected using qRT-PCR via specified primers for human, mouse, and canine 
expression (Supplementary Table 1) on the BioRad CFX384 system. Fold expression was 
determined using the DCq method comparing gene of interest expression to housekeeper gene 
expression (GAPDH, B2M, IPO8). Relative fold expression was compared to unstimulated or 
untreated cells by the 2-DDCq method. 
RNA Sequencing.  
Cells generated for RNA sequencing were derived from stimulated and unstimulated NK 
cells from wild-type C57BL/6 mice. Unstimulated NK cells were collected fresh from the spleens 
of at least three individual mice. Stimulated NK cells were generated in vitro by plating fresh 
splenocytes with anti-Thy1.2 and complement for T cell depletion, followed by culture in 
complete RPMI media supplemented with rhIL-2. Following collection, single cell suspensions 
were generated, Fc receptors blocked (anti-CD16/32, clone 93, BioLegend), and stained with 
the antibodies against CD3, NK1.1, Ly49G2, and Ly49C/I. Cells were sorted using a FACS Aria 
machine (BD Biosciences, San Jose, CA) and post-sort populations were >96% pure. Sorted cells 
were then processed for RNA extraction using the Qiagen RNeasy kit. Stranded RNA-seq 
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libraries were then constructed using TruSeq Stranded Total RNA Sample Prep Kits (Illumina, 
San Diego, CA) according to the manufacturer’s recommendations. The equimolar pooled 
library was sequenced using the HiSeq2000 (Illumina) using TruSeq version 3 and bioinformatics 
pipeline built on RTA version 1.13.48 and CASAVA 1.8.2 software (Illumina). A minimum of 40 
million 100 base read pairs were generated for each library. Raw Fastq files were aligned to the 
mouse genome (mm10) using STAR version 2.3.0. Genes were counted using Rsubread. 
Differential expression and subsequent fold-change values performed using limma-voom.  
Antibody staining and flow cytometry.  
Human cells were prepared in a single cell suspension. Cells were washed with PBS, 
incubated with Human TruStain Fc receptor blocking solution (BioLegend, #422302) then 
stained with the following fluorochrome-conjugated monoclonal antibodies: CD3-FITC (clone 
HIT3a, BioLegend #300306), CD56-PE (clone HCD56, BioLegend #318306), PD-1-APC (clone 
EH12.2H7, BioLegend #329908), PD-L1-PE/Cy7 (clone MIH3, BioLegend #374506), TIGIT-BV421 
(clone A15153G, BioLegend #372710), CD69-BV711 (clone FN50, BioLegend #310944), CD107a-
BV605 (clone H4A3, BioLegend #328626), Ki-67-PE/Cy7 (clone 20Raj1, eBioscience #25-5699-
42). 
Mouse cells were prepared in a single cell suspension. Cells were washed with PBS, 
incubated with Fc block (anti-CD16/32, clone 93, BioLegend #101320), then stained with the 
following fluorochrome-conjugated monoclonal antibodies: CD45-PacBlue (clone 30-F11, 
BioLegend #103126), CD45-FITC (clone #), CD3-BV785 (clone 17A2, BioLegend #100232), CD3-
Pacific Blue (clone #), NKp46-PerCP-Cy5.5 (clone 29A1.4, BioLegend #137610), NKp46-APC 
(clone #), PD-1-PE/Cy7 (clone RMP1-30, BioLegend #109110), TIGIT-APC (clone 1G9, BioLegend 
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#142106), CD49b-PerCP-Cy5.5 (clone HMa2, #108916), NK1.1-PE-TR (clone PK136, Invitrogen 
#61-5941-82), CD69-FITC (clone H1.2F3, BD Biosciences #553236), NKp46-PerCP-Cy5.5 (clone 
29A1.4, BD Biosciences #560800), Thy1.2-APC (clone 53-2.1, eBiosciences #17-0902-82). The 
following additional antibodies against murine PD-1 were used as indicated: PD-1-BV711 (clone 
29F.1A12, BioLegend #135231), PD-1-FITC (clone J43, eBioscience #11-9985-81).  
All human and mouse cells were analyzed using a BD LSRFortessa flow cytometer 
(Becton Dickinson, San Jose, CA) and analyzed using FlowJo Software (Beckton Dickinson, San 
Jose, CA).  
Study Approval.  
All animal experiments were reviewed and approved by the Animal Care and Use 
Committee at the University of California, Davis, University of North Carolina, Chapel Hill, or 
National Cancer Institute, in accordance with the guidelines of the NIH.  
Statistics.  
Prism software (GraphPad Software Inc.) was utilized for graph generation and 
statistical analysis. Except where indicated, data are expressed as mean ± SD. For analysis of 
three or more groups, one-way analysis of variance (ANOVA) tests was performed with Tukey’s 
or Dunnett’s post-test as appropriate. Differences between two normally distributed groups 
were analyzed using the paired or unpaired Student’s t-test where appropriate. P £ 0.05 was 
considered statistically significant. 
4.3 Results 
In vitro activated murine NK cells do not upregulate PD-1  
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Given the previously reported variability of PD-1 expression on murine NK cells, we 
sought to investigate the expression of PD-1 on highly activated and expanded mouse adherent 
lymphokine-activated killer (ALAK) cells. We first obtained splenocytes from young, lean, resting 
wild-type (WT) mice (parent gating shown in Supplemental Figure 1A with NK (NK1.1+CD3-), T 
(NK1.1-CD3+), and NKT (NK1.1+CD3+) cell populations shown in Figure 1A). Without stimulation, 
both NK and T cells exhibit low expression of activation marker CD69, and negligible expression 
of PD-1 (Figure 1B-C). After culturing ALAKs for seven days with 1000 IU/mL rhIL-2, there was a 
clear enrichment of NK1.1+CD3- NK cells (Figure 1D) with corresponding marked upregulation of 
activation marker CD69 on both NK and T cells. However, there was with no upregulation of PD-
1 on NK cells, and minimal upregulation of PD-1 on T cells (Figure 1E-F). In contrast, we 
detected high T cell expression of PD-1 after culturing young WT mouse splenocytes with 
concanavalin (Con) A, although no expression of PD-1 was detected on NK cells (Figure 1G). To 
confirm these findings, splenocytes were again collected from resting C57BL/6 mice. One 
cohort consisted of freshly isolated splenocytes which were sorted for CD3-CD122+Ly49G2+/-
Ly49C/I+/- A second cohort of splenocytes was stimulated in vitro with 500 IU/mL rhIL-2 for 
seven days and then sorted to isolate NK cells. We then compared resting and IL-2-stimulated 
NK cells by RNA sequencing analysis (Figure 1H). Comparison of NK cells pooled from several 
donor mice showed marked upregulation of proliferation, activation, and functional NK markers 
(granzyme B, perforin, IFNg, Ki67, CD69), but no expression of PD-1 mRNA (Figure 1I). Though 
negative by conventional flow cytometry and RNA sequencing, we also analyzed splenocytes 
from Rag2-/- mice, as they are B and T cell-deficient and are an ideal source of pure NK cells in 
the spleen with little risk of T cell contamination. Splenocytes were again cultured in rhIL-2 for 
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seven days and then analyzed by flow cytometry and qRT-PCR. As shown in Figure 1J, 
representative parent gating shows the highly pure NK cell populations from cytokine 
stimulated Rag2-/- splenocytes. As before, these NK cells demonstrate high expression of CD69 
but complete absence of PD-1 expression by flow cytometry (Figure 1K). Using qRT-PCR, 
compared to resting WT splenocytes, we also detected negligible PD-1 mRNA expression in the 
stimulated Rag2-/- splenocytes, though we observed a hundred-fold increase in mRNA 
expression of granzyme B (Figure 1L), confirming the highly activated state. Given reports of 
obesity inducing T cell exhaustion and increased PD-1 expression, we also analyzed spleens of 
older, WT mice with diet-induced obesity (DIO) and detected no PD-1 expression on NK cells, 
despite increased PD-1 on T cells (42) (Supplemental Figure 1B-C). Taken together, these data 
highlight lack of expression or upregulation of PD-1 on NK cells despite robust activation in the 
setting of ex vivo IL-2 exposure.  
Mouse intra-tumoral NK cells do not upregulate PD-1 
Given the importance of murine tumor models in the pre-clinical evaluation of cancer 
immunotherapy, including mechanistic assessment, we then evaluated the extent of PD-1 
expression on murine intra-tumoral NK cells. Overall, the reported expression of PD-1 on 
murine intra-tumoral NK cells has been variable, with some studies identifying PD-1 expression 
on NK cells while others have not (18, 35). Certain tumor lines, in particular, have shown 
marked heterogeneity with the CT26 tumor line being a notable example (18, 35). Given that 
our data on PD-1 expression from extensively cultured murine NK cells may not recapitulate the 
in vivo phenotype, we set out to characterize the phenotype of intra-tumoral NK and T cells 
from multiple syngeneic mouse tumor models with particular attention to PD-1 expression. 
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Importantly, given recent exciting data suggesting that NK cells mediate the anti-tumor effects 
of PD-1 blockade (18), including in tumors with limited T cell responses, we also analyzed the 
absolute numbers and relative percentages of NK and T cell infiltrates from these tumors in 
order to assess the potential for these effector populations to mediate immune responses in 
relation to the tumor bulk. The gating strategy for each tumor model is shown to emphasize the 
heterogeneity between models and the relative contribution of NK and T cells to the overall 
immune infiltrate and tumor infiltrate (Figure 2A, Supplemental Figure 2A). Overall, there was 
considerable heterogeneity across models in regards to the total tumor cells obtained (Figure 
2B), percentage of viable tumor cells present (Figure 2C), and percent of NK and T cells among 
total live tumor cells (Figure 2D). However, in all tumor models utilized, we observed a clear 
paucity of intra-tumoral NK cells relative to both overall live tumor cells present and intra-
tumoral T cells (Figure 2D). We did detect increased expression of activation marker CD69 and 
functional marker granzyme B on intra-tumoral NK cells compared to splenic NK cells (Figure 
2E-F), suggesting that intra-tumoral NK cells are activated. For each tumor model, 
representative staining highlights the relative NK and T cell populations, and percent PD-1 
expression on NK and T cells. (NK cells were defined as CD3-NKp46+ in BALB/c mice and CD3-
NK1.1+NKp46+ in C57BL/6 mice) (Figure 2G). Importantly, in tumors like 3LL where the 
calculated PD-1 expression is 7%, direct examination of the primary flow cytometry plots 
reinforces the insignificance of these data given the scattered and limited events. When 
summarized for each tumor analyzed, PD-1 expression on intra-tumoral NK cells was 
consistently lower than T cells and overall negligible given the limited numbers of intra-tumoral 
NK cells present in the tumor infiltrate (Figure 2H). Supplemental Figure 2B depicts the PD-1 
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gating strategy for CT26 tumors using isotype controls, again showing negligible PD-1 
expression on NK compared to significant expression on T cells. These results were obtained 
using the RMP1-30 anti-PD-1 antibody, but experiments with clones J43 and 29F.1A12 
produced similar results (data not shown). Finally, given the variability reported for NK cell 
expression of PD-1 across studies, we sought to further analyze PD-1 expression on NK cells 
using transgenic PD-1 mice genetically engineered to express the IRES/TdTomato reporter 
mouse linked to a fragment of the PD-1 locus on a BALB/c background (Supplemental Figure 
2C). CT26 cells were implanted subcutaneously in the flanks of these mice as in our prior 
experiments. Tumors from transgenic mice were then excised, and intra-tumoral lymphocytes 
analyzed. Supplemental Figure 2D depicts representative gating for this analysis. Similar to our 
data using CT26 tumors in WT mice, PD-1 expression on intra-tumoral NK cells remained 
negligible compared to the robust PD-1 expression on intra-tumoral T cells as shown by flow 
cytometry (Figure 2I). Quantification of these results for all CT26 tumor-bearing PD1 reporter 
mice revealed significant PD-1 expression on intra-tumoral T cells compared to negligible 
expression on NK cells (Figure 2J).  
In vivo acute MCMV infection leads to upregulation of TIGIT, not PD-1, on mouse highly 
activated NK cells. 
 
 The early response to cytomegalovirus (CMV) infection is dominated by NK cells, 
making acute murine CMV (MCMV) an ideal model to evaluate highly activated NK cells and the 
impact of NK responses on subsequent immunomodulation, including both T cell and memory 
NK responses (43–45). Given our data showing negligible PD-1 expression on cytokine-activated 
and tumor-exposed NK cells in mouse, we chose to evaluate WT and Rag2-/- NK cells in vivo 
following MCMV infection. Mice were infected with 2x104 pfu of MCMV via intraperitoneal 
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injection, and spleen and liver tissue were analyzed three days later for immune phenotype and 
function (Figure 3A). Infection was confirmed by presence of viral titers measured in the liver 
(Figure 3B), and infected mice exhibited significant weight loss post infection (data not shown). 
Infected mice also had serum corticosterone concentrations of 200-300 ng/mL 48 hours after 
infection, as has been previously described (30) (Supplemental Figure 3A). Representative flow 
cytometry shows distinct NK (CD3-NK1.1+) and T (CD3+NK1.1-) cell populations in the spleens of 
uninfected and infected WT mice (Figure 3C), with detailed parent gating strategy shown in 
Supplemental Figure 3B. Compared to uninfected mice, MCMV infected mice exhibited 
statistically significant increases in expression of activation markers CD69 (Figure 3D) and 
Thy1.2 (Figure 3E) by NK cells in the spleen and liver. Under these highly activated conditions, 
there was a biologically insignificant (0.65% to 1.4%), but statistically significant, increase in PD-
1 expression on splenic NK cells as seen by representative flow cytometry (Figure 3F, 3H). In 
contrast, we detected a more robust increase in TIGIT expression in both the spleen (Figure 3G, 
3H). and the liver (Supplemental Figure 3C-D). Using Rag2-/- mice, we confirmed an enrichment 
in NK cells and absence of T cells in the spleen, (Figure 3I). and similar to WT C57BL/6 mice, 
CD69 was markedly elevated on CD3-NK1.1+NKp46+ NK cells (Figure 3J). In these mice, we 
observed negligible expression of PD-1 in the spleen (Figure 3K) and liver (Supplemental Figure 
3C-D), whereas TIGIT was upregulated on activated NK cells from both organs (Figure 3L and 
Supplemental Figure 3C-D) of infected Rag2-/- mice 3 days post infection. We then performed 
qRT-PCR from splenocytes of infected WT and Rag2-/- mice. Splenocytes from Rag2-/- mice 
demonstrated significantly decreased, near absent, transcript expression of PD-1 after MCMV, 
while functional marker granzyme B was markedly upregulated in the infected groups (Figure 
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3M). While no increase in PD-1 on T cells was detected on day 3 by flow cytometry, we did 
identify significantly increased T cell PD-1 expression on day 7, while NK PD-1 expression 
remained negligible compared to the day 3 timepoint (Figure 3N). As before, these results were 
obtained using RMP1-30 anti-PD-1 antibody, but experiments with clones J43 and 29F.1A12 
produced similar results (data not shown).  
Anti-ASGM1 depletes activated PD-1+ T cells following MCMV infection.  
In addition to the subjective nature of flow cytometry gating strategies, there also exist 
challenges in attributing an anti-tumor or anti-viral response solely to NK cells based on 
commonly used depletion strategies. Administration of polyclonal anti-asialo-GM1 (aASGM1) is 
a standard technique to implicate NK cells in the mechanism of anti-tumor or anti-viral 
responses. In particular, recent studies have used ASGM1 depletion in syngeneic tumor models 
to conclude that the loss of anti-tumor effects mediated through PD-1 blockade is contingent 
on NK cells (18). However, concerns exist that ASGM1-based depletion has effects on non-NK 
cellular constituents, including activated T cells, and these non-specific effects of ASGM1 may 
confound attribution exclusively to NK cells and bias results (46). Therefore, we evaluated the 
expression ASGM1 and the impact of ASGM1 depletion on resting T cells and T cells following 
acute MCMV infection in C57BL/6 mice (Figure 4A).  Representative flow cytometry gating 
demonstrates well-defined NK (CD3-NKp46+) and T (CD3+NKp46-) cell subsets in untreated and 
MCMV-infected mice with near total NK cell loss but also partial T cell loss by percentages 
following αASGM1 treatment (Figure 4B). Interestingly, we also observed a partial diminution of 
T cells in the spleen after NK depletion using αNK1.1 in MCMV-infected (but not resting) mice, 
although this decrease in T cells following NK1.1 depletion was not statistically significant 
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(Supplemental Figure 4A-B). Quantification of splenic NK and T cells revealed a near complete 
loss of NK cells after αASGM1 in both resting and post-infection states (Figure 4C). Splenic NK 
cells post-MCMV decreased consistent with trafficking to the liver, as has been described (47). 
In contrast, ASGM1 depletion had no effect on splenic T cells in the resting state, but did lead to 
a significant decrease in splenic T cell numbers 7 days post-MCMV (Figure 4C). Representative 
flow cytometry staining for ASGM1 as a cell surface marker on T cells shows that ASGM1 is 
minimally expressed on unstimulated T cells but increases substantially with MCMV infection 
and is unchanged after ASGM1 depletion (Figure 4D). However, even though the percent of 
splenic T cells which are ASGM1 positive is unchanged with or without αASGM1 following 
MCMV, the total number of ASGM1+ T cells significantly decreases after depletion compared to 
MCMV infection alone (Figure 4E). Similar to ASGM1 expression on activated T cells post-MCMV 
infection, there is also a significant increase in PD-1 expression following MCMV infection, 
including splenic T cells (Figure 4F). Importantly, we observed a significant decrease in 
frequency and total numbers of PD-1+ T cells in the spleens of mice receiving MCMV infection 
and aASGM1 (Figure 4G). Taken together, these data provide further evidence that ASGM1 is 
prominently expressed on activated T cells (and is therefore a target for ASGM1 depleting 
strategies). Moreover, we also observed co-expression of ASGM1 and PD-1 on splenic T cells 
post-MCMV infection with subsequent depletion of this double positive population following 
αASGM1 treatment (Figure 4H), which was an effect we did not identify with NK1.1 depletion 
and MCMV (Supplemental Figure 4C). 
In vitro activation of human PBMCs leads to PD-1 expression on T cells, not NK cells. 
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Despite our inability to demonstrate meaningful expression of PD-1 on murine NK cells 
in vitro or in vivo, reports have also shown PD-1 expression on human NK cells, including after 
exposure to in vitro stimulatory conditions (38). Therefore, we next evaluated PD-1 expression 
on human NK and T cells, starting with in vitro activation strategies using freshly isolated PBMCs 
from healthy human donors. Following culture for 3 days in media only (Figure 5A), “resting” 
human NK cells (CD56+CD3-) and T cells (CD56-CD3+) express low levels (1 – 10%) of activation 
marker CD69. In these conditions, NK cells are negative for PD-1, while T cells express variable, 
but low levels (10 – 20% in most healthy donors) as shown in Figure 5B-C. With 72h of 
concanavalin (Con) A stimulation (Figure 5D), both NK and T cells markedly increase expression 
of CD69, while only T cells express meaningful PD-1 (Figure 5E-F). Following 72h of culture in 
1000 IU/mL rhIL-2 (Figure 5G), the prototypical NK activating cytokine, NK cells also exhibit 
increased CD69 expression, while T cell expression was modestly increased. After rhIL-2 co-
culture, PD-1 expression remained limited to T cells with insignificant expression observed on 
NK cells (Figure 5H-I). We also examined the effect of rhIL-15 given the established role for NK 
cell development and evolving data for induction of NK cell exhaustion (48, 49). Similar to our 
results with rhIL-2, following 72h of culture in 100 ng/mL rhIL-15 (Figure 5J), NK cells increased 
expression of CD69 and remained negative for significant PD-1 expression (Figure 5K), while T 
cells exhibited CD69 upregulation, without significant change in PD-1 expression (Figure 5L). 
Summary data from all human donors are presented for CD69 (Figure 5M) and PD-1 (Figure 
5N). Regardless of ConA, IL-2, or IL-15 activation, we did not observe upregulation of PD-1 on 
NK cells, while T cells dramatically increase expression following ConA stimulation. We also 
examined the NK92 cell line (which has been well characterized (50), but reports of PD-1 
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expression are also variable (18, 51)) after culture in 500 IU/mL rhIL-2. We detected high 
expression of TIGIT but complete absence of PD-1 expression by both flow cytometry and qRT-
PCR as compared to resting PBMCs from a healthy donor (Supplemental Figure 5).    
Ex vivo generation of expanded and activated human NK cells upregulate TIGIT not PD-1.  
PD-1 expression on T cells occurs shortly after TCR engagement and is thus a marker for 
acute activation as well as subsequent exhaustion when faced with chronic antigen exposure 
(52). With the hypothesis that cytokine alone may not be a sufficient stimulus to induce PD-1 
expression on NK cells, we next analyzed isolated human NK cells for PD-1 expression using an 
established method for ex vivo NK cell activation and proliferation, notably co-culture with a 
human leukemia cell line transduced with NK co-stimulatory molecules (K562 clone 9-mb21-
41BBL) (23, 53, 54). We purified human NK cells from healthy donor PBMCs and analyzed cells 
by flow cytometry and qRT-PCR over the course of 21 days for NK purity and expression of 
phenotypic and functional markers (Figure 6A). Bulk PBMCs, day 0 post-isolation NK cells, and 
day 6 post-activation NK cells show the enrichment of the distinct CD56bright and CD56dim 
populations, and subsequent enrichment of the CD56bright population as previously described 
(Figure 6B) (38). After six days, NK cells were highly proliferative as shown by representative 
flow cytometry staining of Ki67 expression (Figure 6C) and by quantitation of Ki67 expression 
from two different donors compared to day 0 NK cells post magnetic bead isolation (Figure 6D). 
We confirmed significant proliferation of NK cells using qRT-PCR to show >100-fold increase in 
mRNA expression of Ki67 expression (Supplemental Figure 6A) with 10-fold expansion of NK 
numbers by day 7, 100-fold expansion by day 12, and approximately 1000-fold expansion by 
day 19 (Figure 6E). Similar to our murine data, expanding NK cells significantly upregulated 
 146 
expression of activation marker CD69 (Figure 6F) and granzyme B (Figure 6G). We also observed 
increases in the expression of degranulation marker CD107a (Figure 6H), all consistent with a 
highly activated and functional NK phenotype. Despite evidence of activation, increased 
functionality, and proliferation, we observed no change in the insignificant expression of PD-1 
by flow cytometry (Figure 6I). Additionally, PD-1 expression was absent by qRT-PCR compared 
to unstimulated, freshly collected PBMCs and PBMCs stimulated with ConA (Figure 6J). As an 
added control for the subjective nature of flow cytometry gating, we also used an isotype 
control in order to confirm the presence or absence of PD-1 expression on NK cells 
(Supplemental Figure 6B-C). In contrast to absent PD-1 expression, we did detect meaningful 
expression of the inhibitory receptor TIGIT on NK cells during ex vivo expansion (Figure 6K), and 
we confirmed TIGIT upregulation by stimulated NK cells by mRNA analysis (Figure 6L). As recent 
studies have shown that dogs provide a tangible link in cancer immunotherapy studies with the 
potential for speeding translation of NK immunotherapy to the clinic (55, 56), we performed a 
similar expansion of NK cells using canine peripheral blood. qRT-PCR analysis at days 14 and 21 
using canine-specific markers revealed significant upregulation of activation marker NKp46 with 
increases in Ki67, TIM-3, and TIGIT. Importantly, as with ex vivo expansion of murine and 
human NK cells, we detected insignificant expression of PD-1 (Supplemental Figure 6D).   
Tumor infiltrating NK cells from human tumors show increased TIGIT but negligible PD-1 
expression.  
 
We then turned our attention to an assessment of NK cells from human cancer patients. 
Although prior reports have identified PD-1 expression on circulating or intra-tumoral NK cells, 
these studies have reported wide variation (from 0-70%) and have been inconsistent depending 
on tumor type evaluated (present in hepatocellular and squamous carcinoma of the neck, and 
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absent in colon cancer and melanoma) with similar inconsistency in flow gating strategies (28, 
57). Since an important factor in mediating anti-tumor effects is the number of effector cells 
present, we set out to investigate not only PD-1 expression on the NK and T cell repertoire from 
primary surgical specimens, but also the absolute number of NK and T cells present in the 
tumor. We chose to focus on soft tissue sarcomas and colon cancer, as pre-clinical studies have 
suggested that sarcomas and colorectal tumors are NK responsive (58–60). Preoperative CT and 
PET/CT imaging shows size, localization and gross appearance of patient-derived tumors (Figure 
7A). H&E staining demonstrates standard morphology and viable tumor from representative 
sarcoma and colon cancer specimens (Figure 7B). As shown in Supplemental Figure 7A, we 
again used conservative flow cytometry gating to identify peripheral and intra-tumoral NK and 
T (and NKT) cells. As shown in Figure 7C-D, representative flow cytometry shows NK and T cell 
populations from peripheral blood (Figure 7C) and the tumor (Figure 7D) of patient SA-1338 
(Round Cell Sarcoma). Peripheral NK cells expressed negligible PD-1, but prominent TIGIT 
compared to peripheral T cells that expressed both PD-1 and TIGIT (Figure 7C). Within the 
tumor matched from the same patient (Figure 7D), (similar to our murine tumor data) we 
observed a greater infiltrate of T cells compared to NK cells. In addition, the intra-tumoral NK 
infiltrate showed a near exclusive predominance of CD56dim NK cells in the tumor compared to 
the blood. Notably, intra-tumoral NK cells did not express PD-1, whereas T cells strongly did. 
Conversely TIGIT expression was present on both NK and T cells (Figure 7D). We also analyzed 
PBMCs and tumor infiltrating lymphocytes from a colon cancer patient (Figure 7E-F). Within the 
peripheral blood, the distribution of NK and T cells was comparable to sarcoma patients, and 
we observed similar immune phenotype with an absence of PD-1 expression on NK cells, but 
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positive PD-1 expression on T cells. We again identified notable expression of TIGIT on both 
peripheral NK and T cells (Figure 7E). Within the tumor microenvironment of colon cancer, 
there was a much higher proportion of NK cells (compared to sarcomas), although PD-1 
expression on NK cells remained negative with strong expression of TIGIT. Comparatively, there 
was approximately 20 – 30% expression of both PD-1 and TIGIT on intra-tumoral T cells (Figure 
7F). We then quantitated the percent of cells in the tumors represented by TILs, NK and T cells 
as well as total number of TILs, NK and T cells. We observed consistently low numbers of TILs 
and T cells among sarcomas with noticeably low frequencies and numbers of intra-tumoral NK 
cells (~1% of total live cells) as shown in Supplemental Figure 7B-C. When comparing peripheral 
versus intra-tumoral expression of PD-1 on NK and T cells, NK cells were consistently negative 
for PD-1, while T cells exhibited an increase in expression within the tumor microenvironment 
(Figure 7G). This was in comparison to TIGIT, which was expressed on both NK and T cells, in the 
periphery and intra-tumoral microenvironment (Figure 7H). When examining each tumor 
individually, PD-1 expression on NK cells was consistently negligible, while T cell expression was 
consistently robust and statistically greater (Figure 7I). Conversely, TIGIT was consistently 
expressed on both NK and T cells with no significant difference in cell surface expression levels 
(Figure 7J).  
4.4 Discussion 
Given the unequivocal successes of checkpoint blockade with anti-PD-1 monoclonal 
antibodies targeting T cell exhaustion in cancer therapy, there is considerable interest in 
identifying exhaustion pathways in NK cells to augment the clinical success of these effector 
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cells. Ultimately, however, a key question in NK biology remains regarding what are the 
fundamental markers of exhaustion in NK cells, how specific inhibitory molecules impact NK 
function in vivo, and consequently shape anti-viral, anti-tumor, and immunoregulatory 
functions. 
The paradigm of PD-1 expression on T cells is characterized by early upregulation of PD-
1 following TCR engagement with sustained expression in situations of chronic antigen 
exposure (61, 62). PD-1 upregulation and PD-1/PD-L1 signaling leads to important downstream 
events, including diminished TCR and CD28 signaling with loss of effector function, decreased 
proliferation, cytokine production, and T cell survival in cases of prolonged expression and T cell 
exhaustion (63). It is now well-established that in the setting of chronic antigen exposure, PD-1 
plays a critical role in dampening the T cell response and thereby limiting autoimmunity. 
Although the impact of PD-1 inhibition on T cell function has emerged as critical component of 
cancer immunotherapy, less is known about mechanisms of PD-1 expression in NK cells, 
whether NK cells manifest an exhausted (versus anergic or senescent) phenotype, and whether 
similarly complex immunoregulatory mechanisms contingent upon PD-1 expression occur in 
shorter-lived, polyclonal NK cells. In contrast to T cells, the functional status of NK cells is 
regulated by the cumulative effect of multiple activating and inhibitory signals, rather than 
direct competition between antigen-triggered co-stimulatory and co-inhibitory receptors (such 
as CD28 and PD-1) (64). These critical differences between NK cells and T cells raise the 
question of what role PD-1 would play on NK cells given the diverse and frequently antagonistic 
immunological functions they fulfill in eliminating pathogens versus suppressing potential auto-
immunity (65). These questions are further clouded by some studies showing PD-1 expression 
 150 
exclusively on activated NK cells (38) while others identifying PD-1 expression on NK cells with a 
dysfunctional phenotype (18, 36).  
   In our diverse pre-clinical models and cross-species evaluations using ex vivo activation, 
viral infection models, multiple tumor models, and human tumor samples, we were unable to 
identify biologically meaningful PD-1 expression on NK cells despite evidence of strong NK 
activation in these diverse settings. Although we relied heavily on flow cytometric assessment 
for our immune phenotyping of NK and T cells and expression of key markers, including PD-1, 
we also validated our flow results using both qRT-PCR and RNA sequencing techniques to 
reinforce our flow cytometry data. Notably, our data stand in contrast to recent studies which 
have found evidence of PD-1 expression on subsets of mouse and human NK cells under similar 
conditions (18, 30, 38). For example, in mice, PD-1 was detected on NK cells following acute 
MCMV infection, although expression was limited to the spleen and to a relatively narrow time 
frame (30). While we also detected a small, but significant increase in PD-1 expression on 
splenic NK cells post MCMV, this increase was negligible and raises the question of the 
potential biological significance of an increase in PD-1 expression of approximately 1 – 2%. In 
addition, we did not observe PD-1 induction on NK cells by qRT-PCR analysis using Rag2-/- mice 
suggesting that these incremental changes in flow cytometry expression may be subject to 
confounding factors. For example, specimen processing has been shown to interfere with 
lymphocyte marker detection, notably on T cells (66, 67), and technical factors such as these 
may introduce false positive results, especially when small differences are detected.  
Another important factor impacting synthesis of the published data is the differences in 
tissue expression of PD-1 on NK cells which have been observed. Unlike Quatrini and colleagues 
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who identified PD-1 expression specifically on splenic NK cells after MCMV infection mediated 
by glucocorticoid signaling (30), Hsu et al. did not observe PD-1 expression on splenic NK cells in 
tumor-bearing mice (18). In contrast, these authors identified markedly variable PD-1 
expression on tumor-infiltrating NK cells in multiple syngeneic tumor models (18). Though PD-1 
expression was variable, putative NK depletion (using αASGM1) inhibited the anti-tumor effects 
of PD-1 blockade, suggesting an inhibitory effect of PD-1 expression on NK cells. However, as 
our data also reinforce, ASGM1 depletion has pleotropic effects, and prior groups have shown 
expression of ASGM1 on T cells, macrophages, activated monocytes, and basophils under 
certain conditions (46, 68, 69). Slifka et al. showed in vivo depletion of NK cells with anti-
ASGM1 Ab resulted in the removal of 90% of virus-specific CD8+ T cells and 50–80% of virus-
specific CD4+ T cells in an LCMV model (70). Moore et al. demonstrated upregulation of ASGM1 
on activated CD8+ T cells in both BALB/c and C57BL/6 mice following respiratory syncytial virus 
infection (71). 
Our data further show that ASGM1 expression is associated with activated T cells, and T 
cell activation is clearly associated with PD-1 upregulation. Therefore, ASGM1 depletion of 
activated T cells preferentially eliminates PD-1+ T cells, thus confounding interpretation of NK-
related anti-tumor effects related to PD-1 inhibition when combined with ASGM1 depletion. 
Hsu et al. also performed NK1.1 depletions in C57BL/6 tumor models as further evidence 
implicating NK cells in the mechanism of anti-tumor effects mediated by PD-1 inhibition (18). 
Although NK1.1 depletion is more selective for NK cell depletion, it also depletes NKT cells and, 
as we observed, appears to have non-specific effects on activated T cells as well. Therefore, it is 
difficult to categorize any of these depletion strategies as “NK specific”.  
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Another important caveat of studies showing expression of PD-1 by NK cells is that they 
almost exclusively rely on flow cytometry to assess PD-1 expression. Although flow cytometry 
clearly provides high dimensional and highly granular data, analysis and determination of 
whether cells “positively” or “negatively” bind fluorescently-labelled antibodies to molecules of 
interest is accomplished by sequential manual gating of cellular “events” into populations 
based on visual inspection. Therefore, despite the sophisticated nature of data acquisition by 
flow cytometry, gating strategies for data interpretation remain subjective, and this subjectivity 
is prone to potential bias and/or variability. In fact, the subjective nature of manual gating 
strategies has been shown to lead to disparate and contradictory results even in the hands of 
experienced researchers provided identical data sets. Maecker and colleagues observed that a 
significant portion of inter-laboratory variability in flow cytometry data analysis could be 
eliminated by centralization of data interpretation in one or a handful of selected laboratories 
along with the use of a dynamic gating strategy based on computer-generated clustering 
algorithms (72). Moreover, despite the use of these strategies, the subjectivity and potential 
variability in flow cytometry data interpretation was improved, but not completely eliminated. 
An additional pitfall of flow cytometry is the potential for changes in the molecular or 
metabolic condition of cellular preparations to skew the binding properties of either the 
antibodies or epitopes of interest, leading to variable or unpredictable results. This technical 
limitation of flow cytometry was recently detailed in a publication by Metzger et al. (73) . Based 
on novel data suggesting PD-1 could be expressed on melanoma cells (74), the authors 
discovered that dying immune and tumor cells unmask and express a nuclear antigen that 
cross-reacts with mouse anti-PD-1 monoclonal antibodies and thereby provides a source of 
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false-positive PD-1 expression (73). Importantly, in this study, the spurious PD-1 staining related 
to dying cells occurred even in the presence of a viability fluorochrome to delineate live and 
dead cells. Consequently, technical and analytic nuances have significant implications for 
determining the robustness and validity of flow cytometry data interpretation, in this case with 
respect to PD-1 expression. This is further complicated by the cellular phenomenon of 
trogocytosis, which has been identified on NK cells with subsequent functional effects (75, 76). 
In cases where the data obtained are difficult to reconcile, especially in the case of NK PD-1 
expression where questions regarding the biology of PD-1 expression on NK cells remain, these 
technical limitations can be significant. For that reason, in our study, we also employed PCR and 
RNA sequencing, in addition to the analysis of NK cells from T- and B-cell deficient Rag2 -/- mice, 
in order to provide key confirmatory experiments supporting our flow cytometry data showing 
insignificant expression of PD-1 on NK cells across diverse human samples and mouse models. 
In addition, we used PCR on pure NK populations (mouse ALAKs and ex vivo expanded human 
NK cells) to assess PD-1 expression at the RNA level, further supporting our flow cytometry data 
showing negligible PD-1 expression on NK cells. 
Although we cannot completely eliminate the potential for NK cells to express PD-1 on a 
small fraction of NK cells in highly selected situations, our data from both mouse and human 
tumors show that NK cells are overall a small fraction of the immune infiltrate. Therefore, it is 
difficult to envision a situation where a single digit fraction of PD-1+ NK cells of a small sub-
population of intra-tumoral NK cells are mediating biologically significant anti-tumor effects. 
Given our extensive analysis of multi-species NK cells in diverse viral, tumor, and cytokine-
activated models showing negligible expression of PD-1 on NK cells, our data do not support 
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direct effects of anti-PD-1 therapy on augmenting NK responses. It is conceivable that PD-1 and 
PD-L1 inhibition may exert indirect effects on NK effector function leading to heightened NK 
responses independent of direct expression of PD-1 by NK cells. As PD-L1 is frequently 
expressed on tumor cells, anti-PD-L1 antibodies (as well as other monoclonal antibodies) may 
activate NK cells via antibody-dependent cellular cytotoxicity (ADCC) rather than intrinsic 
signaling via the PD-1 pathway. It is also possible that the effects of PD-1 or PD-L1 inhibition on 
NK cells could be mediated through PD-L1 signaling on NK cells or through augmenting 
paracrine or endocrine signaling by T cells. Recently, Zhou et al. illustrated the inhibitory 
interaction of PD-L1+ liver resident NK (LrNK) cells against PD-1+ T cells in the response to viral 
hepatitis showing that LrNK cells inhibit T cells and dampen the anti-viral response while 
decreasing immunopathology (69). As NK cells have been observed to exert 
immunosuppressive effects on cytotoxic T cells, disrupting PD-1/PD-L1 interactions between NK 
and T cells may also release inhibitory signals on T cells and thereby indirectly implicate NK cells 
in augmented T cell function.  Similarly, Dong et al. identified a PD-1-independent mechanism 
of antitumor efficacy via the activation of PD-L1+ NK cells using an anti-PD-L1 antibody. This 
study provides another potential explanation for why some patients who lack PD-L1 expression 
on tumor cells may still respond to ICI, although in this case PD-L1 blockade (77). Finally, while 
studies of PD-1 expression on NK cells are mixed, there are other studies which have observed 
additional checkpoint markers such as TIGIT, LAG-3, and Tim-3 as critical regulators of NK 
function in the absence of PD-1 expression (28, 35, 40). 
Overall, our results highlight the growing body of literature showing the absence of 
significant PD-1 expression on mouse and human NK cells under multiple heterogenous 
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conditions where NK cells are highly activated (28, 35, 73). To our knowledge, this is the most 
comprehensive analysis of NK PD-1 expression utilizing multiple species, conditions, and 
detection methods. In doing so, we repeatedly identified negligible expression of PD-1 on NK 
cells across multiple viral and tumor models as well as with highly clinically relevant human 
specimens. Fundamentally, the relative paucity of NK cells within mouse and human tumors 
raises challenges for augmenting the anti-tumor effects of endogenous NK cells through PD-1 
inhibition (78). PD-1/PD-L1 immune checkpoint blockade has unequivocally revolutionized 
cancer therapy with a transformational impact on growing numbers of cancer patients. 
However, it is also clear that the PD-1/ PD-L1 axis has critical immuno-regulatory functions 
which govern fundamental aspects of immune signaling and immune cross-talk. Nevertheless, 
among cytotoxic lymphocytes, this critical axis primarily regulates T cell function, and the extent 
to which other immune cellular constituents such as NK cells are physiologically regulated by 
PD-1 remains unclear. Overall, our data indicate that NK responses in multiple models across 
multiple species are not contingent on PD-1 expression or upregulation, whereas TIGIT is 
repeatedly upregulated following NK activation. A better understanding of the expression and 
functional implications of these inhibitory markers in the biology and application of NK cells will 






Figure 4.1: In vitro activated murine NK cells do not upregulate PD-1. Resting and activated NK 
cells were prepared from WT C57BL/6 and Rag2-/- splenocytes. (A) Representative NK1.1 and 
CD3 gating shows NK and T cell populations from resting mice. (B-C) Untreated NK cells (CD3-
NK1.1+NKp46+) and T cells (CD3+NK1.1-) are not activated with low CD69 expression. NK cells 
lack PD-1 expression, while T cell PD-1 expression is also low. (D) Adherent lymphokine-
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activated killer (ALAK) cells were prepared by culturing splenocytes in 1000 IU/mL rhIL-2 for 7 
days. Parent gating shows enriched NK cell population compared to resting splenocytes. With 
cytokine activation, (E) NK cells are highly activated by CD69 expression but still lack PD-1 
expression, (F) while T cells exhibit moderate CD69 expression while PD-1 expression remains 
low. (G) Culture with T cell mitogen ConA leads to robust PD-1 expression on T cells, while 
expression on NK cells remains insignificant. (H-I) Schema for RNA sequencing analysis of 
resting versus IL-2 stimulated sorted NK cells from WT mice. Despite marked upregulation of 
activation and proliferation markers, no expression of PD-1 is observed. (J) Utilizing Rag2-/- 
splenocytes for isolation of pure NK cells, ALAK cells were generated. (K) NK cells are highly 
activated by CD69 expression, but PD-1 remains absent. (L) Comparing WT ALAK cells and Rag2-
/- ALAK cells to unstimulated WT splenocytes, mRNA expression of PD-1 was negligible on Rag2-
/- NK cells, while expression of granzyme B is robustly upregulated. Mean ± SD for n = 3 
donors/group, representative of 2-3 individual experiments. ****P < 0.0001, one-way ANOVA 





Figure 4.2: Mouse intra-tumoral NK cells do not upregulate PD-1. (A) Gating strategy for 
analysis of intra-tumoral NK and T cells generated by SC implantation of CT26 tumors in BALB/c 
mice. Analysis of tumors revealed marked heterogeneity in (B) total cells present, (C) percent of 
live cells, (D) and percent of live cells represented by NK and T cells. (E – F) NK cells in CT26 
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tumors showed increased expression of activation marker CD69 and functional marker 
granzyme B, compared to splenic NK cells. (G) Representative NK cell (CD3-NKp46+ for BALB/c 
or CD3-NK1.1+NKp46+ for C57BL/6) and T cell (CD3+NK1.1-) parent gating with expression of PD-
1 on NK and T cells for CT26, 4T1, B16, and 3LL SC tumors. (H) Aggregate expression across 
tumor models shows consistently negligible expression of PD-1 on NK cells with significantly 
higher expression on T cells within tumors. (I) PD-1 reporter mice were implanted with SC CT26 
tumors and tumor infiltrating NK and T cells were analyzed for PD-1 expression. Using the 
reporter system, PD-1 expression on intra-tumoral NK cells remains minimal compared to T 
cells as seen by representative flow plots and (J) summary data. (A-H) Mean ± SD for n = 3-14 
mice/group and representative of 2 – 3 experiments. (I – J) Mean ± SD for n = 3 mice/group. *P 




Figure 4.3: In vivo acute MCMV infection leads to upregulation of TIGIT, not PD-1, on mouse 
highly activated NK cells. (A) WT C57BL/6 and Rag2-/- mice were infected with 2x104 pfu 
MCMV. (B) At 72 h, viral titers were elevated in the liver. (C) Representative parent gating from 
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spleens of uninfected and MCMV-infected C57BL/6 mice shows NK and T cell populations. 
Compared to uninfected mice, MCMV-infected mice had significant upregulation of (D) CD69 
and (E) Thy1.2 on NK cells in the spleen and liver 3 days post infection. (F) PD-1 expression on 
NK cells in WT mice remained minimal, while (G) TIGIT was upregulated. (H) Though biologically 
insignificant (1-2% increase), the measured increase in PD-1 was statistically significant, while 
TIGIT was upregulated by 15-25% under identical conditions. (I) Parent gating of splenocytes 
from acute MCMV infection in the Rag2-/- mice with marked upregulation of (J) CD69, while (K) 
PD-1 was negligible, and (L) TIGIT upregulation was significant. (M) Isolated splenocytes were 
analyzed by qRT-PCR. PD-1 mRNA expression on MCMV-infected Rag2-/- splenocytes was 
negligible compared to uninfected WT splenocytes, while both infected groups exhibited 
marked upregulation of granzyme B. PD-1 expression on T cells remained minimal at day 3 
(data not shown), (N) but was upregulated on post-infection day 7, while NK expression of PD-1 
remained negligible. Mean ± SD for n = 3 mice/group, representative of 3 individual 
experiments. *P <0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired Student’s t test (D, 





Figure 4.4: Anti-ASGM1 depletes activated PD-1+ T cells following MCMV infection. (A) 
Schema depicting NK depletion strategies and MCMV infection in C57BL/6 mice. (B) 
Representative parent gating for NK and T cell populations in untreated, MCMV-infected, and 
MCMV-infected mice with ASGM1 depletion. (C) Total NK and T cells collected from the spleens 
of each group, with significant loss of NK cells with aASGM1 and MCMV + aASGM1, and 
significant loss of T cells with MCMV + aASGM1 only. (D) Representative ASGM1 expression on 
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T cells from each treatment group illustrating the increase in ASGM1 expression with virally-
induced T cell activation. (E) Mean percent ASGM1+ T cells was significantly higher in the 
MCMV-infected groups, while total ASGM1+ T cells was significantly lower following MCMV + 
aASGM1. (F) Representative PD-1 expression on T cells from each treatment group illustrates 
the increase in PD-1 expression with virally-induced T cell activation. (G) Mean percent PD-1+ T 
cells was significantly higher in the MCMV-infected groups, while total PD-1+ T cells was 
significantly lower following MCMV + aASGM1. (H) Representative gating shows the proportion 
of ASGM1+PD-1+ in the MCMV infected groups and the impact of ASGM1 depletion on reducing 
activated, PD-1+ T cells after viral infection. Mean ± SD for n = 2-5 mice/group. Representative 






Figure 4.5. In vitro activation of human PBMCs leads to PD-1 expression on T cells, not NK 
cells. (A) Representative gating showing NK and T cell populations from freshly isolated human 
PBMCs after 72 h in media. (B) Resting CD56+CD3- NK cells lack expression of activation marker 
CD69 and are negative for PD-1, (C) while resting CD56-CD3+ T cells also lack expression of 
CD69, but have baseline expression of PD-1. (D) After culture in ConA for 72 h, NK cells have 
increased CD56 expression, (E) with activation by CD69 upregulation and continued absence of 
PD-1. (F) With ConA stimulation, T cells exhibit increased CD69 expression and robust PD-1 
expression. (G) After culture in 1000 IU/mL rhIL-2 for 72 h, (H) NK cells upregulate CD69 with 
negligible PD-1 expression. (I) In contrast, CD3+ T cells exhibit moderate increases in both CD69 
and PD-1. (J) After culture in 100 ng/mL rhIL-15 for 72 h, (K) NK cells also upregulate CD69 with 
negligible PD-1 expression. (L) Similar to IL-2 stimulation, CD3+ T cells exhibit moderate 
increases in both CD69 and PD-1. (M) Summary data show significantly increased expression of 
CD69 on NK and T cells with either ConA, IL-2, or IL-15 compared to media alone. (N) Under 
identical conditions, PD-1 was significantly upregulated on ConA-stimulated T cells with no 
change in PD-1 expression on NK cells under any condition. Mean ± SD for n = 6 unique human 
donors. Representative of 2 – 3 individual experiments. ***P < 0.001, ****P < 0.0001, one-way 





Figure 4.6: Ex vivo generation of expanded and activated human NK cells upregulate TIGIT not 
PD-1. (A) Schema for generation of ex vivo human NK cells isolated from healthy donor PBMCs, 
then co-cultured with K562.clone 9 cell line and 100 IU/mL rhIL-2. (B) Representative flow 
cytometry gating shows NK and T cell populations before and after NK isolation, then during NK 
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expansion. (C) After 6 days, NK cells are highly proliferative as seen by representative flow 
cytometry for Ki67 and (D) a significant increase in Ki67+ NK cells at day 6. (E) Co-culture 
demonstrates robust NK expansion. In addition to NK cell expansion, there is a significant 
upregulation of (F) CD69 expression, (G) granzyme B expression, and (H) CD107a degranulation. 
Although isolated NK cells are highly proliferative with upregulation of activation and functional 
markers, (I) there was no expression of PD-1 shown by representative staining and summary 
data across all time points analyzed. (J) Isolated NK cells were also analyzed for PD-1 mRNA 
expression by qRT-PCR and compared to unstimulated (day 0) PBMCs. PD-1 expression on 
isolated and expanded NK cells was undetectable by qRT-PCR at all time points. (K) In contrast, 
we detected consistent and significant upregulation of TIGIT on NK cells seen by representative 
flow on day 6, and summarized for all time points analyzed. (L) qRT-PCR analysis confirmed 
significant upregulation of TIGIT mRNA expression at all time points compared to unstimulated 
(day 0) PBMCs. Means ± SD for n = 3 (B, F-L) or n = 2 (C-E) individual human donors. 
Representative of 3 – 4 individual experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 





Figure 4.7: Tumor infiltrating NK cells from human tumors show increased TIGIT and 
negligible PD-1 expression. Tumor infiltrating lymphocytes (TILs) were analyzed from freshly 
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resected human tumor specimens for expression of PD-1 and TIGIT and compared to circulating 
PBMCs from matched donors. (A) Preoperative CT, PET/CT, and intra-operative surgical 
specimens showing relative size of tumors analyzed. (B) Representative H&E staining from each 
specimen. Representative flow cytometry of NK and T cell populations and PD-1 and TIGIT 
expression on NK and T cells from (C) peripheral blood and (D) tumor of a patient with Round 
Cell Sarcoma. (C-D) PD-1 expression on peripheral and intra-tumoral NK cells was negligible 
compared to expression on T cells, while TIGIT was expressed on both NK and T cells. 
Representative staining from (E) peripheral blood and (F) tumor from a patient with colon 
cancer showing a much greater infiltration of immune cells and higher proportion of NK cells. 
(G) No upregulation of PD-1 was detected on infiltrating NK cells compared to peripheral, while 
T cell PD-1 expression did increase. (H) TIGIT was highly expressed on NK and T cells in both the 
periphery and intra-tumoral microenvironment. (I) PD-1 expression was negligible on NK cells in 
all tumors analyzed, while PD-1 expression was consistently, and significantly higher. (J) TIGIT 
was expressed on both NK and T cells in all tumors analyzed.  Mean ± SD for n = 5 tumors. *P < 





Supplementary Figure 4.S1: In vitro activated murine NK cells do not upregulate PD-1. (A) 
Gating strategy for analysis of NK and T cells from cytokine activated mouse splenocytes, gating 
of singlets, cells, live cells, NK1.1 vs CD3. (B) Representative histogram showing PD-1 staining 
intensity on NK cells and T cells isolated from the spleens of lean and DIO mice, and (C) 
summary data for PD-1 expression. T cells from DIO mice show increased PD-1 expression, 
while NK cell expression of PD-1 remained absent in both groups. (B-C) Mean ± SD for n = 3 





Supplementary Figure 4.S2: Mouse intra-tumoral NK cells do not upregulate PD-1. (A) Gating 
strategy for analysis of intra-tumoral NK and T cells generated by subcutaneous implantation of 
4T1, B16, and 3LL tumors in BALB/c or C57BL/6 mice. NK cells further gated on NKp46+ in 
C57BL/6 mice. (B) Representative flow cytometry showing PD-1 expression on NK and T cells 
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compared to isotype control in CT26 tumor. (C) Schematic genetic map showing the design of 
the PD-1 reporter mouse and TdTomato fluorescent protein insertion. (D) Representative 




Supplementary Figure 4.S3: In vivo acute MCMV infection leads to upregulation of TIGIT, not 
PD-1, on mouse highly activated NK cells. (A) Similar corticosterone levels were measured in 
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the serum of MCMV-infected WT and Rag2-/- mice at 48 h post-infection. (B) Representative 
gating strategy from Rag2-/- spleen that was used for analysis of NK and T cells in both spleen 
and liver of all mice evaluated. (C) Representative flow cytometry and (D) summary data 
showing marked increase in activation marker CD69 expression with MCMV infection, and no 
significant PD-1 expression on NK cells. TIGIT expression increases significantly on liver NK cells 
with acute MCMV infection. Mean ± SD for n = 3 mice/group, representative of 3 individual 





Supplementary Figure 4.S4: Anti-ASGM1 depletes activated PD-1+ T cells following MCMV 
infection. (A) Parent gating showing NK and T cell populations in all treatment groups. NK cells 
are depleted with ASGM1 and NK1.1 targeting, while T cells are depleted in ASGM1 depletion 
with MCMV infection only. (B) Percent T cells in each treatment group compared to untreated 
or MCMV infection only group. (C) ASGM1+PD-1+ proportion remains present in group with 
MCMV infection and NK1.1 depletion. Mean ± SD for n = 2-5 mice/group, representative of 2 





Supplementary Figure 4.S5: In vitro activation of human PBMCs leads to PD-1 expression on T 
cells, not NK cells. (A) Representative gating for analysis of NK92 cells after in vitro culture in 
500 IU/mL rhIL-2. Cells are CD3-CD56bright and (B) highly express TIGIT, (C) but completely lack 
expression of PD-1 as seen by gating comparing FMO, isotype, and PD-1 stain. (D) qRT-PCR 
analysis of NK92 cells confirms no expression of PD-1 and increased expression of TIGIT as 
compared to resting, healthy human PBMCs. ConA stimulated PBMCs shown for positive 




Supplementary Figure 4.S6: Ex vivo generation of expanded and activated human NK cells 
upregulate TIGIT not PD-1. (A) qRT-PCR analysis of expanded human NK cells showing 
increased mRNA expression of proliferation marker Ki67, as compared to unstimulated day 0 
PBMCs. (B) Representative gating from day 6 co-culture expansion showing PD-1 isotype and 
PD-1 stain on NK cells, (C) and representative histogram of staining intensity compared to 
isotype control. (D) qRT-PCR analysis of expanded canine NK cells showing increased expression 
of NKp46, Ki67, TIM-3, and TIGIT, with minimal expression of PD-1 at day 14 and 21, as 
compared to freshly isolated canine NK cells. Means ± SD for n = 3 individual human donors. (D) 
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Representative of single canine donor expansion. Experiments were repeated 3-5 times for 





Supplementary Figure 4.S7: Tumor infiltrating NK cells from human tumors show increased 
TIGIT and negligible PD-1 expression. (A) Representative gating strategy for analysis of 
peripheral and intra-tumoral NK and T cells from human cancer patients. (B) Percent of live 
cells, and (C) total cells represented by TILs, NK cells and T cells among all sarcomas analyzed. 
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CHAPTER 5: DISCUSSION 
5.1 Cancer Immunotherapy Summary 
Cancer immunotherapy, manipulating the immune system to eliminate tumor cells, has 
demonstrated increased efficacy as a therapy for patients with cancer.  There are many types of 
immunotherapies that target different facets of both the innate and adaptive immune system.  
Cancer vaccines help develop a tumor specific response by introducing tumor antigens, in 
addition to an immune boosting adjuvant, to mount a productive adaptive anti-tumor immune 
response.  An aspect of cancer vaccines that needs advancement is the fact that many cancers 
express antigens that are shared by non-cancerous cells.  A robust immune response against 
these antigens results in on-target off-tumor toxicity.  Another form of cancer immunotherapy 
is adoptive cell transfer, where autologous T cell are taken and modified to be specific against 
the cancer antigens.  While this is an exciting new field of cancer immunotherapy, additional 
research remains to be done.  Finally, immune checkpoint inhibitors allow activated immune 
cells in the tumor microenvironment (TME) to remain fully functional by blocking inhibitory 
receptors.  With the addition of PD-1 blockade to the TME, the CD8+ cytotoxic T cells are 
proposed to remain functional and aid in tumor elimination [1].  One complication to this model 
of PD-1 blockade success is that more immune cell subsets than CD8+ T cells have been shown 
to express PD-1 [2-5].  While in the TME PD-1 blockade may boost the cytotoxic capabilities of 
activated CD8+ T cells, it is likely that it additionally affects other cell subsets in the TME 
expressing PD-1, which are largely unstudied.  In some cancers, a large portion of patients 
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benefit from immune checkpoint inhibition, while in other cancers, like triple negative breast 
cancer, only a small fraction benefit from any increase in overall survival [6].  A looming 
unanswered question in immunotherapy is why only a fraction of patients respond to immune 
checkpoint therapy.  This dissertation aims to address ways to improve immune checkpoint 
inhibition therapy. 
5.2 Summary of Findings 
First, we looked at different subtypes of breast cancer and found that the subtype 
claudin low, a type of TNBC, is heavily immune infiltrated with different subsets of immune 
cells, including CD8+ T cells, CD4+Foxp3- T cells, CD4+Foxp3+ Tregs, and CD19+ B cells.  We found 
that the total number of Tregs is greater than the total number of CD8+ T cells by a ratio of about 
1.5 Tregs to 1 CD8+ T cell.  Despite heavy immune infiltration, the claudin-low tumors do not 
respond to dual immune checkpoint inhibition therapy.  Additionally, of the T cell subsets, Tregs 
express the highest levels of PD-1 in this cancer model.  We found that T cell depletion alone 
delays tumor growth and improves survival.  Methods of Treg depletion in the TME that are not 
specific to Tregs, such as PI3K p110 inhibition or CXCL12/CXCR4 blockade, while reducing the 
number of Tregs does not provide specificity for a productive anti-tumor immune response that 
results in tumor elimination as both effective and regulatory T cells are inhibited.  Only specific 
and complete genetic depletion of Tregs improved efficacy of immune checkpoint inhibition in 
this model of cancer.  These data were the first to provide a mechanism for the poor response 
to checkpoint inhibitor therapy for patients with TNBC and highlighted the role of PD-1+ Tregs in 
the tumor as possibly inhibiting a productive immune response in this immune infiltrated 
tumor.  A biomarker used to predict response to immunotherapy has often been immune 
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infiltration.  Our work has contributed to the field of immunotherapy by suggesting that instead 
of immune infiltration as a biomarker, the whole tumor microenvironment should be 
considered including the immunosuppressive cells.   
The second somewhat unexpected finding from this manuscript was that in the TME 
Tregs had the greatest expression of PD-1.   This led to the hypothesis that anti-PD-1 mAb could 
enhance the function of PD-1-expressing Tregs which would limit the activity of checkpoint 
blockade in TNBC.  To evaluate this hypothesis, the role of PD-1 blockade on PD-1+ Tregs in 
claudin-low tumors was investigated.  In evaluating transcriptional differences between Tregs 
from tumor treated with PD-1 blockade versus untreated, 27 differentially regulated genes, 
including Jun, Fos, and Bcl2, were identified in Tregs in the TME exposed to anti-PD-1 mAb 
versus control.  These findings suggested that anti-PD-1 mAb enhanced the survival of tumor-
infiltrated Tregs .  This was confirmed by evaluating proliferation and apoptosis ex vivo.  Tregs 
treated with PD-1 blockade proliferate to higher levels than untreated Tregs in vitro and in vivo.  
These Tregs also are protected from glucocorticoid inducted apoptosis ex vivo, which was 
correlated with higher Bcl-2 expression.  Finally, Tregs treated with PD-1 blockade also suppress 
more efficiently than their untreated counterparts.  Taken together, these findings suggest that 
immune checkpoint inhibition targeting PD-1 can enhance the function and survival of Tregs in 
the TME.  This work contributes to the field of immunotherapy by demonstrating that PD-1 
blockade can function on cell subsets other than cytotoxic CD8+ T cells which can lead to 
profound effects on the immune response in the tumor.  In our work, PD-1 expressing Tregs 
respond to checkpoint therapy by increasing the immunosuppressive environment in the tumor 
and preventing a productive anti-tumor immune response.  Our work highlights the need to 
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understand the tumor microenvironment before determining which patients should receive 
immune checkpoint inhibitors.  Thus, we would predict that the ratio of PD-1 expression on 
CD8+ T cells vs CD4+ Tregs prior to therapy could be a potential biomarker for response to anti-
PD-1 mAb therapy.  This could be performed in future clinical trials with the caveat that 
expression needs to be evaluated in the TME.   
 Finally, in collaboration with Dr. William Murphy’s lab, we explored the role of PD-1 on 
the natural killer cell subset.  Natural killer (NK) cells are a group of innate immune cells that 
play a major role in anti-tumor immunity through directly killing tumor cells and production of 
IFNg [7].  In an increasing number of studies, PD-1 expression has been detected on a subset of 
NK cells in cancer patients [8-12].  It is still unclear what may cause PD-1 expression on NK cells, 
and in what context this expression might occur as not all NK cells are shown to express PD-1.  
There are also studies to suggest that PD-1 blockade may boost NK cells function during cancer 
immunotherapy [2].  But since only a small, widely variable, percentage of NK cells express PD-
1, an important unanswered question is if these PD-1+ NK cells are biologically relevant during 
immune checkpoint inhibition.  We found that NK cells do not express PD-1 during normal 
resting conditions, which is to be expected as other cell subsets only upregulate PD-1 
expression after activation.  When NK cells are cultured ex vivo with activating cytokine IL-2, 
PD-1 expression is negligible despite upregulation of NK cell activation and functional markers.  
Additionally, NK cells isolated from tumor bearing mice have limited upregulation of PD-1 as the 
percentage of NK cells expressing PD-1 is only as high as 7 percent, which is significantly lower 
than the percentage of PD-1+ T cells.  During infection with the viral pathogen MCMV, which is 
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known to activate NK cells, there is additionally a small increase of NK cells expressing PD-1, but 
much lower than PD-1 expression on T cells.   
Thus, these data show that NK cell expression of PD-1 is negligible compared to the 
expression by CD8+ T cells.  It seems quite unlikely that alterations in the function of NK cells 
after anti-PD-1 mAb therapy is a significant contributor to the clinical outcome.  This 
phenomenon is true for both NK cells isolated from the tumors of mice and humans.  This work 
highlights challenges to our understanding of whether PD-1 expression on innate or adaptive 
immune cells correlates with their function in controlling tumor growth in patients or animal 
models treated with checkpoint inhibitor therapy.  We also found that PD-1 expression was 
variable on subsets of NK cells.  The function of PD-1 on those NK subsets that have greater 
expression of PD-1 is currently not known.  This work contributes to the field of immunotherapy 
by demonstrating that while a cell may be capable of expressing an immune checkpoint 
receptor, it does not mean that it will have a biologically relevant impact during immune 
checkpoint inhibition.  This work also highlights the fact that there are still many answered 
questions about the role of PD-1 on less studied cell subsets.    
5.3 Evaluating the Immune Tumor Microenvironment 
A main conclusion from the work in this dissertation is that understanding the immune 
landscape in the TME is crucial for increasing the effectiveness of immunotherapy.  The 
immune infiltrated, or “hot” tumor is not a reliable biomarker for predicting who will benefit 
from immune checkpoint therapy.  Instead, the immune subsets infiltrating into tumor should 
be analyzed to determine the proportions of cytotoxic to suppressive cells and which cell 
subsets are expressing targetable immune checkpoint receptors, such as PD-1.  The concept of 
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understanding each individual patient’s tumor immune landscape prior to determining the 
most beneficial immunotherapy unique for that patient is termed personalized medicine.  As 
cancer is a heterogenous disease, and immune responses between patients vary, determining 
both the tumor type and potential neoantigens in addition to the complete immune infiltration 
picture for each individual patient is crucial to developing a personalized treatment plan.  
Thankfully, this has become faster and less expensive in recent years with the advancement of 
sequencing technology.  Large scale sequencing was expensive and inefficient until Next 
Generation Sequencing Technologies were developed, allowing for rapid sequencing of 
individual patients to become a reality [13].  This allowed for large data sets to be made publicly 
available with transcriptomic, genomic, and epigenomic data ranging from immune gene 
signatures found in the tumors, to mutations in common cancer antigens [14].   
An even more detailed understanding of immune infiltration into the tumor has become 
possible recently with the advancement of single-cell RNA sequencing (scRNA-seq) [15].  This 
technology has helped uncover the heterogeneity of tumor infiltrating lymphocytes and has 
helped characterized less-defined immune cell subsets [16].  10x Genomics as a means of 
performing scRNA-seq is growing in use due to its low cost and easy use, but has low RNA 
capture efficiency.  Because of this, it is hard to detect subtle differences among cell subsets, 
especially when a low number of immune cells are present within the tumor sample.  With 
further advances in efficiency and cost, a detailed snapshot of the tumor infiltrating 
lymphocytes will established before a treatment regimen is determined.  With scRNA-seq 
technology, in addition to determining the transcriptome profiles for individual immune cells 
infiltrating the tumor, it is also possible to sequence the T cell receptor to determine the clonal 
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lineages of the T cell response.  A recent study analyzed the TCR sequences of T cells infiltrating 
into a tumor before and after PD-1 therapy, and determined that instead of expanding the 
existing population of T cells within the tumor, the immune checkpoint therapy recruited in 
clonally distinct T cells [17].  This study suggests that PD-1 blockade therapy may be more 
complex than just reinvigorating dysfunctional T cells within the tumor.  The expanded TCR 
clones found in the tumor after PD-1 blockade, while not detected within the tumor pre-
treatment, could be found circulating in the peripheral blood suggesting they were being 
recruited to the tumor from the circulation.  It is possible that the single cell sequencing 
technology required for this study was not sensitive enough to detect the expanded T cells in 
the tumor prior to treatment.  Even with this study’s flaws, it demonstrates how these 
emerging technologies such as scRNA-seq and TCR sequencing of immune cells infiltrating into 
tumors will greatly inform the way we understand immunotherapy and aid in developing better 
strategies.  Single cell immune monitoring can also be achieved through flow cytometry, 
although limitations are that the number of immune cell markers available at one time are 
limited, which also must be known in advance.   
Another technology that will enhance personalized medicine and immunotherapy is 
mass cytometry (CyTOF).  CyTOF is similar to traditional flow cytometry, but rather than 
conjugate monoclonal antibodies to fluorescent markers, the monoclonal antibodies are 
conjugated to heavy-metal isotopes allowing for minimization of spectral overlap.  To combat 
the limitation of the number of molecular features able to be captured, CyTOF allows for 
collecting data on more molecular markers while reducing signal overlap and background noise 
[18 19].  One benefit to CyTOF analysis over scRNA-seq is that you are able to capture immune 
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marker data on very few cells.  This is applicable for immunotherapy biomarker discovery 
because if the patient tumor sample has immune cells present in very low numbers, it is 
possible for these to remain undetected in transcriptome analysis, although the sensitivity for 
detection in CyTOF will be greater [20].  One limitation to all of these technologies is that they 
do not provide any information on the spatial positioning of the immune cells within the tumor 
microenvironment.  It has been proposed that there is a type of tumor called immune excluded 
that has tumor infiltrating immune cells present, but these cells are restricted to the periphery 
of the tumor and not able to mediate a productive anti-tumor immune response.  These single 
cell analysis technologies would be able to detect the immune cells present, but not be able to 
determine their spatial location and sequestered nature.  For a complete picture, these 
technologies may be combined with imaging technologies for a spatial and detailed account of 
the immune cells within the tumor.  I believe that a complete and detailed analysis of the 
immune landscape within the tumor is critical to improve patient outcomes and improve 
checkpoint immunotherapy.  Understanding the heterogenous nature of the tumor infiltrating 
lymphocytes will also allow researchers to find more reliable biomarkers to predict responders 
and non-responders to immunotherapy.    
5.4 Combatting Immunosuppression in the Tumor Microenvironment  
Another main conclusion from the body of work for this dissertation is that even after 
successfully boosting the anti-tumor immune response, there is the potential that any 
productive immune response can be terminated by suppressive cells within the tumor.  It has 
long been a goal of researchers in immunotherapy to find ways to preferentially boost the 
cytotoxic immune cells while dampening the suppressive immune cells.  This has proven to be a 
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difficult task.  Regulatory T cells (Tregs) are a main subset of suppressive cells found enriched in 
many solid tumors.  There has been some work to target Tregs for depletion, such as low-dose 
Cyclophosphimide [21] and PI3K p110d inhibitors [22], but these strategies have not been 
robust enough to significantly improve immunotherapy [23].  Another strategy to target 
suppressive Tregs in the tumor is blockade of the suppressive molecule CTLA-4.  CTLA-4 is highly 
expressed on Tregs and is one of their main methods of suppression by blocking co-stimulation 
of conventional T cells [24].  CLTA-4 blocking antibody, ipilimumab, was originally developed as 
a checkpoint blockade to boost cytotoxic T cell response [25], but has subsequently been found 
to inhibit Tregs [26-28].  Studies using CTLA-4 blocking monoclonal antibodies in patients with 
advanced melanoma resulted in increased CD8+ T cell activation and inhibition of Tregs [29 30].  
Since CTLA-4 is a main suppressive mechanism employed by these cells, blocking CTLA-4 during 
immunotherapy seems to be a potential way to inhibit suppressive Treg activity in the tumor.       
 Myeloid derived suppressor cells (MDSCs), another suppressive cell type impeding a 
productive anti-tumor immune response, are an additional potential target for enhancing 
cancer therapies.  There are several ongoing clinical trials with the goal of enhancing immune 
checkpoint inhibition by targeting MDSCs either through reduction in frequency, blocking 
recruitment, or suppressing function [31].  All-trans retinoic acid has been shown to 
differentiate MDSCs into macrophages [32] and enhance anti-tumor immunity in mouse models 
of cancer.  In patients with non-small cell lung cancer, addition of retinoic acid to conventional 
chemotherapy treatment improved overall outcomes [33].  Additionally, antibodies blocking 
integrin cell adhesion molecule CD11b has been shown to prevent migration of MDSCs into 
tumors in mouse models [34 35].  The limitation to this type of prevention is that in addition to 
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MDSCs, all myeloid lineage cells express CD11b including neutrophils, macrophages, 
monocytes, and dendritic cells, some of which can be beneficial to the anti-tumor immune 
response.  Another study targeting MDSC recruitment has shown that MCSCs infiltrating into 
tumors express CCR5, and so blockade of CCR5 ligands is being tested as a way to block MDSC 
tumor infiltration [36].  The phosphodiesterase-5 inhibitor sildenafil has been shown to 
downregulate suppressive molecules ARG-1 and iNOS in MDSCs, lowering their suppressive 
capabilities.  In mouse models of cancer, treatment with sildenafil led to enhanced T cell 
infiltration and a reduction in tumor growth [37 38].  Clinical trials targeting MDSCs in addition 
to immunotherapy have provided promising results, although these trials are still in the early 
phases and need to be studied long term [31].    
5.5 Concluding Remarks 
I believe that moving forward, due to the heterogeneity of cancer and the anti-tumor 
immune response, personalized medicine will be crucial in determining the most beneficial 
immunotherapies for individual patients.  There are many challenges ahead for immunotherapy 
to optimize patient response rates and limit toxicity.  Immunotherapy research should focus 
efforts on an exhaustive characterization of tumor infiltrating lymphocytes, and finding ways to 
preferentially boost the anti-tumor immune response while depleting or dampening the 
suppressive cells in the TME.  Currently, a significant impediment to this approach has been the 
extremely limited number of therapies that only target immunosuppressive immune pathways 
or cells.  It is possible that the future of cancer immunotherapy will be a tumor biopsy or 
resection that is then analyzed on a single cell basis for the precise composition and activation 
status of the tumor infiltrating immune cells, which then allows for targeted therapy to boost 
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only a productive anti-tumor immune response with limited negative side effects, individualized 
for each patient.  Repeated tumor biopsies may be critical to understand the effects of 




1. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during 
chronic viral infection. Nature 2006;439(7077):682-7 doi: 10.1038/nature04444. 
2. Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by 
PD-1/PD-L1 blockade. J Clin Invest 2018;128(10):4654-68 doi: 10.1172/JCI99317. 
3. Quatrini L, Wieduwild E, Escaliere B, et al. Endogenous glucocorticoids control host resistance 
to viral infection through the tissue-specific regulation of PD-1 expression on NK cells. 
Nat Immunol 2018;19(9):954-62 doi: 10.1038/s41590-018-0185-0. 
4. Yu Y, Tsang JC, Wang C, et al. Single-cell RNA-seq identifies a PD-1(hi) ILC progenitor and 
defines its development pathway. Nature 2016;539(7627):102-06 doi: 
10.1038/nature20105. 
5. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and 
Function. Immunity 2018;49(2):264-74 e4 doi: 10.1016/j.immuni.2018.06.012. 
6. Wein L, Luen SJ, Savas P, Salgado R, Loi S. Checkpoint blockade in the treatment of breast 
cancer: current status and future directions. Br J Cancer 2018;119(1):4-11 doi: 
10.1038/s41416-018-0126-6. 
7. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural 
killer cells. Science 2011;331(6013):44-9 doi: 10.1126/science.1198687. 
8. Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and 
monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 
2018;131(16):1809-19 doi: 10.1182/blood-2017-07-796342. 
9. Liu Y, Cheng Y, Xu Y, et al. Increased expression of programmed cell death protein 1 on NK 
cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in 
digestive cancers. Oncogene 2017;36(44):6143-53 doi: 10.1038/onc.2017.209. 
10. Pesce S, Greppi M, Tabellini G, et al. Identification of a subset of human natural killer cells 
expressing high levels of programmed death 1: A phenotypic and functional 
characterization. J Allergy Clin Immunol 2017;139(1):335-46 e3 doi: 
10.1016/j.jaci.2016.04.025. 
11. Beldi-Ferchiou A, Lambert M, Dogniaux S, et al. PD-1 mediates functional exhaustion of 
activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016;7(45):72961-77 doi: 
10.18632/oncotarget.12150. 
12. Benson DM, Jr., Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer 
cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal 
anti-PD-1 antibody. Blood 2010;116(13):2286-94 doi: 10.1182/blood-2010-02-271874. 
 198 
13. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation 
sequencing technologies. Nat Rev Genet 2016;17(6):333-51 doi: 10.1038/nrg.2016.49. 
14. Pavlopoulou A, Spandidos DA, Michalopoulos I. Human cancer databases (review). Oncol 
Rep 2015;33(1):3-18 doi: 10.3892/or.2014.3579. 
15. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat 
Rev Immunol 2018;18(1):35-45 doi: 10.1038/nri.2017.76. 
16. Zheng C, Zheng L, Yoo JK, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by 
Single-Cell Sequencing. Cell 2017;169(7):1342-56 e16 doi: 10.1016/j.cell.2017.05.035. 
17. Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following 
PD-1 blockade. Nat Med 2019;25(8):1251-59 doi: 10.1038/s41591-019-0522-3. 
18. Bandura DR, Baranov VI, Ornatsky OI, et al. Mass cytometry: technique for real time single 
cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass 
spectrometry. Anal Chem 2009;81(16):6813-22 doi: 10.1021/ac901049w. 
19. Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and 
drug responses across a human hematopoietic continuum. Science 2011;332(6030):687-
96 doi: 10.1126/science.1198704. 
20. Hartmann FJ, Babdor J, Gherardini PF, et al. Comprehensive Immune Monitoring of Clinical 
Trials to Advance Human Immunotherapy. Cell Rep 2019;28(3):819-31 e4 doi: 
10.1016/j.celrep.2019.06.049. 
21. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor 
immunity but are sensitive to cyclophosphamide which allows immunotherapy of 
established tumors to be curative. Eur J Immunol 2004;34(2):336-44 doi: 
10.1002/eji.200324181. 
22. Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-
mediated immune tolerance to cancer. Nature 2014;510(7505):407-11 doi: 
10.1038/nature13444. 
23. Taylor NA, Vick SC, Iglesia MD, et al. Treg depletion potentiates checkpoint inhibition in 
claudin-low breast cancer. J Clin Invest 2017;127(9):3472-83 doi: 10.1172/JCI90499. 
24. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through 
a CD28-B7-dependent mechanism. J Immunol 2006;177(2):1052-61 doi: 
10.4049/jimmunol.177.2.1052. 
25. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 
blockade. Science 1996;271(5256):1734-6 doi: 10.1126/science.271.5256.1734. 
 199 
26. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance 
antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol 
Res 2013;1(1):32-42 doi: 10.1158/2326-6066.CIR-13-0013. 
27. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating 
regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp 
Med 2013;210(9):1695-710 doi: 10.1084/jem.20130579. 
28. Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc gamma receptors contribute to the 
antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 
2013;210(9):1685-93 doi: 10.1084/jem.20130573. 
29. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med 2010;363(8):711-23 doi: 10.1056/NEJMoa1003466. 
30. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by 
cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic 
melanoma. Proc Natl Acad Sci U S A 2003;100(14):8372-7 doi: 
10.1073/pnas.1533209100. 
31. Weber R, Fleming V, Hu X, et al. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer 
Activity of Immune Checkpoint Inhibitors. Front Immunol 2018;9:1310 doi: 
10.3389/fimmu.2018.01310. 
32. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of 
reactive oxygen species. J Leukoc Biol 2003;74(2):186-96 doi: 10.1189/jlb.0103010. 
33. Arrieta O, Gonzalez-De la Rosa CH, Arechaga-Ocampo E, et al. Randomized phase II trial of 
All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line 
treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 
2010;28(21):3463-71 doi: 10.1200/JCO.2009.26.6452. 
34. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 
(CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell 
recruitment. Proc Natl Acad Sci U S A 2010;107(18):8363-8 doi: 
10.1073/pnas.0911378107. 
35. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer 
survival and functionally regulates response to chemotherapy. Cancer Discov 
2011;1(1):54-67 doi: 10.1158/2159-8274.CD-10-0028. 
36. Blattner C, Fleming V, Weber R, et al. CCR5(+) Myeloid-Derived Suppressor Cells Are 
Enriched and Activated in Melanoma Lesions. Cancer Res 2018;78(1):157-67 doi: 
10.1158/0008-5472.CAN-17-0348. 
 200 
37. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous 
antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 
2006;203(12):2691-702 doi: 10.1084/jem.20061104. 
38. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived 
suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma 
model. Proc Natl Acad Sci U S A 2011;108(41):17111-6 doi: 10.1073/pnas.1108121108. 
  
 201 
APPENDIX: ADDITIONAL PUBLISHED WORK 
In addition to the chapters presented in this dissertation, I also contributed work to two 
other publications during my graduate school training. 
During my rotation with Jason Whitmire, I contributed work to a manuscript published 
in Cell Reports examining how genetic variants can result in severe hemorrhagic disease from 
lymphocytic choriomeningitis virus (LCMV) in mice mimicking that seen in humans from 
arenaviruses.  I performed histological studies on B6.PL mice after LCMV infection that were 
critical for development of the project.  I performed infections, harvested organs, and ran flow 
cytometry that was all verified and duplicated for the final manuscript.  I wrote the results and 
methods section for my experiments, which were loosely incorporated into the paper.  I also 
edited the final drafts of the paper before submission.  The citation for the manuscript is: 
Misumi I, Cook KD, Mitchell JE, Lund MM, Vick SC, Lee RH, Uchimura T, Bergmeier W, 
Mieczkowski P, Pardo-Manuel de Villena F, Ting JPY, Whitmire JK.  Identification of a locus in 
mice that regulates the collateral damage and lethality of virus infection.  Cell Rep. 2019 Apr 
30;27(5):1387-1396.   
In collaboration with Chuck Perou’s lab, I contributed to a manuscript that was 
published in Cell demonstrating the role of B cells and IgG secretion in a model of claudin-low 
breast cancer with increased mutational burden.  The Perou lab submitted the manuscript to 
Cell and received reviewer comments asking the authors to investigate the B cell response after 
regulatory T cell depletion, and so I assisted in these experiments.  I provided Foxp3-DTR mice 
from my colony and assisted with tumor injections in these mice.  I then performed all 
diphtheria toxin injections and monitored these mice in the BSL2 facility for tumor growth 
 202 
following the timeline and protocol I developed for the manuscript Vick SC and Taylor NT et al. J 
Clin Invest 2017.  I also edited the final drafts of the paper and provided helpful feedback 
before submission.  The citation for the manuscript is:  Hollern DP, Xu N, Thennavan A, 
Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, Ford J, Liu S, 
Vick SC, Martin M, Parker JS, Vincent BG, Serody JS, Perou CM.  B cells and T follicular helper 
cells mediate response to checkpoint inhibitors in high mutation burden mouse models of 
breast cancer.  Cell. 2019 Nov 14;179(5):1191-1206.           
 
 
